Scholars@Duke
Darell Doty Bigner

Darell Doty Bigner

E. L. and Lucille F. Jones Cancer Distinguished Research Professor, in the School of Medicine
Neurosurgery
bigne001@mc.duke.edu
Duke Box 3156, Durham, NC 27710
177 Med Sci Res Bldg, Durham, NC 27710

Scholarly Works - Journal articles

Lymphotropic Virotherapy Induces DC and High Endothelial Venule Inflammation, Promoting the Antitumor Efficacy of Intratumor Virus Administration.

Journal article Cancer Immunol Res · February 3, 2026 Tumor-draining lymph nodes are a pivotal site for antitumor T-cell priming. However, their mechanistic roles in cancer immune surveillance and immunotherapy response remain poorly defined. Intratumor (IT) virotherapy generates antitumor T-cell immunity thr ... Full text Link to item Cite

Lymphotropic Virotherapy Engages DC and High Endothelial Venule Inflammation to Mediate Cancer In Situ Vaccination.

Journal article medRxiv · April 25, 2025 Intratumor (IT) inoculation of the rhino:poliovirus chimera, PVSRIPO, yielded objective radiographic responses with long-term survival in 20% of patients with recurrent glioblastoma (rGBM). PVSRIPO infects dendritic cells (DCs) and sets up non-cytopathogen ... Full text Link to item Cite

The safety and accuracy of intratumoral catheter placement to infuse viral immunotherapies in children with malignant brain tumors: a multi-institutional study.

Journal article J Neurosurg Pediatr · April 1, 2024 OBJECTIVE: Relatively little is known about the safety and accuracy of catheter placement for oncolytic viral therapy in children with malignant brain tumors. Accordingly, this study combines data from two phase I clinical trials that employed viral immuno ... Full text Open Access Link to item Cite

Development of a high-throughput screening platform to identify new therapeutic agents for Medulloblastoma Group 3.

Journal article SLAS Discov · March 2024 Pediatric brain tumors (PBTs) represent about 25 % of all pediatric cancers and are the most common solid tumors in children and adolescents. Medulloblastoma (MB) is the most frequently occurring malignant PBT, accounting for almost 10 % of all pediatric c ... Full text Link to item Cite

Repurposing Clemastine to Target Glioblastoma Cell Stemness.

Journal article Cancers (Basel) · September 18, 2023 Brain tumor-initiating cells (BTICs) and tumor cell plasticity promote glioblastoma (GBM) progression. Here, we demonstrate that clemastine, an over-the-counter drug for treating hay fever and allergy symptoms, effectively attenuated the stemness and suppr ... Full text Link to item Cite

Polio virotherapy targets the malignant glioma myeloid infiltrate with diffuse microglia activation engulfing the CNS.

Journal article Neuro Oncol · September 5, 2023 BACKGROUND: Malignant gliomas commandeer dense inflammatory infiltrates with glioma-associated macrophages and microglia (GAMM) promoting immune suppression, evasion, and tumor progression. Like all cells in the mononuclear phagocytic system, GAMM constitu ... Full text Open Access Link to item Cite

Recombinant polio-rhinovirus immunotherapy for recurrent paediatric high-grade glioma: a phase 1b trial.

Journal article Lancet Child Adolesc Health · July 2023 BACKGROUND: Outcomes of recurrent paediatric high-grade glioma are poor, with a median overall survival of less than 6 months. Viral immunotherapy, such as the polio-rhinovirus chimera lerapolturev, is a novel approach for treatment of recurrent paediatric ... Full text Link to item Cite

Intratumor childhood vaccine-specific CD4+ T-cell recall coordinates antitumor CD8+ T cells and eosinophils.

Journal article J Immunother Cancer · April 2023 BACKGROUND: Antitumor mechanisms of CD4+ T cells remain crudely defined, and means to effectively harness CD4+ T-cell help for cancer immunotherapy are lacking. Pre-existing memory CD4+ T cells hold potential to be leveraged for this purpose. Moreover, the ... Full text Link to item Cite

Immunotoxin-αCD40 therapy activates innate and adaptive immunity and generates a durable antitumor response in glioblastoma models.

Journal article Sci Transl Med · February 8, 2023 D2C7-immunotoxin (IT), a dual-specific IT targeting wild-type epidermal growth factor receptor (EGFR) and mutant EGFR variant III (EGFRvIII) proteins, demonstrates encouraging survival outcomes in a subset of patients with glioblastoma. We hypothesized tha ... Full text Link to item Cite

Tacedinaline (CI-994), a class I HDAC inhibitor, targets intrinsic tumor growth and leptomeningeal dissemination in MYC-driven medulloblastoma while making them susceptible to anti-CD47-induced macrophage phagocytosis via NF-kB-TGM2 driven tumor inflammation.

Journal article J Immunother Cancer · January 2023 BACKGROUND: While major advances have been made in improving the quality of life and survival of children with most forms of medulloblastoma (MB), those with MYC-driven tumors (Grp3-MB) still suffer significant morbidity and mortality. There is an urgent n ... Full text Link to item Cite

Multimodality analysis confers a prognostic benefit of a T-cell infiltrated tumor microenvironment and peripheral immune status in patients with melanoma.

Journal article J Immunother Cancer · September 2022 BACKGROUND: We previously reported results from a phase 1 study testing intratumoral recombinant poliovirus, lerapolturev, in 12 melanoma patients. All 12 patients received anti-PD-1 systemic therapy before lerapolturev, and 11 of these 12 patients also re ... Full text Link to item Cite

Phase I trial of intratumoral PVSRIPO in patients with unresectable, treatment-refractory melanoma.

Journal article J Immunother Cancer · April 2021 BACKGROUND: While programmed cell death protein 1 (PD-1) and programmed death-ligand 1 (PD-L1) antagonists have improved the prognosis for many patients with melanoma, around 60% fail therapy. PVSRIPO is a non-neurovirulent rhinovirus:poliovirus chimera th ... Full text Link to item Cite

Viral infection of cells within the tumor microenvironment mediates antitumor immunotherapy via selective TBK1-IRF3 signaling.

Journal article Nat Commun · March 25, 2021 Activating intra-tumor innate immunity might enhance tumor immune surveillance. Virotherapy is proposed to achieve tumor cell killing, while indirectly activating innate immunity. Here, we report that recombinant poliovirus therapy primarily mediates antit ... Full text Link to item Cite

Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy.

Journal article Nat Commun · January 13, 2021 Several immunotherapy clinical trials in recurrent glioblastoma have reported long-term survival benefits in 10-20% of patients. Here we perform genomic analysis of tumor tissue from recurrent WHO grade IV glioblastoma patients acquired prior to immunother ... Full text Open Access Link to item Cite

Genetically stable poliovirus vectors activate dendritic cells and prime antitumor CD8 T cell immunity.

Journal article Nat Commun · January 27, 2020 Viruses naturally engage innate immunity, induce antigen presentation, and mediate CD8 T cell priming against foreign antigens. Polioviruses can provide a context optimal for generating antigen-specific CD8 T cells, as they have natural tropism for dendrit ... Full text Link to item Cite

MTAP Loss Promotes Stemness in Glioblastoma and Confers Unique Susceptibility to Purine Starvation.

Journal article Cancer Res · July 1, 2019 Homozygous deletion of methylthioadenosine phosphorylase (MTAP) is one of the most frequent genetic alterations in glioblastoma (GBM), but its pathologic consequences remain unclear. In this study, we report that loss of MTAP results in profound epigenetic ... Full text Link to item Cite

Improved efficacy against malignant brain tumors with EGFRwt/EGFRvIII targeting immunotoxin and checkpoint inhibitor combinations.

Journal article J Immunother Cancer · May 29, 2019 BACKGROUND: D2C7-IT is a novel immunotoxin (IT) targeting wild-type epidermal growth factor receptor (EGFRwt) and mutant EGFR variant III (EGFRvIII) proteins in glioblastoma. In addition to inherent tumoricidal activity, immunotoxins induce secondary immun ... Full text Open Access Link to item Cite

Sensitive and rapid detection of TERT promoter and IDH mutations in diffuse gliomas.

Journal article Neuro Oncol · March 18, 2019 BACKGROUND: Mutations in telomerase reverse transcriptase promoter (TERTp) and isocitrate dehydrogenase 1 and 2 (IDH) offer objective markers to assist in classifying diffuse gliomas into genetic subgroups. However, traditional mutation detection technique ... Full text Link to item Cite

MGMT: Immunohistochemical Detection in High-Grade Astrocytomas.

Journal article J Neuropathol Exp Neurol · January 1, 2019 Glioma therapeutic resistance to alkylating chemotherapy is mediated via O6-methylguanine-DNA methyltransferase (MGMT). We hypothesized that a CD45/HAM56/MGMT double-stained cocktail would improve MGMT discrimination in tumor cells versus inflammatory and ... Full text Link to item Cite

Synergistic antitumor effects of 9.2.27-PE38KDEL and ABT-737 in primary and metastatic brain tumors.

Journal article PLoS One · 2019 Standard treatment, unfortunately, yields a poor prognosis for patients with primary or metastatic cancers in the central nervous system, indicating a necessity for novel therapeutic agents. Immunotoxins (ITs) are a class of promising therapeutic candidate ... Full text Open Access Link to item Cite

Bevacizumab, irinotecan, temozolomide, tyrosine kinase inhibition, and MEK inhibition are effective against pleomorphic xanthoastrocytoma regardless of V600E status.

Journal article J Neurooncol · November 2018 INTRODUCTION: Pleomorphic xanthoastrocytoma (PXA) is a rare Grade II and III glioma. Surgical resection is the mainstay of treatment, however, adjuvant therapy is sometimes necessary. Given the rarity of PXA, chemotherapeutic efficacy data is limited. The ... Full text Link to item Cite

T-Cell Exhaustion Signatures Vary with Tumor Type and Are Severe in Glioblastoma.

Journal article Clin Cancer Res · September 1, 2018 Purpose: T-cell dysfunction is a hallmark of glioblastoma (GBM). Although anergy and tolerance have been well characterized, T-cell exhaustion remains relatively unexplored. Exhaustion, characterized in part by the upregulation of multiple immune checkpoin ... Full text Link to item Cite

Mutant allele quantification reveals a genetic basis for TP53 mutation-driven castration resistance in prostate cancer cells.

Journal article Sci Rep · August 21, 2018 The concept that human cancer is in essence a genetic disease driven by gene mutations has been well established, yet its utilization in functional studies of cancer genes has not been fully explored. Here, we describe a simple genetics-based approach that ... Full text Link to item Cite

A Rationally Designed Fully Human EGFRvIII:CD3-Targeted Bispecific Antibody Redirects Human T Cells to Treat Patient-derived Intracerebral Malignant Glioma.

Journal article Clin Cancer Res · August 1, 2018 Purpose: Conventional therapy for malignant glioma fails to specifically target tumor cells. In contrast, substantial evidence indicates that if appropriately redirected, T cells can precisely eradicate tumors. Here we report the rational development of a ... Full text Link to item Cite

Poliovirus Receptor (CD155) Expression in Pediatric Brain Tumors Mediates Oncolysis of Medulloblastoma and Pleomorphic Xanthoastrocytoma.

Journal article J Neuropathol Exp Neurol · August 1, 2018 Poliovirus oncolytic immunotherapy is a putatively novel approach to treat pediatric brain tumors. This work sought to determine expression of the poliovirus receptor (PVR), CD155, in low-grade and malignant pediatric brain tumors and its ability to infect ... Full text Link to item Cite

Recurrent Glioblastoma Treated with Recombinant Poliovirus.

Journal article N Engl J Med · July 12, 2018 BACKGROUND: The prognosis of patients with recurrent World Health Organization (WHO) grade IV malignant glioma is dismal, and there is currently no effective therapy. We conducted a dose-finding and toxicity study in this population of patients, evaluating ... Full text Link to item Cite

Sym004-induced EGFR elimination is associated with profound anti-tumor activity in EGFRvIII patient-derived glioblastoma models.

Journal article J Neurooncol · July 2018 BACKGROUND: Sym004 is a mixture of two monoclonal antibodies (mAbs), futuximab and modotuximab, targeting non-overlapping epitopes on the epidermal growth factor receptor (EGFR). Previous studies have shown that Sym004 is more efficient at inducing interna ... Full text Open Access Link to item Cite

The genomic landscape of TERT promoter wildtype-IDH wildtype glioblastoma.

Journal article Nat Commun · May 25, 2018 The majority of glioblastomas can be classified into molecular subgroups based on mutations in the TERT promoter (TERTp) and isocitrate dehydrogenase 1 or 2 (IDH). These molecular subgroups utilize distinct genetic mechanisms of telomere maintenance, eithe ... Full text Link to item Cite

Dendritic Cells Enhance Polyfunctionality of Adoptively Transferred T Cells That Target Cytomegalovirus in Glioblastoma.

Journal article Cancer Res · January 1, 2018 Median survival for glioblastoma (GBM) remains <15 months. Human cytomegalovirus (CMV) antigens have been identified in GBM but not normal brain, providing an unparalleled opportunity to subvert CMV antigens as tumor-specific immunotherapy targets. A recen ... Full text Link to item Cite

Adaptive Evolution of the GDH2 Allosteric Domain Promotes Gliomagenesis by Resolving IDH1R132H-Induced Metabolic Liabilities.

Journal article Cancer Res · January 1, 2018 Hotspot mutations in the isocitrate dehydrogenase 1 (IDH1) gene occur in a number of human cancers and confer a neomorphic enzyme activity that catalyzes the conversion of α-ketoglutarate (αKG) to the oncometabolite D-(2)-hydroxyglutarate (D2HG). In malign ... Full text Link to item Cite

AJAP1 expression modulates glioma cell motility and correlates with tumor growth and survival.

Journal article Int J Oncol · January 2018 Glioblastoma multiforme (GBM) is one of the most common primary malignant brain tumors. Unraveling the molecular and genetic complexity that determines GBM's pronounced migratory property could provide new options for therapeutic targeting that may signifi ... Full text Link to item Cite

Application of mutagen sensitivity assay in a glioma case-control study.

Journal article Toxicol Rep · 2018 Few risk factors for glioma have been identified other than ionizing radiation. The alkylating agent acrylamide is a compound found in both occupational and the general environment and identified as one of the forty known or suspected neurocarcinogens in a ... Full text Link to item Cite

Elevated expression of podoplanin and its clinicopathological, prognostic, and therapeutic values in squamous non-small cell lung cancer.

Journal article Cancer Manag Res · 2018 BACKGROUND: Squamous non-small cell lung cancer (SqNSCLC), as a leading cause of cancer-related deaths worldwide, has limited treatment options and poor prognosis. Thus, novel targeted therapies are desperately needed. MATERIALS AND METHODS: SqNSCLC cases ... Full text Link to item Cite

Validation of an Immunohistochemistry Assay for Detection of CD155, the Poliovirus Receptor, in Malignant Gliomas.

Journal article Arch Pathol Lab Med · December 2017 CONTEXT: - The oncolytic polio-rhinovirus recombinant (PVSRIPO) has demonstrated promise in currently ongoing phase I/II clinical trials against recurrent glioblastoma and was granted breakthrough therapy designation by the Food and Drug Administration/Cen ... Full text Link to item Cite

Cic Loss Promotes Gliomagenesis via Aberrant Neural Stem Cell Proliferation and Differentiation.

Journal article Cancer Res · November 15, 2017 Inactivating mutations in the transcriptional repression factor Capicua (CIC) occur in approximately 50% of human oligodendrogliomas, but mechanistic links to pathogenesis are unclear. To address this question, we generated Cic-deficient mice and human oli ... Full text Link to item Cite

Patient-derived DIPG cells preserve stem-like characteristics and generate orthotopic tumors.

Journal article Oncotarget · September 29, 2017 Diffuse intrinsic pontine glioma (DIPG) is a devastating brain tumor, with a median survival of less than one year. Due to enormous difficulties in the acquisition of DIPG specimens and the sophisticated technique required to perform brainstem orthotopic i ... Full text Link to item Cite

Cancer immunotherapy with recombinant poliovirus induces IFN-dominant activation of dendritic cells and tumor antigen-specific CTLs.

Journal article Sci Transl Med · September 20, 2017 Tumors thrive in an immunosuppressive microenvironment that impedes antitumor innate and adaptive immune responses. Thus, approaches that can overcome immunosuppression and engage antitumor immunity are needed. This study defines the adjuvant and cancer im ... Full text Link to item Cite

The role of angiogenesis in Group 3 medulloblastoma pathogenesis and survival.

Journal article Neuro Oncol · September 1, 2017 BACKGROUND: Of the 4 medulloblastoma subgroups, Group 3 is the most aggressive but the importance of angiogenesis is unknown. This study sought to determine the role of angiogenesis and identify clinically relevant biomarkers of tumor vascularity and survi ... Full text Link to item Cite

Selection of novel affinity-matured human chondroitin sulfate proteoglycan 4 antibody fragments by yeast display.

Journal article Protein Eng Des Sel · September 1, 2017 Chondroitin sulfate proteoglycan 4 (CSPG4) is a promising target for cancer immunotherapy due to its high level of expression in a number of malignant tumors, and its essential role in tumor growth and progression. Clinical application of CSPG4-targeting i ... Full text Link to item Cite

Patient-derived DIPG cells preserve stem-like characteristics and generate orthotopic tumors.

Journal article Oncotarget · July 28, 2017 Diffuse intrinsic pontine glioma (DIPG) is a devastating brain tumor, with a median survival of less than one year. Due to enormous difficulties in the acquisition of DIPG specimens and the sophisticated technique required to perform brainstem orthotopic i ... Full text Link to item Cite

Mutant IDH1 Disrupts the Mouse Subventricular Zone and Alters Brain Tumor Progression.

Journal article Mol Cancer Res · May 2017 IDH1 mutations occur in the majority of low-grade gliomas and lead to the production of the oncometabolite, D-2-hydroxyglutarate (D-2HG). To understand the effects of tumor-associated mutant IDH1 (IDH1-R132H) on both the neural stem cell (NSC) population a ... Full text Link to item Cite

Long-term Survival in Glioblastoma with Cytomegalovirus pp65-Targeted Vaccination.

Journal article Clin Cancer Res · April 15, 2017 Purpose: Patients with glioblastoma have less than 15-month median survival despite surgical resection, high-dose radiation, and chemotherapy with temozolomide. We previously demonstrated that targeting cytomegalovirus pp65 using dendritic cells (DC) can e ... Full text Link to item Cite

Production and quality control assessment of a GLP-grade immunotoxin, D2C7-(scdsFv)-PE38KDEL, for a phase I/II clinical trial.

Journal article Appl Microbiol Biotechnol · April 2017 D2C7-(scdsFv)-PE38KDEL (D2C7-IT) is a novel recombinant Pseudomonas exotoxin A-based immunotoxin (IT), targeting both wild-type epidermal growth factor receptor (EGFRwt) and mutant EGFR variant III (EGFRvIII) proteins overexpressed in glioblastomas. Initia ... Full text Link to item Cite

Immunotoxin Therapy for Lung Cancer.

Journal article Chin Med J (Engl) · March 5, 2017 Full text Link to item Cite

Development and validation of a cell-based fluorescent method for measuring antibody affinity.

Journal article J Immunol Methods · March 2017 Monoclonal antibodies have become essential tools for diagnostic and therapeutic purposes. Antibody affinity is one of the critical factors influencing the therapeutic success of tumor-targeting antibodies. Therefore, developing an accurate and reliable me ... Full text Link to item Cite

Editorial

Journal article Geomechanics for Energy and the Environment · March 1, 2017 Full text Cite

Recombinant oncolytic poliovirus, PVSRIPO, has potent cytotoxic and innate inflammatory effects, mediating therapy in human breast and prostate cancer xenograft models.

Journal article Oncotarget · November 29, 2016 Intratumoral inoculation of viruses with tumor-selective cytotoxicity may induce cancer cell death and, thereby, shrink neoplastic lesions. It is unlikely, however, that viral tumor cell killing alone could produce meaningful, durable clinical responses, a ... Full text Link to item Cite

Rapid Reprogramming of Primary Human Astrocytes into Potent Tumor-Initiating Cells with Defined Genetic Factors.

Journal article Cancer Res · September 1, 2016 Cancer stem-like cells (CSC) are thought to drive brain cancer, but their cellular and molecular origins remain uncertain. Here, we report the successful generation of induced CSC (iCSC) from primary human astrocytes through the expression of defined genet ... Full text Link to item Cite

Preclinical toxicity evaluation of a novel immunotoxin, D2C7-(scdsFv)-PE38KDEL, administered via intracerebral convection-enhanced delivery in rats.

Journal article Invest New Drugs · April 2016 D2C7-(scdsFv)-PE38KDEL (D2C7-IT) is a novel immunotoxin that reacts with wild-type epidermal growth factor receptor (EGFRwt) and mutant EGFRvIII proteins overexpressed in glioblastomas. This study assessed the toxicity of intracerebral administration of D2 ... Full text Link to item Cite

Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis.

Journal article Lancet Oncol · April 2016 BACKGROUND: Patients with incomplete surgical resection of medulloblastoma are controversially regarded as having a marker of high-risk disease, which leads to patients undergoing aggressive surgical resections, so-called second-look surgeries, and intensi ... Full text Open Access Link to item Cite

CAR T Cells Targeting Podoplanin Reduce Orthotopic Glioblastomas in Mouse Brains.

Journal article Cancer Immunol Res · March 2016 Glioblastoma (GBM) is the most common and lethal primary malignant brain tumor in adults with a 5-year overall survival rate of less than 10%. Podoplanin (PDPN) is a type I transmembrane mucin-like glycoprotein, expressed in the lymphatic endothelium. Seve ... Full text Link to item Cite

MiR-215 Is Induced Post-transcriptionally via HIF-Drosha Complex and Mediates Glioma-Initiating Cell Adaptation to Hypoxia by Targeting KDM1B.

Journal article Cancer Cell · January 11, 2016 The hypoxic tumor microenvironment serves as a niche for maintaining the glioma-initiating cells (GICs) that are critical for glioblastoma (GBM) occurrence and recurrence. Here, we report that hypoxia-induced miR-215 is vital for reprograming GICs to fit t ... Full text Open Access Link to item Cite

Abstract A157: Oncolytic poliovirus mediated immune events

Journal article Cancer Immunology Research · January 1, 2016 AbstractIntroduction: Tumor-targeted therapies that efficiently eliminate malignant cells and in the process engage the innate and adaptive immune system are desirable for preventing cancer recurrence. We ha ... Full text Cite

EGFR/EGFRvIII-targeted immunotoxin therapy for the treatment of glioblastomas via convection-enhanced delivery.

Journal article Receptors Clin Investig · 2016 Glioblastoma is the most aggressive malignant brain tumor among all primary brain and central nervous system tumors. The median survival time for glioblastoma patients given the current standard of care treatment (surgery, radiation, and chemotherapy) is l ... Full text Link to item Cite

Phosphorylation of Glutathione S-Transferase P1 (GSTP1) by Epidermal Growth Factor Receptor (EGFR) Promotes Formation of the GSTP1-c-Jun N-terminal kinase (JNK) Complex and Suppresses JNK Downstream Signaling and Apoptosis in Brain Tumor Cells.

Journal article J Biol Chem · December 25, 2015 Under normal physiologic conditions, the glutathione S-transferase P1 (GSTP1) protein exists intracellularly as a dimer in reversible equilibrium with its monomeric subunits. In the latter form, GSTP1 binds to the mitogen-activated protein kinase, JNK, and ... Full text Link to item Cite

Abstract A08: IGF1R as a key target in high risk, metastatic medulloblastoma

Journal article Cancer Research · December 1, 2015 AbstractThe risk or presence of metastasis in childhood medulloblastoma represents a substantial cause of morbidity and mortality. Relatively little has been known about the molecular mechanisms of medullobl ... Full text Cite

Ex vivo generation of dendritic cells from cryopreserved, post-induction chemotherapy, mobilized leukapheresis from pediatric patients with medulloblastoma.

Journal article J Neurooncol · October 2015 Generation of patient-derived, autologous dendritic cells (DCs) is a critical component of cancer immunotherapy with ex vivo-generated, tumor antigen-loaded DCs. An important factor in the ability to generate DCs is the potential impact of prior therapies ... Full text Link to item Cite

Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas.

Journal article N Engl J Med · June 25, 2015 BACKGROUND: Diffuse low-grade and intermediate-grade gliomas (which together make up the lower-grade gliomas, World Health Organization grades II and III) have highly variable clinical behavior that is not adequately predicted on the basis of histologic cl ... Full text Link to item Cite

A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study.

Journal article Neuro Oncol · June 2015 BACKGROUND: The epidermal growth factor receptor variant III deletion mutation, EGFRvIII, is expressed in ∼30% of primary glioblastoma and linked to poor long-term survival. Rindopepimut consists of the unique EGFRvIII peptide sequence conjugated to keyhol ... Full text Link to item Cite

Proteomic profiling of patient-derived glioblastoma xenografts identifies a subset with activated EGFR: implications for drug development.

Journal article J Neurochem · June 2015 The development of drugs to inhibit glioblastoma (GBM) growth requires reliable pre-clinical models. To date, proteomic level validation of widely used patient-derived glioblastoma xenografts (PDGX) has not been performed. In the present study, we characte ... Full text Link to item Cite

Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients.

Journal article Nature · March 19, 2015 After stimulation, dendritic cells (DCs) mature and migrate to draining lymph nodes to induce immune responses. As such, autologous DCs generated ex vivo have been pulsed with tumour antigens and injected back into patients as immunotherapy. While DC vacci ... Full text Open Access Link to item Cite

Novel role of hematopoietic stem cells in immunologic rejection of malignant gliomas.

Journal article Oncoimmunology · March 2015 Adoptive cellular therapy (ACT) after lymphodepletive conditioning can induce dramatic clinical responses, but this approach has been largely limited to melanoma due to a lack of reliable methods for expanding tumor-specific lymphocytes from the majority o ... Full text Link to item Cite

Oncolytic polio virotherapy of cancer.

Journal article Cancer · November 1, 2014 Recently, the century-old idea of targeting cancer with viruses (oncolytic viruses) has come of age, and promise has been documented in early stage and several late-stage clinical trials in a variety of cancers. Although originally prized for their direct ... Full text Link to item Cite

Induction of viral, 7-methyl-guanosine cap-independent translation and oncolysis by mitogen-activated protein kinase-interacting kinase-mediated effects on the serine/arginine-rich protein kinase.

Journal article J Virol · November 2014 UNLABELLED: Protein synthesis, the most energy-consuming process in cells, responds to changing physiologic priorities, e.g., upon mitogen- or stress-induced adaptations signaled through the mitogen-activated protein kinases (MAPKs). The prevailing status ... Full text Link to item Cite

miR-33a promotes glioma-initiating cell self-renewal via PKA and NOTCH pathways.

Journal article J Clin Invest · October 2014 Glioblastoma (GBM) is the most common and lethal brain tumor in adults. Glioma-initiating cells (GICs) are stem-like cells that have been implicated in glioblastoma progression and recurrence; however, the distinct properties of GICs and non-GICs within GB ... Full text Link to item Cite

EGFR phosphorylation of DCBLD2 recruits TRAF6 and stimulates AKT-promoted tumorigenesis.

Journal article J Clin Invest · September 2014 Aberrant activation of EGFR in human cancers promotes tumorigenesis through stimulation of AKT signaling. Here, we determined that the discoidina neuropilin-like membrane protein DCBLD2 is upregulated in clinical specimens of glioblastomas and head and nec ... Full text Open Access Link to item Cite

Malignant brainstem gliomas in adults: clinicopathological characteristics and prognostic factors.

Journal article J Neurooncol · August 2014 Adult malignant brainstem gliomas (BSGs) are poorly characterized due to their relative rarity. We have examined histopathologically confirmed cases of adult malignant BSGs to better characterize the patient and tumor features and outcomes, including the n ... Full text Link to item Cite

Exome sequencing identifies somatic gain-of-function PPM1D mutations in brainstem gliomas.

Journal article Nat Genet · July 2014 Gliomas arising in the brainstem and thalamus are devastating tumors that are difficult to surgically resect. To determine the genetic and epigenetic landscape of these tumors, we performed exomic sequencing of 14 brainstem gliomas (BSGs) and 12 thalamic g ... Full text Link to item Cite

Idh1 mutations as a immunotherapeutic target for brain tumors.

Journal article Neuro Oncol · July 2014 Immunotherapy promises an exquisitely precise therapeutic approach, and substantial evidence suggests that activated T cells can eradicate large tumors, even within the "immunologically privileged" brain. EGFRvIII and isocitrate dehydrogenase 1 (IDH1) muta ... Full text Link to item Cite

Oncolytic polio/rhinovirus recombinant (pvsripo) in recurrent glioblastoma (gbm): first phase I clinical trial evaluating the intratumoral administration.

Journal article Neuro Oncol · July 2014 PVSRIPO is the live attenuated, oral (SABIN) serotype 1 poliovirus vaccine containing a heterologous internal ribosomal entry site stemming from human rhinovirus type 2. PVSRIPO recognizes nectin-like molecule-5, an oncofetal cell adhesion molecule and tum ... Full text Link to item Cite

Oncolytic poliovirus immunotherapy of glioblastoma.

Journal article Neuro Oncol · July 2014 With the exception of Burkitt lymphoma, almost all solid cancers are susceptible to infection with poliovirus, due to widespread ectopic expression of the poliovirus receptor, the onco-fetal cell adhesion molecule Necl5/CD155. We engineered a profoundly CN ... Full text Link to item Cite

Tert promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal.

Journal article Neuro Oncol · July 2014 Malignant cells must maintain their telomeres, but genetic mechanisms responsible for telomere maintenance in tumors have only recently been discovered. In particular, mutations of the telomere binding proteins alpha thalassemia/mental retardation syndrome ... Full text Link to item Cite

Identification and preliminary treatment data of xenografts representing tcga-defined subtypes.

Journal article Neuro Oncol · July 2014 The Cancer Genome Atlas (TCGA) Network recently catalogued recurrent genomic abnormalities in glioblastoma (GBM). This genomic profiling lead to the molecular classification of GBMs into four subtypes: Proneural, Neural, Classical and Mesenchymal. The impo ... Full text Link to item Cite

AJAP1 is dysregulated at an early stage of gliomagenesis and suppresses invasion through cytoskeleton reorganization.

Journal article CNS Neurosci Ther · May 2014 AIMS: Down-regulation of AJAP1 in glioblastoma multiforme (GBM) has been reported. However, the expression profiles of AJAP1 in gliomas and the underlying mechanisms of AJAP1 function on invasion are still poorly understood. METHODS: The gene profiles of A ... Full text Link to item Cite

Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas.

Journal article Oncotarget · March 30, 2014 Frequent mutations in isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) and the promoter of telomerase reverse transcriptase (TERT) represent two significant discoveries in glioma genomics. Understanding the degree to which these two mutations co-occur or o ... Full text Open Access Link to item Cite

The genetic landscape of anaplastic astrocytoma.

Journal article Oncotarget · March 30, 2014 Anaplastic astrocytoma WHO grade III (A3) is a lethal brain tumor that often occurs in middle aged patients. Clinically, it is challenging to distinguish A3 from glioblastoma multiforme (GBM) WHO grade IV. To reveal the genetic landscape of this tumor type ... Full text Link to item Cite

EGFRvIII-specific chimeric antigen receptor T cells migrate to and kill tumor deposits infiltrating the brain parenchyma in an invasive xenograft model of glioblastoma.

Journal article PLoS One · 2014 Glioblastoma (GBM) is the most common primary malignant brain tumor in adults and is uniformly lethal. T-cell-based immunotherapy offers a promising platform for treatment given its potential to specifically target tumor tissue while sparing the normal bra ... Full text Open Access Link to item Cite

Exome sequencing identifies somatic gain-of-function PPM1D mutations in brainstem gliomas

Journal article Nature Genetics · January 1, 2014 Gliomas arising in the brainstem and thalamus are devastating tumors that are difficult to surgically resect. To determine the genetic and epigenetic landscape of these tumors, we performed exomic sequencing of 14 brainstem gliomas (BSGs) and 12 thalamic g ... Full text Cite

Intracerebral delivery of a third generation EGFRvIII-specific chimeric antigen receptor is efficacious against human glioma.

Journal article J Clin Neurosci · January 2014 Chimeric antigen receptors (CAR)-transduced T cells hold great promise in the treatment of malignant disease. Here, we demonstrate that intracerebral injection with a human, epidermal growth factor receptor variant III (EGFRvIII)-specific, third generation ... Full text Link to item Cite

A novel recombinant immunotoxin-based therapy targeting wild-type and mutant EGFR improves survival in murine models of glioblastoma.

Journal article Oncoimmunology · December 1, 2013 Both the amplification of the gene coding for wild-type (wt) epidermal growth factor receptor (EGFR) and the overexpression of the EGFR deletion mutant, commonly known as EGFRvIII, are hallmarks of glioblastoma. We have recently reported a novel, recombina ... Full text Open Access Link to item Cite

Regulatory T cells are redirected to kill glioblastoma by an EGFRvIII-targeted bispecific antibody.

Journal article Oncoimmunology · December 1, 2013 Regulatory T cells (Tregs) play a central role in in tumor escape from immunosurveillance. We report that a bispecific T-cell engager (BiTE) targeting a mutated form of the epidermal growth factor receptor, i.e., EGFRvIII, potently redirects Tregs to kill ... Full text Link to item Cite

TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma

Journal article Acta Neuropathologica · December 1, 2013 Telomerase reverse transcriptase (TERT) promoter mutations were recently shown to drive telomerase activity in various cancer types, including medulloblastoma. However, the clinical and biological implications of TERT mutations in medulloblastoma have not ... Full text Cite

A novel recombinant immunotoxin-based therapy targeting wild-type and mutant EGFR improves survival in murine models of glioblastoma

Journal article Oncoimmunology · December 1, 2013 Both the amplification of the gene coding for wild-type (wt) epidermal growth factor receptor (EGFR) and the overexpression of the EGFR deletion mutant, commonly known as EGFRvIII, are hallmarks of glioblastoma. We have recently reported a novel, recombina ... Full text Cite

Regulatory T cells are redirected to kill glioblastoma by an EGFRviii-targeted bispecific antibody

Journal article Oncoimmunology · December 1, 2013 Regulatory T cells (Tregs) play a central role in in tumor escape from immunosurveillance. We report that a bispecific T-cell engager (BiTE) targeting a mutated form of the epidermal growth factor receptor, i.e., EGFRvIII, potently redirects Tregs to kill ... Full text Cite

Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis.

Journal article J Neurosurg · December 2013 OBJECT: Recurrent malignant gliomas have inherent resistance to traditional chemotherapy. Novel therapies target specific molecular mechanisms involved in abnormal signaling and resistance to apoptosis. The proteasome is a key regulator of multiple cellula ... Full text Link to item Cite

TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma.

Journal article Acta Neuropathol · December 2013 Telomerase reverse transcriptase (TERT) promoter mutations were recently shown to drive telomerase activity in various cancer types, including medulloblastoma. However, the clinical and biological implications of TERT mutations in medulloblastoma have not ... Full text Link to item Cite

KMT2D maintains neoplastic cell proliferation and global histone H3 lysine 4 monomethylation.

Journal article Oncotarget · November 2013 KMT2D (lysine (K)-specific methyltransferase 2D), formerly named MLL2 (myeloid/lymphoid or mixed-lineage leukemia 2, also known as ALR/MLL4), is a histone methyltransferase that plays an important role in regulating gene transcription. In particular, it ta ... Full text Link to item Cite

Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis.

Journal article Lancet Oncol · November 2013 BACKGROUND: Recurrent medulloblastoma is a therapeutic challenge because it is almost always fatal. Studies have confirmed that medulloblastoma consists of at least four distinct subgroups. We sought to delineate subgroup-specific differences in medullobla ... Full text Link to item Cite

The somatic genomic landscape of glioblastoma.

Journal article Cell · October 10, 2013 We describe the landscape of somatic genomic alterations based on multidimensional and comprehensive characterization of more than 500 glioblastoma tumors (GBMs). We identify several novel mutated genes as well as complex rearrangements of signature recept ... Full text Link to item Cite

The integrated landscape of driver genomic alterations in glioblastoma.

Journal article Nat Genet · October 2013 Glioblastoma is one of the most challenging forms of cancer to treat. Here we describe a computational platform that integrates the analysis of copy number variations and somatic mutations and unravels the landscape of in-frame gene fusions in glioblastoma ... Full text Link to item Cite

Rational design and generation of recombinant control reagents for bispecific antibodies through CDR mutagenesis.

Journal article J Immunol Methods · September 30, 2013 Developments in the field of bispecific antibodies have progressed rapidly in recent years, particularly in their potential role for the treatment of malignant disease. However, manufacturing stable molecules has proven to be costly and time-consuming, whi ... Full text Link to item Cite

Human regulatory T cells kill tumor cells through granzyme-dependent cytotoxicity upon retargeting with a bispecific antibody.

Journal article Cancer Immunol Res · September 2013 A major mechanism by which human regulatory T cells (T(regs)) have been shown to suppress and kill autologous immune cells is through the granzyme-perforin pathway. However, it is unknown whether T(regs) also possess the capacity to kill tumor cells using ... Full text Link to item Cite

Construction of an immunotoxin, D2C7-(scdsFv)-PE38KDEL, targeting EGFRwt and EGFRvIII for brain tumor therapy.

Journal article Clin Cancer Res · September 1, 2013 PURPOSE: The EGF receptor gene (EGFR) is most frequently amplified and overexpressed, along with its deletion mutant, EGFRvIII, in glioblastoma. We tested the preclinical efficacy of the recombinant immunotoxin, D2C7-(scdsFv)-PE38KDEL, which is reactive wi ... Full text Link to item Cite

107 Dose-finding and safety study of an oncolytic polio/rhinovirus recombinant against recurrent glioblastoma.

Journal article Neurosurgery · August 2013 Current therapies for glioblastoma are limited by ineffective delivery beyond the blood-brain barrier, limited diffusion of regionally-delivered macromolecules, and lack of tumor specificity. Sustained direct intracerebral infusion at slow flow rates [conv ... Full text Link to item Cite

Antibody, T-cell and dendritic cell immunotherapy for malignant brain tumors.

Journal article Future Oncol · July 2013 Modest improvement in brain tumor patient survival has been achieved through advances in surgical, adjuvant radiation and chemotherapeutic strategies. However, these traditional approaches have been unsuccessful in permanently controlling these aggressive ... Full text Link to item Cite

An EGFRvIII-targeted bispecific T-cell engager overcomes limitations of the standard of care for glioblastoma.

Journal article Expert Rev Clin Pharmacol · July 2013 While advanced surgical techniques, radiation therapy and chemotherapeutic regimens provide a tangible benefit for patients with glioblastoma (GBM), the average survival from the time of diagnosis remains less than 15 months. Current therapy for GBM is lim ... Full text Link to item Cite

Isocitrate dehydrogenase 1: what it means to the neurosurgeon: a review.

Journal article J Neurosurg · June 2013 Isocitrate dehydrogenase 1 (IDH1) mutations have been discovered to be frequent and highly conserved in secondary glioblastoma multiforme and lower-grade gliomas. Although IDH1 mutations confer a unique genotype that has been associated with a favorable pr ... Full text Link to item Cite

BLyS levels correlate with vaccine-induced antibody titers in patients with glioblastoma lymphodepleted by therapeutic temozolomide.

Journal article Cancer Immunol Immunother · June 2013 B lymphocyte stimulator (BLyS) is a cytokine involved in differentiation and survival of follicular B cells along with humoral response potentiation. Lymphopenia is known to precipitate dramatic elevation in serum BLyS; however, the use of this effect to e ... Full text Link to item Cite

Recombinant anti-podoplanin (NZ-1) immunotoxin for the treatment of malignant brain tumors.

Journal article Int J Cancer · May 15, 2013 Our study demonstrates the glioma tumor antigen podoplanin to be present at very high levels (>90%) in both glioblastoma (D2159MG, D08-0308MG and D08-0493MG) and medulloblastoma (D283MED, D425MED and DAOY) xenografts and cell line. We constructed a novel r ... Full text Link to item Cite

Current immunotherapeutic targets in gliomas

Journal article · May 1, 2013 The prospect for high-grade astrocytic tumor patients continues to be dismal, evenwith advances in surgery, radiotherapy, and chemotherapy. There is a need for thedevelopment of novel therapies that would eliminate the heterogeneous and diffuseastrocytic t ... Cite

TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal.

Journal article Proc Natl Acad Sci U S A · April 9, 2013 Malignant cells, like all actively growing cells, must maintain their telomeres, but genetic mechanisms responsible for telomere maintenance in tumors have only recently been discovered. In particular, mutations of the telomere binding proteins alpha thala ... Full text Link to item Cite

A novel bispecific antibody recruits T cells to eradicate tumors in the "immunologically privileged" central nervous system.

Journal article Oncoimmunology · April 1, 2013 Bispecific T-cell engagers (BiTEs) may break multiple barriers that currently limit the use of immunotherapy in glioblastoma patients. We have recently described a novel BiTE specific for a mutated form of the epidermal growth factor receptor, EGFRvIII, th ... Full text Link to item Cite

Exomic sequencing of four rare central nervous system tumor types.

Journal article Oncotarget · April 2013 A heterogeneous population of uncommon neoplasms of the central nervous system (CNS) cause significant morbidity and mortality. To explore their genetic origins, we sequenced the exomes of 12 pleomorphic xanthoastrocytomas (PXA), 17 non-brainstem pediatric ... Full text Link to item Cite

Reversing the Warburg effect as a treatment for glioblastoma.

Journal article J Biol Chem · March 29, 2013 Glioblastoma multiforme (GBM), like most cancers, possesses a unique bioenergetic state of aerobic glycolysis known as the Warburg effect. Here, we documented that methylene blue (MB) reverses the Warburg effect evidenced by the increasing of oxygen consum ... Full text Link to item Cite

Rindopepimut: anti-EGFRvIII peptide vaccine, oncolytic.

Journal article Drugs Future · March 2013 Glioblastoma, the most common primary malignant brain tumor, is among the most difficult cancers to treat. Despite the aggressive standard of care, including surgical removal followed by radiotherapy with concomitant and adjuvant chemotherapy, the often su ... Full text Link to item Cite

Disruption of wild-type IDH1 suppresses D-2-hydroxyglutarate production in IDH1-mutated gliomas.

Journal article Cancer Res · January 15, 2013 Point mutations at Arg132 of the cytoplasmic NADP(+)-dependent isocitrate dehydrogenase 1 (IDH1) occur frequently in gliomas and result in a gain of function to produce the "oncometabolite" D-2-hydroxyglutarate (D-2HG). The mutated IDH1 allele is usually a ... Full text Open Access Link to item Cite

Systemic administration of a bispecific antibody targeting EGFRvIII successfully treats intracerebral glioma.

Journal article Proc Natl Acad Sci U S A · January 2, 2013 Bispecific antibodies (bscAbs), particularly those of the bispecific T-cell engager (BiTE) subclass, have been shown to effectively redirect T cells against cancer. Previous efforts to target antigens expressed in both tumors and normal tissues have produc ... Full text Link to item Cite

The integrated landscape of driver genomic alterations in glioblastoma

Journal article Nature Genetics · 2013 Glioblastoma is one of the most challenging forms of cancer to treat. Here we describe a computational platform that integrates the analysis of copy number variations and somatic mutations and unravels the landscape of in-frame gene fusions in glioblastoma ... Full text Cite

Mibefradil, a novel therapy for glioblastoma multiforme: cell cycle synchronization and interlaced therapy in a murine model.

Journal article J Neurooncol · January 2013 Glioblastoma multiforme (GBM) is a devastating disease with a dismal prognosis and a very limited response to treatment. The current standard of care for GBM usually consists of surgery, radiation and chemotherapy with the alkylating agent temozolomide, al ... Full text Link to item Cite

Myeloablative temozolomide enhances CD8⁺ T-cell responses to vaccine and is required for efficacy against brain tumors in mice.

Journal article PLoS One · 2013 Temozolomide (TMZ) is an alkylating agent shown to prolong survival in patients with high grade glioma and is routinely used to treat melanoma brain metastases. A prominent side effect of TMZ is induction of profound lymphopenia, which some suggest may be ... Full text Open Access Link to item Cite

Affinity-matured recombinant immunotoxin targeting gangliosides 3'-isoLM1 and 3',6'-isoLD1 on malignant gliomas.

Journal article MAbs · 2013 About 60 percent of glioblastomas highly express the gangliosides 3'-isoLM1 and 3',6'-isoLD1 on the cell surface, providing ideal targets for brain tumor immunotherapy. A novel recombinant immunotoxin, DmAb14m-(scFv)-PE38KDEL (DmAb14m-IT), specific for the ... Full text Link to item Cite

Induction of the unfolded protein response drives enhanced metabolism and chemoresistance in glioma cells.

Journal article PLoS One · 2013 The unfolded protein response (UPR) is an endoplasmic reticulum (ER)-based cytoprotective mechanism acting to prevent pathologies accompanying protein aggregation. It is frequently active in tumors, but relatively unstudied in gliomas. We hypothesized that ... Full text Link to item Cite

Convection enhanced delivery of macromolecules for brain tumors.

Journal article Curr Drug Discov Technol · December 2012 The blood brain barrier (BBB) poses a significant challenge for drug delivery of macromolecules into the brain. Convection-enhanced delivery (CED) circumvents the BBB through direct intracerebral infusion using a hydrostatic pressure gradient to transfer t ... Full text Link to item Cite

A heterozygous IDH1R132H/WT mutation induces genome-wide alterations in DNA methylation.

Journal article Genome Res · December 2012 Monoallelic point mutations of the NADP(+)-dependent isocitrate dehydrogenases IDH1 and IDH2 occur frequently in gliomas, acute myeloid leukemias, and chondromas, and display robust association with specific DNA hypermethylation signatures. Here we show th ... Full text Link to item Cite

Protein typing of circulating microvesicles allows real-time monitoring of glioblastoma therapy.

Journal article Nat Med · December 2012 Glioblastomas shed large quantities of small, membrane-bound microvesicles into the circulation. Although these hold promise as potential biomarkers of therapeutic response, their identification and quantification remain challenging. Here, we describe a hi ... Full text Link to item Cite

Enzyme redesign guided by cancer-derived IDH1 mutations.

Journal article Nat Chem Biol · November 2012 Mutations in an enzyme can result in a neomorphic catalytic activity in cancers. We applied cancer-associated mutations from isocitrate dehydrogenases to homologous residues in the active sites of homoisocitrate dehydrogenases to derive enzymes that cataly ... Full text Link to item Cite

Mechanism of anti-glioma activity and in vivo efficacy of the cannabinoid ligand KM-233.

Journal article J Neurooncol · November 2012 Glioblastoma multiforme (GBM) is the most common and devastating form of primary central nervous system malignancy. The prognosis for patients diagnosed with GBM is poor, having a median survival rate of 12-15 months. Despite modern advances in the develop ... Full text Link to item Cite

Global identification of MLL2-targeted loci reveals MLL2's role in diverse signaling pathways.

Journal article Proc Natl Acad Sci U S A · October 23, 2012 Myeloid/lymphoid or mixed-lineage leukemia (MLL)-family genes encode histone lysine methyltransferases that play important roles in epigenetic regulation of gene transcription. MLL genes are frequently mutated in human cancers. Unlike MLL1, MLL2 (also know ... Full text Link to item Cite

Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients.

Journal article Br J Cancer · October 23, 2012 BACKGROUND: Bevacizumab improves outcome for most recurrent glioblastoma patients, but the duration of benefit is limited and survival after initial bevacizumab progression is poor. We evaluated bevacizumab continuation beyond initial progression among rec ... Full text Open Access Link to item Cite

Subgroup-specific structural variation across 1,000 medulloblastoma genomes.

Journal article Nature · August 2, 2012 Medulloblastoma, the most common malignant paediatric brain tumour, is currently treated with nonspecific cytotoxic therapies including surgery, whole-brain radiation, and aggressive chemotherapy. As medulloblastoma exhibits marked intertumoural heterogene ... Full text Link to item Cite

Mutant IDH1 is required for IDH1 mutated tumor cell growth.

Journal article Oncotarget · August 2012 Frequent somatic hotspot mutations in isocitrate dehydrogenase 1 (IDH1) have been identified in gliomas, acute myeloid leukemias, chondrosarcomas, and other cancers, providing a likely avenue for targeted cancer therapy. However, whether mutant IDH1 protei ... Full text Open Access Link to item Cite

Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas.

Journal article Oncotarget · July 2012 Mutations in the critical chromatin modifier ATRX and mutations in CIC and FUBP1, which are potent regulators of cell growth, have been discovered in specific subtypes of gliomas, the most common type of primary malignant brain tumors. However, the frequen ... Full text Open Access Link to item Cite

Central nervous system

Journal article · March 1, 2012 Several different types of tumors, benign and malignant, have been identified in the central nervous system (CNS). The prognoses for these tumors are related to several factors, such as the age of the patient and the location and histology of the tumor. In ... Full text Cite

Deletion or epigenetic silencing of AJAP1 on 1p36 in glioblastoma.

Journal article Mol Cancer Res · February 2012 Glioblastoma is universally fatal because of its propensity for rapid recurrence due to highly migratory tumor cells. Unraveling the genomic complexity that underlies this migratory characteristic could provide therapeutic targets that would greatly comple ... Full text Link to item Cite

A pilot study of IL-2Rα blockade during lymphopenia depletes regulatory T-cells and correlates with enhanced immunity in patients with glioblastoma.

Journal article PLoS One · 2012 BACKGROUND: Preclinical studies in mice have demonstrated that the prophylactic depletion of immunosuppressive regulatory T-cells (T(Regs)) through targeting the high affinity interleukin-2 (IL-2) receptor (IL-2Rα/CD25) can enhance anti-tumor immunotherapy ... Full text Open Access Link to item Cite

Radioimmunotargeting of malignant glioma by monoclonal antibody D2C7 reactive against both wild-type and variant III mutant epidermal growth factor receptors.

Journal article Nucl Med Biol · January 2012 INTRODUCTION: Malignant glioma remains a significant therapeutic challenge, and immunotherapeutics might be a beneficial approach for these patients. A monoclonal antibody (MAb) specific for multiple molecular targets could expand the treatable patient pop ... Full text Link to item Cite

Somatic mutations in the chromatin remodeling gene ARID1A occur in several tumor types.

Journal article Hum Mutat · January 2012 Mutations in the chromatin remodeling gene ARID1A have recently been identified in the majority of ovarian clear cell carcinomas (OCCCs). To determine the prevalence of mutations in other tumor types, we evaluated 759 malignant neoplasms including those of ... Full text Link to item Cite

Aberrant Otx2 expression enhances migration and induces ectopic proliferation of hindbrain neuronal progenitor cells.

Journal article PLoS One · 2012 Dysregulation of Otx2 is a hallmark of the pediatric brain tumor medulloblastoma, yet its functional significance in the establishment of these tumors is unknown. Here we have sought to determine the functional consequences of Otx2 overexpression in the mo ... Full text Link to item Cite

Toxin-based targeted therapy for malignant brain tumors.

Journal article Clin Dev Immunol · 2012 Despite advances in conventional treatment modalities for malignant brain tumors-surgery, radiotherapy, and chemotherapy-the prognosis for patients with high-grade astrocytic tumor remains dismal. The highly heterogeneous and diffuse nature of astrocytic t ... Full text Open Access Link to item Cite

Immunotherapy of brain tumors.

Journal article Handb Clin Neurol · 2012 Full text Link to item Cite

Monoclonal antibody blockade of IL-2 receptor α during lymphopenia selectively depletes regulatory T cells in mice and humans.

Journal article Blood · September 15, 2011 Lymphodepletion augments adoptive cell transfer during antitumor immunotherapy, producing dramatic clinical responses in patients with malignant melanoma. We report that the lymphopenia induced by the chemotherapeutic agent temozolomide (TMZ) enhances vacc ... Full text Link to item Cite

Mutations in CIC and FUBP1 contribute to human oligodendroglioma.

Journal article Science · September 9, 2011 Oligodendrogliomas are the second most common malignant brain tumor in adults and exhibit characteristic losses of chromosomes 1p and 19q. To identify the molecular genetic basis for this alteration, we performed exomic sequencing of seven tumors. Among ot ... Full text Link to item Cite

Convection-enhanced delivery.

Journal article J Neurosurg · September 2011 Full text Link to item Cite

Colocalization of gadolinium-diethylene triamine pentaacetic acid with high-molecular-weight molecules after intracerebral convection-enhanced delivery in humans.

Journal article Neurosurgery · September 2011 BACKGROUND: Convection-enhanced delivery (CED) permits site-specific therapeutic drug delivery within interstitial spaces at increased dosages through circumvention of the blood-brain barrier. CED is currently limited by suboptimal methodologies for monito ... Full text Link to item Cite

Reply to M.S. Lesniak

Journal article Journal of Clinical Oncology · August 1, 2011 Full text Cite

Altered telomeres in tumors with ATRX and DAXX mutations.

Journal article Science · July 22, 2011 The proteins encoded by ATRX and DAXX participate in chromatin remodeling at telomeres and other genomic sites. Because inactivating mutations of these genes are common in human pancreatic neuroendocrine tumors (PanNETs), we examined the telomere status of ... Full text Link to item Cite

Affinity-matured anti-glycoprotein NMB recombinant immunotoxins targeting malignant gliomas and melanomas.

Journal article Int J Cancer · July 1, 2011 Glycoprotein NMB (GPNMB), a transmembrane glycoprotein highly expressed in high-grade gliomas (HGGs), is an attractive target in cancer immunotherapy. We isolated a GPNMB-specific scFv clone, G49, from a human synthetic phage-display library. To obtain mut ... Full text Link to item Cite

Bispecific antibodies engage T cells for antitumor immunotherapy.

Journal article Expert Opin Biol Ther · July 2011 INTRODUCTION: Although considerable evidence supports the hypothesis that T cells play a critical role in the immune response against cancer, the ability to mount and sustain tumor-specific cellular responses in vivo remains a challenge. A strategy that ha ... Full text Link to item Cite

The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma.

Journal article Clin Cancer Res · June 15, 2011 PURPOSE: To determine if the addition of bevacizumab to radiation therapy and temozolomide, followed by bevacizumab, temozolomide, and irinotecan, for newly diagnosed glioblastoma patients is safe and effective. EXPERIMENTAL DESIGN: A total of 75 patients ... Full text Link to item Cite

Reply to M.C. Chamberlain

Journal article Journal of Clinical Oncology · June 10, 2011 Full text Cite

Medical diagnostic radiation exposures and risk of gliomas.

Journal article Radiat Res · June 2011 High-dose ionizing radiation is an established risk factor for glioma, but it remains unknown whether moderate- and low-dose radiation increase glioma risk. In this analysis, we assessed the evidence that self-reported exposures to diagnostic ionizing radi ... Full text Link to item Cite

Abstract 4417: Characterization of xenograft-derived EGFRvIII-positive GBM cell cultures reveals functional interactions between EGFRvIII, wild-type EGFR, and p53

Journal article Cancer Research · April 15, 2011 AbstractIn 20% – 30% of all glioblastomas (GBMs), the most common and deadly form of glioma, gene rearrangements in amplified epidermal growth factor receptor (EGFR) cause amplification of a highly oncogenic ... Full text Cite

A review of VEGF/VEGFR-targeted therapeutics for recurrent glioblastoma.

Journal article J Natl Compr Canc Netw · April 2011 Glioblastoma, the most common primary malignant brain tumor among adults, is a highly angiogenic and deadly tumor. Angiogenesis in glioblastoma, driven by hypoxia-dependent and independent mechanisms, is primarily mediated by vascular endothelial growth fa ... Full text Link to item Cite

Monitoring radiographic brain tumor progression.

Journal article Toxins (Basel) · March 2011 Determining radiographic progression in primary malignant brain tumors has posed a significant challenge to the neuroncology community. Glioblastoma multiforme (GBM, WHO Grade IV) through its inherent heterogeneous enhancement, growth patterns, and irregul ... Full text Link to item Cite

Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma.

Journal article Neuro Oncol · March 2011 Epidermal growth factor receptor variant III (EGFRvIII) is a tumor-specific mutation widely expressed in glioblastoma multiforme (GBM) and other neoplasms, but absent from normal tissues. Immunotherapeutic targeting of EGFRvIII could eliminate neoplastic c ... Full text Link to item Cite

Imaging of convection enhanced delivery of toxins in humans.

Journal article Toxins (Basel) · March 2011 Drug delivery of immunotoxins to brain tumors circumventing the blood brain barrier is a significant challenge. Convection-enhanced delivery (CED) circumvents the blood brain barrier through direct intracerebral application using a hydrostatic pressure gra ... Full text Link to item Cite

Compact point-detection fluorescence spectroscopy system for quantifying intrinsic fluorescence redox ratio in brain cancer diagnostics.

Journal article J Biomed Opt · March 2011 We report the development of a compact point-detection fluorescence spectroscopy system and two data analysis methods to quantify the intrinsic fluorescence redox ratio and diagnose brain cancer in an orthotopic brain tumor rat model. Our system employs on ... Full text Link to item Cite

Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome.

Journal article Proc Natl Acad Sci U S A · February 22, 2011 Point mutations of the NADP(+)-dependent isocitrate dehydrogenases 1 and 2 (IDH1 and IDH2) occur early in the pathogenesis of gliomas. When mutated, IDH1 and IDH2 gain the ability to produce the metabolite (R)-2-hydroxyglutarate (2HG), but the downstream e ... Full text Link to item Cite

2-hydroxyglutarate production, but not dominant negative function, is conferred by glioma-derived NADP-dependent isocitrate dehydrogenase mutations.

Journal article PLoS One · February 4, 2011 BACKGROUND: Gliomas frequently contain mutations in the cytoplasmic NADP(+)-dependent isocitrate dehydrogenase (IDH1) or the mitochondrial NADP(+)-dependent isocitrate dehydrogenase (IDH2). Several different amino acid substitutions recur at either IDH1 R1 ... Full text Link to item Cite

Assessment of type of allergy and antihistamine use in the development of glioma.

Journal article Cancer Epidemiol Biomarkers Prev · February 2011 BACKGROUND: Allergies have been associated with decreased risk of glioma; but, associations between duration and timing of allergies, and antihistamine use and glioma risk have been less consistent. The objective was to investigate this association by anal ... Full text Link to item Cite

Cellular redox modulator, ortho Mn(III) meso-tetrakis(N-n-hexylpyridinium-2-yl)porphyrin, MnTnHex-2-PyP(5+) in the treatment of brain tumors.

Journal article Anticancer Agents Med Chem · February 2011 Despite intensive efforts to improve multimodal treatment of brain tumor, survival remains limited. Current therapy consists of a combination of surgery, irradiation and chemotherapy with predisposition to long-term complications. Identifying novel targete ... Full text Link to item Cite

The genetic landscape of the childhood cancer medulloblastoma.

Journal article Science · January 28, 2011 Medulloblastoma (MB) is the most common malignant brain tumor of children. To identify the genetic alterations in this tumor type, we searched for copy number alterations using high-density microarrays and sequenced all known protein-coding genes and micro ... Full text Link to item Cite

A novel method for volumetric MRI response assessment of enhancing brain tumors.

Journal article PLoS One · January 26, 2011 Current radiographic response criteria for brain tumors have difficulty describing changes surrounding postoperative resection cavities. Volumetric techniques may offer improved assessment, however usually are time-consuming, subjective and require expert ... Full text Link to item Cite

Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma.

Journal article J Neurooncol · January 2011 Sorafenib, an oral VEGFR-2, Raf, PDGFR, c-KIT and Flt-3 inhibitor, is active against renal cell and hepatocellular carcinomas, and has recently demonstrated promising activity for lung and breast cancers. In addition, various protracted temozolomide dosing ... Full text Link to item Cite

Allan J. Yates, MD, PhD, FRCP(C) (1943–2010)

Journal article Journal of Neuropathology & Experimental Neurology · December 2010 Full text Cite

Multiple phenotypic changes in mice after knockout of the B3gnt5 gene, encoding Lc3 synthase--a key enzyme in lacto-neolacto ganglioside synthesis.

Journal article BMC Dev Biol · November 18, 2010 BACKGROUND: Ganglioside biosynthesis occurs through a multi-enzymatic pathway which at the lactosylceramide step is branched into several biosynthetic series. Lc3 synthase utilizes a variety of galactose-terminated glycolipids as acceptors by establishing ... Full text Open Access Link to item Cite

Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma.

Journal article J Clin Oncol · November 1, 2010 PURPOSE: Immunologic targeting of tumor-specific gene mutations may allow precise eradication of neoplastic cells without toxicity. Epidermal growth factor receptor variant III (EGFRvIII) is a constitutively activated and immunogenic mutation not expressed ... Full text Link to item Cite

Decoupling of DNA damage response signaling from DNA damages underlies temozolomide resistance in glioblastoma cells.

Journal article J Biomed Res · November 2010 Glioblastoma multiforme (GBM) is the most aggressive primary brain tumor in adults. Current therapy includes surgery, radiation and chemotherapy with temozolomide (TMZ). Major determinants of clinical response to TMZ include methylation status of the O6-me ... Full text Link to item Cite

Anti-EGFRvIII monoclonal antibody armed with 177Lu: in vivo comparison of macrocyclic and acyclic ligands.

Journal article Nucl Med Biol · October 2010 INTRODUCTION: Monoclonal antibody (mAb) L8A4 binds specifically to the epidermal growth factor receptor variant III (EGFRvIII) that is present on gliomas but not on normal tissues, and is internalized rapidly after receptor binding. Because of the short ra ... Full text Link to item Cite

Evaluation of anti-podoplanin rat monoclonal antibody NZ-1 for targeting malignant gliomas.

Journal article Nucl Med Biol · October 2010 INTRODUCTION: Podoplanin/aggrus is a mucin-like sialoglycoprotein that is highly expressed in malignant gliomas. Podoplanin has been reported to be a novel marker to enrich tumor-initiating cells, which are thought to resist conventional therapies and to b ... Full text Link to item Cite

Epidermal growth factor receptor variant III mediates head and neck cancer cell invasion via STAT3 activation.

Journal article Oncogene · September 16, 2010 Epidermal growth factor receptor (EGFR) is frequently overexpressed in head and neck squamous cell carcinoma (HNSCC) where aberrant signaling downstream of this receptor contributes to tumor growth. EGFR variant III (EGFRvIII) is the most commonly altered ... Full text Link to item Cite

MRP3: a molecular target for human glioblastoma multiforme immunotherapy.

Journal article BMC Cancer · September 1, 2010 BACKGROUND: Glioblastoma multiforme (GBM) is refractory to conventional therapies. To overcome the problem of heterogeneity, more brain tumor markers are required for prognosis and targeted therapy. We have identified and validated a promising molecular th ... Full text Open Access Link to item Cite

HDMX regulates p53 activity and confers chemoresistance to 3-bis(2-chloroethyl)-1-nitrosourea.

Journal article Neuro Oncol · September 2010 Glioblastoma multiforme (GBM) is one of the deadliest tumors afflicting humans, and the mechanisms of its onset and progression remain largely undefined. Our attempts to elucidate its molecular pathogenesis through DNA copy-number analysis by genome-wide d ... Full text Link to item Cite

Recombinant single-chain variable fragment antibodies against extracellular epitopes of human multidrug resistance protein MRP3 for targeting malignant gliomas.

Journal article Int J Cancer · August 1, 2010 Multidrug resistance protein 3 (MRP3), a multidrug resistance protein identified by serial analysis of gene expression as a glioblastoma multiforme (GBM)-associated molecule, is highly expressed in GBM, but not in normal brain cells. Thus, MRP3 is a candid ... Full text Link to item Cite

Integrated genomic analyses identify ERRFI1 and TACC3 as glioblastoma-targeted genes.

Journal article Oncotarget · August 2010 The glioblastoma genome displays remarkable chromosomal aberrations, which harbor critical glioblastoma-specific genes contributing to several oncogenetic pathways. To identify glioblastoma-targeted genes, we completed a multifaceted genome-wide analysis t ... Full text Link to item Cite

IDH1(R132) mutation identified in one human melanoma metastasis, but not correlated with metastases to the brain.

Journal article Biochem Biophys Res Commun · July 30, 2010 Isocitrate dehydrogenase 1 (IDH1) and isocitrate dehydrogenase 2 (IDH2) are enzymes which convert isocitrate to alpha-ketoglutarate while reducing nicotinamide adenine dinucleotide phosphate (NADP+to NADPH). IDH1/2 were recently identified as mutated in a ... Full text Open Access Link to item Cite

Convection-enhanced delivery of free gadolinium with the recombinant immunotoxin MR1-1.

Journal article J Neurooncol · May 2010 A major obstacle in glioblastoma (GBM) therapy is the restrictive nature of the blood-brain barrier (BBB). Convection-enhanced delivery (CED) is a novel method of drug administration which allows direct parenchymal infusion of therapeutics, bypassing the B ... Full text Link to item Cite

Abstract 5611: Interleukin-2 receptor α (IL-2R α/CD25)-specific antibodies eliminate regulatory T-cells (TRegs) and enhance tumor-specific immune responses

Journal article Cancer Research · April 15, 2010 AbstractInterleukin-2 Receptor α (IL-2R α / CD25)-specific Antibodies Eliminate Regulatory T-cells (TRegs) and enhance Tumor-specific Immune ResponsesDuke University Medical ... Full text Cite

Genetic and epigenetic inactivation of Kruppel-like factor 4 in medulloblastoma.

Journal article Neoplasia · January 2010 Although medulloblastoma is the most common pediatric malignant brain tumor, its molecular underpinnings are largely unknown. We have identified rare, recurrent homozygous deletions of Kruppel-like Factor 4 (KLF4) in medulloblastoma using high-resolution s ... Full text Link to item Cite

GMab-1, a high-affinity anti-3'-isoLM1/3',6'-isoLD1 IgG monoclonal antibody, raised in lacto-series ganglioside-defective knockout mice.

Journal article Biochem Biophys Res Commun · January 1, 2010 The lacto-series gangliosides 3'-isoLM1 and 3',6'-isoLD1 have been identified as tumor-associated antigens whose formation is initiated by the Lc3-synthase. Until now, high-affinity IgG monoclonal antibodies (mAbs) against 3'-isoLM1 and 3',6'-isoLD1, which ... Full text Link to item Cite

OTX2 is critical for the maintenance and progression of Shh-independent medulloblastomas.

Journal article Cancer Res · January 1, 2010 OTX2 is a developmentally regulated transcription factor involved in early morphogenesis of the central nervous system. This gene is amplified and overexpressed in medulloblastoma cell lines, but the nature and extent of its genetic alterations in primary ... Full text Link to item Cite

Central nervous system.

Journal article Cancer Biomark · 2010 Several different types of tumors, benign and malignant, have been identified in the central nervous system (CNS). The prognoses for these tumors are related to several factors, such as the age of the patient and the location and histology of the tumor. In ... Full text Link to item Cite

A monoclonal antibody IMab-1 specifically recognizes IDH1R132H, the most common glioma-derived mutation.

Journal article Biochem Biophys Res Commun · December 18, 2009 IDH1 (isocitrate dehydrogenase 1) mutations have been identified as early and frequent genetic alterations in astrocytomas, oligodendrogliomas, and oligoastrocytomas as well as secondary glioblastomas. In contrast, primary glioblastomas very rarely contain ... Full text Link to item Cite

Mutant metabolic enzymes are at the origin of gliomas.

Journal article Cancer Res · December 15, 2009 Mutations of the isocitrate dehydrogenase (IDH) metabolic enzymes IDH1 and IDH2 have been found to be frequent and early genetic alterations in astrocytomas and oligodendrogliomas. All mutations identified to date affect a single amino acid located within ... Full text Link to item Cite

Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study.

Journal article Br J Cancer · December 15, 2009 BACKGROUND: We evaluated bevacizumab with metronomic etoposide among recurrent malignant glioma patients in a phase 2, open-label trial. METHODS: A total of 59 patients, including 27 with glioblastoma (GBM) and 32 with grade 3 malignant glioma, received 10 ... Full text Open Access Link to item Cite

Detection of amino-terminal extracellular domain of somatostatin receptor 2 by specific monoclonal antibodies and quantification of receptor density in medulloblastoma.

Journal article Hybridoma (Larchmt) · December 2009 Somatostatin receptor 2 (SSTR2) is expressed by most medulloblastomas (MEDs). We isolated monoclonal antibodies (MAbs) to the 12-mer (33)QTEPYYDLTSNA(44), which resides in the extracellular domain of the SSTR2 amino terminus, screened the peptide-bound MAb ... Full text Open Access Link to item Cite

Glioblastoma proto-oncogene SEC61gamma is required for tumor cell survival and response to endoplasmic reticulum stress.

Journal article Cancer Res · December 1, 2009 Glioblastoma multiforme is the most prevalent type of adult brain tumor and one of the deadliest tumors known to mankind. The genetic understanding of glioblastoma multiforme is, however, limited, and the molecular mechanisms that facilitate glioblastoma m ... Full text Link to item Cite

In Tribute to Mike Traynor (1939–2009)

Journal article Neuro-oncology · December 2009 Full text Cite

Heat shock protein 70-binding protein 1 is highly expressed in high-grade gliomas, interacts with multiple heat shock protein 70 family members, and specifically binds brain tumor cell surfaces.

Journal article Cancer Sci · October 2009 Chaperone proteins and heat shock proteins (HSP) are essential components of cellular protein folding systems under normal conditions; their expression and activities are upregulated during stress. Chronically stressed tumors frequently exhibit high chaper ... Full text Link to item Cite

A sphingosine kinase inhibitor induces cell death in temozolomide resistant glioblastoma cells.

Journal article Cancer Chemother Pharmacol · October 2009 PURPOSE: Sphingosine kinase is an oncogene that is up-regulated in several solid tumors. The product of the sphingosine kinase activity, sphingosine-1-phosphate is a potent mitogen involved in diverse cell processes such as cell survival and migration. Cur ... Full text Link to item Cite

EGFRvIII-targeted vaccination therapy of malignant glioma.

Journal article Brain Pathol · October 2009 Given the highly infiltrative growth pattern of malignant glioma and the lack of specificity associated with currently available treatment regimens, alternative strategies designed to eradicate cancer cells while limiting collateral toxicity in normal tiss ... Full text Link to item Cite

An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme.

Journal article Mol Cancer Ther · October 2009 Conventional therapies for glioblastoma multiforme (GBM) fail to target tumor cells exclusively, such that their efficacy is ultimately limited by nonspecific toxicity. Immunologic targeting of tumor-specific gene mutations, however, may allow more precise ... Full text Link to item Cite

Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma.

Journal article Neuro Oncol · October 2009 This phase I clinical trial conducted with patients who had recurrent or progressive malignant glioma (MG) was designed to determine the maximum tolerated dose (MTD) and toxicity of three different 5-day dosing regimens of temozolomide (TMZ) in combination ... Full text Link to item Cite

Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy.

Journal article Cancer · August 1, 2009 BACKGROUND: Glioblastoma multiforme (GBM), the most lethal type of brain tumor, has a 1-year median survival. The effect of carmustine wafers on the survival of newly diagnosed GBM patients treated with radiotherapy (RT) and concurrent temozolomide (TMZ) p ... Full text Link to item Cite

Glioblastoma multiforme: a review of where we have been and where we are going.

Journal article Expert Opin Investig Drugs · August 2009 Malignant gliomas such as glioblastoma multiforme (GBM) present some of the greatest challenges in the management of cancer patients worldwide, despite notable recent achievements in oncology. Even with aggressive surgical resections using state-of-the-art ... Full text Link to item Cite

Treatment of HER2-positive breast carcinomatous meningitis with intrathecal administration of alpha-particle-emitting (211)At-labeled trastuzumab.

Journal article Nucl Med Biol · August 2009 INTRODUCTION: Carcinomatous meningitis (CM) is a devastating disease characterized by the dissemination of malignant tumor cells into the subarachnoid space along the brain and spine. Systemic treatment with monoclonal antibody (mAb) trastuzumab can be eff ... Full text Link to item Cite

Sample type bias in the analysis of cancer genomes.

Journal article Cancer Res · July 15, 2009 There is widespread agreement that cancer gene discovery requires high-quality tumor samples. However, whether primary tumors or cultured samples are superior for cancer genomics has been a longstanding subject of debate. This debate has recently become mo ... Full text Link to item Cite

Tyrosine phosphorylation of the human glutathione S-transferase P1 by epidermal growth factor receptor.

Journal article J Biol Chem · June 19, 2009 Epidermal growth factor receptor (EGFR) gene amplification, mutations, and/or aberrant activation are frequent abnormalities in malignant gliomas and other human cancers and have been associated with an aggressive clinical course and a poor therapeutic out ... Full text Link to item Cite

Glioblastoma multiforme: a review of therapeutic targets.

Journal article Expert Opin Ther Targets · June 2009 Glioblastoma is the commonest primary brain tumor, as well as the deadliest. Malignant gliomas such as glioblastoma multiforme (GBM) present some of the greatest challenges in the management of cancer patients worldwide, despite notable recent achievements ... Full text Link to item Cite

Bifunctional DNA alkylator 1,3-bis(2-chloroethyl)-1-nitrosourea activates the ATR-Chk1 pathway independently of the mismatch repair pathway.

Journal article Mol Pharmacol · June 2009 The presence of DNA damage initiates signaling through the ataxia-telangiectasia mutated kinase (ATM) and the ATM- and the Rad3-related kinase (ATR), which phosphorylate, thus activating, the checkpoint kinases (Chk) 1 and 2, which leads to cell cycle arre ... Full text Link to item Cite

Effect of daclizumab on TReg counts and EGFRvIII-specific immune responses in GBM.

Journal article J Clin Oncol · May 20, 2009 2034 Background: TRegs are increased in patients with GBM and constitutively express the high affinity interleukin-2 receptor (IL-2Rα). Treatment with an antibody that blocks IL-2Rα signaling functionally inactivates and eliminates TRegs without inducing a ... Link to item Cite

Epidermal growth factor receptor variant III (EGFRvIII) vaccine (CDX-110) in GBM.

Journal article J Clin Oncol · May 20, 2009 2021 Background: Unlike conventional therapies for GBM, immunologic targeting of tumor-specific gene mutations allows precise eradication of neoplastic cells with reduced toxicity. EGFRvIII is a constitutively activated and immunogenic mutation not express ... Link to item Cite

Phase I trial of vendetanib and oral etoposide for recurrent malignant gliomas.

Journal article J Clin Oncol · May 20, 2009 e13016 Background: Recurrent malignant gliomas have a poor prognosis, with a median survival of 6-15 months, with grade 4 glioblastomas more aggressive than grade 3 anaplastic astrocytomas or oligodendrogliomas. Vascular endothelial growth factor (VEGF) an ... Link to item Cite

Temozolomide (TMZ) and bevacizumab (BV) as initial treatment for unresectable or multifocal glioblastoma multiforme (GBM).

Journal article J Clin Oncol · May 20, 2009 e13025 Background: GBMs are vascular tumors and inherently resistant to therapy. The prognosis for patients is poor with a median survival of 9-15 months. Patients with unresectable or multifocal GBMs have an even poorer prognosis, with a median survival o ... Link to item Cite

Identification of microbial DNA in human cancer.

Journal article BMC Med Genomics · May 8, 2009 BACKGROUND: Microorganisms have been associated with many types of human diseases; however, a significant number of clinically important microbial pathogens remain to be discovered. METHODS: We have developed a genome-wide approach, called Digital Karyotyp ... Full text Link to item Cite

Proteomic and immunologic analyses of brain tumor exosomes.

Journal article FASEB J · May 2009 Brain tumors are horrific diseases with almost universally fatal outcomes; new therapeutics are desperately needed and will come from improved understandings of glioma biology. Exosomes are endosomally derived 30-100 nm membranous vesicles released from ma ... Full text Link to item Cite

Glioblastoma Multiforme Oncogenomics and Signaling Pathways.

Journal article Clin Med Oncol · April 8, 2009 In the adult population, glioblastoma multiforme is one of the most common primary brain tumors encountered. Unfortunately, this highly malignant tumor represents over 50% of all types of primary central nervous system gliomas. The vast majority of GBMs de ... Full text Link to item Cite

Association between glioma and history of allergies, asthma, and eczema: a case-control study with three groups of controls.

Journal article Cancer Epidemiol Biomarkers Prev · April 2009 Because glioma etiology is largely unknown, the inverse association of glioma risk with atopic conditions is promising and deserves close scrutiny. We examined the association between a history of allergies, asthma, and eczema, and glioma risk using siblin ... Full text Link to item Cite

Multiple recurrent genetic events converge on control of histone lysine methylation in medulloblastoma.

Journal article Nat Genet · April 2009 We used high-resolution SNP genotyping to identify regions of genomic gain and loss in the genomes of 212 medulloblastomas, malignant pediatric brain tumors. We found focal amplifications of 15 known oncogenes and focal deletions of 20 known tumor suppress ... Full text Link to item Cite

Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma.

Journal article J Clin Oncol · March 10, 2009 PURPOSE: This phase II trial was designed to define the role of O(6)-benzylguanine (O(6)-BG) in restoring temozolomide sensitivity in patients with recurrent or progressive, temozolomide-resistant malignant glioma and to evaluate the safety of administerin ... Full text Link to item Cite

BCNU-sequestration by metallothioneins may contribute to resistance in a medulloblastoma cell line.

Journal article Cancer Chemother Pharmacol · March 2009 PURPOSE: Resistance of neoplastic cells to the alkylating drug BCNU [1,3-bis(2-chloroethyl)-1-nitrosourea] has been correlated with expression of O (6)-methylguanine-DNA methyltransferase, which repairs the O (6)-chloroethylguanine produced by the drug. Ot ... Full text Link to item Cite

Human exposure to selected animal neurocarcinogens: a biomarker-based assessment and implications for brain tumor epidemiology.

Journal article J Toxicol Environ Health B Crit Rev · March 2009 This review is based on the proceedings from the Second Lebow Conference, held in Chicago in 2007. The conference concentrated on developing a framework for innovative studies in the epidemiology of environmental exposures, focusing specifically on the pot ... Full text Link to item Cite

IDH1 and IDH2 mutations in gliomas.

Journal article N Engl J Med · February 19, 2009 BACKGROUND: A recent genomewide mutational analysis of glioblastomas (World Health Organization [WHO] grade IV glioma) revealed somatic mutations of the isocitrate dehydrogenase 1 gene (IDH1) in a fraction of such tumors, most frequently in tumors that wer ... Full text Link to item Cite

Aptamers selected against the unglycosylated EGFRvIII ectodomain and delivered intracellularly reduce membrane-bound EGFRvIII and induce apoptosis.

Journal article Biol Chem · February 2009 Epidermal growth factor receptor variant III (EGFRvIII) is a glycoprotein uniquely expressed in glioblastoma, but not in normal brain tissues. To develop targeted therapies for brain tumors, we selected RNA aptamers against the histidine-tagged EGFRvIII ec ... Full text Link to item Cite

Phase II trial of Gliadel plus O6-benzylguanine in adults with recurrent glioblastoma multiforme.

Journal article Clin Cancer Res · February 1, 2009 PURPOSE: This phase II trial was designed to define the efficacy of Gliadel wafers in combination with an infusion of O6-benzylguanine (O6-BG) that suppresses tumor O6-alkylguanine-DNA alkyltransferase (AGT) levels in patients with recurrent glioblastoma m ... Full text Link to item Cite

Mutational inactivation of PTPRD in glioblastoma multiforme and malignant melanoma.

Journal article Cancer Res · December 15, 2008 An additional tumor suppressor gene on chromosome 9p telomeric to the CDKN2A/B locus has long been postulated to exist. Using Affymetrix 250K single nucleotide polymorphism arrays to screen for copy number changes in glioblastoma multiforme (GBM), we detec ... Full text Link to item Cite

Detection of humoral response in patients with glioblastoma receiving EGFRvIII-KLH vaccines.

Journal article J Immunol Methods · November 30, 2008 The epidermal growth factor receptor variant III (EGFRvIII) is a consistent tumor-specific mutation that is widely expressed in glioblastoma multiforme (GBM) and other neoplasms. As such it represents a truly tumor-specific target for antitumor immunothera ... Full text Link to item Cite

Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas.

Journal article Clin Cancer Res · November 1, 2008 PURPOSE: Although patients with newly diagnosed WHO grade 3 malignant glioma have a more favorable prognosis than those with WHO grade 4 malignant glioma, salvage therapies following recurrence offer essentially palliative benefit. We did a phase II trial ... Full text Link to item Cite

Comprehensive genomic characterization defines human glioblastoma genes and core pathways.

Journal article Nature · October 23, 2008 Human cancer cells typically harbour multiple chromosomal aberrations, nucleotide substitutions and epigenetic modifications that drive malignant transformation. The Cancer Genome Atlas (TCGA) pilot project aims to assess the value of large-scale multi-dim ... Full text Link to item Cite

Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma.

Journal article Semin Immunol · October 2008 Conventional therapies for malignant gliomas (MGs) fail to target tumor cells exclusively, such that their efficacy is ultimately limited by non-specific toxicity. Immunologic targeting of tumor-specific gene mutations, however, may allow more precise erad ... Full text Link to item Cite

An integrated genomic analysis of human glioblastoma multiforme.

Journal article Science · September 26, 2008 Glioblastoma multiforme (GBM) is the most common and lethal type of brain cancer. To identify the genetic alterations in GBMs, we sequenced 20,661 protein coding genes, determined the presence of amplifications and deletions using high-density oligonucleot ... Full text Link to item Cite

Mismatch repair deficiency does not mediate clinical resistance to temozolomide in malignant glioma.

Journal article Clin Cancer Res · August 1, 2008 PURPOSE: A major mechanism of resistance to methylating agents, including temozolomide, is the DNA repair protein O(6)-alkylguanine-DNA alkyltransferase (AGT). Preclinical data indicates that defective DNA mismatch repair (MMR) results in tolerance to temo ... Full text Link to item Cite

Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors.

Journal article Neuro Oncol · June 2008 The purpose of this study is to determine the maximum tolerated dose (MTD), dose-limiting toxicity (DLT), and intracerebral distribution of a recombinant toxin (TP-38) targeting the epidermal growth factor receptor in patients with recurrent malignant brai ... Full text Link to item Cite

The gene expression profiles of medulloblastoma cell lines resistant to preactivated cyclophosphamide.

Journal article Curr Cancer Drug Targets · May 2008 The total expression profiles of two medulloblastoma cell lines resistant to the preactivated form of cyclophosphamide (4-hydroperoxycyclophosphamide, 4-HC) were examined using the Affymetrix GeneChip U133A array. Our primary objective was to look for poss ... Full text Link to item Cite

Immunotherapy against angiogenesis-associated targets: evidence and implications for the treatment of malignant glioma.

Journal article Expert Rev Anticancer Ther · May 2008 Angiogenesis, the growth of new blood vessels from previously existing vasculature, is a requirement for tumor growth and metastasis. The first US FDA-approved drugs targeting angiogenesis have shown potential in the treatment of malignant gliomas. Immunot ... Full text Link to item Cite

Identification of p18 INK4c as a tumor suppressor gene in glioblastoma multiforme.

Journal article Cancer Res · April 15, 2008 Genomic alterations leading to aberrant activation of cyclin/cyclin-dependent kinase (cdk) complexes drive the pathogenesis of many common human tumor types. In the case of glioblastoma multiforme (GBM), these alterations are most commonly due to homozygou ... Full text Link to item Cite

A pilot study: 131I-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost.

Journal article Neuro Oncol · April 2008 The purpose of this study was to determine the feasibility and assess the efficacy and toxicity, among newly diagnosed malignant glioma patients, of administering (131)I-labeled murine antitenascin monoclonal antibody 81C6 ((131)I-81C6) into a surgically c ... Full text Link to item Cite

Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: case study.

Journal article Neuro Oncol · February 2008 Cytotoxic chemotherapy that induces lymphopenia is predicted to ablate the benefits of active antitumor immunization. Temozolomide is an effective chemotherapeutic agent for patients with glioblastoma multiforme, but it induces significant lymphopenia. Alt ... Full text Link to item Cite

Utility of EGFR and PTEN numerical aberrations in the evaluation of diffusely infiltrating astrocytomas. Laboratory investigation.

Journal article J Neurosurg · February 2008 OBJECT: Diffusely infiltrating astrocytomas are the most common primary brain tumors. As a group, they demonstrate an inherent tendency toward malignant progression. Histological grading using the guidelines of the World Health Organization (WHO) remains t ... Full text Link to item Cite

Development of a real-time RT-PCR assay for detecting EGFRvIII in glioblastoma samples.

Journal article Clin Cancer Res · January 15, 2008 PURPOSE: Epidermal growth factor receptor variant III (EGFRvIII) is an oncogenic, constitutively active mutant form of the EGFR that is commonly expressed in glioblastoma and is also detected in a number of epithelial cancers. EGFRvIII presents a unique an ... Full text Link to item Cite

EGFRvIII-targeted immunotoxin induces antitumor immunity that is inhibited in the absence of CD4+ and CD8+ T cells.

Journal article Cancer Immunol Immunother · January 2008 PURPOSE: Immunotoxins as anti-cancer therapeutics have several potential advantages over conventional agents including a high specificity, extraordinary potency, and a lack of an identified mechanism for resistance. It has been clearly demonstrated that Ps ... Full text Link to item Cite

Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6.

Journal article J Nucl Med · January 2008 UNLABELLED: alpha-Particle-emitting radionuclides, such as (211)At, with a 7.2-h half-life, may be optimally suited for the molecularly targeted radiotherapy of strategically sensitive tumor sites, such as those in the central nervous system. Because of th ... Full text Link to item Cite

O (4)-benzylfolic acid inactivates O (6)-alkylguanine-DNA alkyltransferase in brain tumor cell lines.

Journal article Cancer Chemother Pharmacol · November 2007 PURPOSE: The DNA repair protein, O (6)-alkylguanine-DNA alkyltransferase (AGT), is a primary source of tumor resistance to agents such as temozolomide and chloroethylnitrosoureas that form DNA lesions at the O (6)-position of guanines. To increase the effi ... Full text Link to item Cite

Bevacizumab plus irinotecan in recurrent glioblastoma multiforme.

Journal article J Clin Oncol · October 20, 2007 PURPOSE: The prognosis for patients with recurrent glioblastoma multiforme is poor, with a median survival of 3 to 6 months. We performed a phase II trial of bevacizumab, a monoclonal antibody to vascular endothelial growth factor, in combination with irin ... Full text Link to item Cite

The heat shock response and chaperones/heat shock proteins in brain tumors: surface expression, release, and possible immune consequences.

Journal article J Neurosci · October 17, 2007 The heat shock response is a highly conserved "stress response" mechanism used by cells to protect themselves from potentially damaging insults. It often involves the upregulated expression of chaperone and heat shock proteins (HSPs) to prevent damage and ... Full text Link to item Cite

Targeted alpha-particle radiotherapy with 211At-labeled monoclonal antibodies.

Journal article Nucl Med Biol · October 2007 An attractive feature of targeted radionuclide therapy is the ability to select radionuclides and targeting vehicles with characteristics that are best suited for a particular clinical application. One combination that has been receiving increasing attenti ... Full text Link to item Cite

The combination of novel low molecular weight inhibitors of RAF (LBT613) and target of rapamycin (RAD001) decreases glioma proliferation and invasion.

Journal article Mol Cancer Ther · September 2007 Monotherapies have proven largely ineffective for the treatment of glioblastomas, suggesting that increased patient benefit may be achieved by combining therapies. Two protumorigenic pathways known to be active in glioblastoma include RAS/RAF/mitogen-activ ... Full text Link to item Cite

Activity of VNP40101M (Cloretazine) in the treatment of CNS tumor xenografts in athymic mice.

Journal article Neuro Oncol · July 2007 VNP40101M, or 1,2-bis(methylsulfonyl)-1-(2-choloroethyl)-2-(methylamino)carbonylhydrazine (Cloretazine), is a bifunctional prodrug that belongs to a class of DNA-modifying agents-the sulfonylhydrazines-that has been synthesized and been shown to have activ ... Full text Link to item Cite

Clinical utility of a patient-specific algorithm for simulating intracerebral drug infusions.

Journal article Neuro Oncol · July 2007 Convection-enhanced delivery (CED) is a novel drug delivery technique that uses positive infusion pressure to deliver therapeutic agents directly into the interstitial spaces of the brain. Despite the promise of CED, clinical trials have demonstrated that ... Full text Link to item Cite

Targeting SPARC expression decreases glioma cellular survival and invasion associated with reduced activities of FAK and ILK kinases.

Journal article Oncogene · June 14, 2007 Secreted protein acidic and rich in cysteine (SPARC) is an extracellular glycoprotein expressed in several solid cancers, including malignant gliomas, upon adoption of metastatic or invasive behaviors. SPARC expression in glioma cells promotes invasion and ... Full text Link to item Cite

A novel low-molecular weight inhibitor of focal adhesion kinase, TAE226, inhibits glioma growth.

Journal article Mol Carcinog · June 2007 Glioblastomas are highly lethal cancers that resist current therapies. Novel therapies under development target molecular mechanisms that promote glioblastoma growth. In glioblastoma patient specimens, the non-receptor tyrosine kinase focal adhesion kinase ... Full text Link to item Cite

Tumor resection cavity administered iodine-131-labeled antitenascin 81C6 radioimmunotherapy in patients with malignant glioma: neuropathology aspects.

Journal article Nucl Med Biol · May 2007 INTRODUCTION: The neurohistological findings in patients treated with targeted beta emitters such as (131)I are poorly described. We report a histopathologic analysis from patients treated with combined external beam therapy and a brachytherapy consisting ... Full text Link to item Cite

Antitenascin-C monoclonal antibody radioimmunotherapy for malignant glioma patients.

Journal article Expert Rev Anticancer Ther · May 2007 Adults with primary malignant glioma have an unacceptably poor outcome. Most of these tumors recur at or adjacent to the site of origin, which indicates that failure to eradicate local tumor growth is a major factor contributing to poor outcome. Therefore, ... Full text Link to item Cite

Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function.

Journal article Clin Cancer Res · April 1, 2007 PURPOSE: Patients with malignant glioma suffer global compromise of their cellular immunity, characterized by dramatic reductions in CD4(+) T cell numbers and function. We have previously shown that increased regulatory T cell (T(reg)) fractions in these p ... Full text Link to item Cite

Using the theory of planned behavior to understand the determinants of exercise intention in patients diagnosed with primary brain cancer.

Journal article Psychooncology · March 2007 The purpose of the present study was to examine the demographic, medical, and social cognitive determinants of exercise intentions in a institution-based cohort of primary brain tumor patients. Using a cross-sectional survey, 100 primary brain tumor patien ... Full text Link to item Cite

Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma.

Journal article Clin Cancer Res · February 15, 2007 PURPOSE: Recurrent grade III-IV gliomas have a dismal prognosis with minimal improvements in survival seen following currently available salvage therapy. This study was conducted to determine if the combination of a novel antiangiogenic therapy, bevacizuma ... Full text Link to item Cite

Intracerebral infusate distribution by convection-enhanced delivery in humans with malignant gliomas: descriptive effects of target anatomy and catheter positioning.

Journal article Neurosurgery · February 2007 OBJECTIVE: Convection-enhanced delivery (CED) holds tremendous potential for drug delivery to the brain. However, little is known about the volume of distribution achieved within human brain tissue or how target anatomy and catheter positioning influence d ... Full text Link to item Cite

Antitenascin antibody 81C6 armed with 177Lu: in vivo comparison of macrocyclic and acyclic ligands.

Journal article Nucl Med Biol · February 2007 INTRODUCTION: When labeled with iodine-131, the antitenascin monoclonal antibody (mAb) 81C6 has shown promise as a targeted radiotherapeutic in patients with brain tumors. Because of its more favorable gamma-ray properties, lutetium-177 might be a better l ... Full text Link to item Cite

Phase II study of Cloretazine for the treatment of adults with recurrent glioblastoma multiforme.

Journal article Neuro Oncol · January 2007 Cloretazine (VNP40101M) is a newly synthesized alkylating agent belonging to a novel class of alkylating agents called 1,2-bis(sulfonyl)hydrazines. Agents that belong to this class do not produce vinylating and chloroethylating species, and hence this clas ... Full text Link to item Cite

Exercise interest and preferences among patients diagnosed with primary brain cancer.

Journal article Support Care Cancer · January 2007 GOALS OF THE WORK: The purpose of the present investigation was to examine the interest and exercise preferences of an institution-based sample of brain tumor patients. Secondary aims were to examine potential differences in participant's interest and pref ... Full text Link to item Cite

Glioma stem cells promote radioresistance by preferential activation of the DNA damage response.

Journal article Nature · December 7, 2006 Ionizing radiation represents the most effective therapy for glioblastoma (World Health Organization grade IV glioma), one of the most lethal human malignancies, but radiotherapy remains only palliative because of radioresistance. The mechanisms underlying ... Full text Link to item Cite

Quantitative analysis of O6-alkylguanine-DNA alkyltransferase in malignant glioma.

Journal article Mol Cancer Ther · October 2006 Promoter hypermethylation of the DNA repair protein O(6)-alkylguanine-DNA alkyltransferase (AGT) has been associated with an enhanced response to chloroethylating and methylating agents in patients with malignant glioma. The purpose of this study was to co ... Full text Link to item Cite

Neuro-Oncology: Editorial

Journal article Neuro Oncology · October 1, 2006 Full text Cite

Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting.

Journal article Clin Cancer Res · September 1, 2006 PURPOSE: Epidermal growth factor receptor (EGFR) is overexpressed in head and neck squamous cell carcinoma (HNSCC) where expression levels correlate with decreased survival. Therapies that block EGFR have shown limited efficacy in clinical trials and prima ... Full text Link to item Cite

AAL881, a novel small molecule inhibitor of RAF and vascular endothelial growth factor receptor activities, blocks the growth of malignant glioma.

Journal article Cancer Res · September 1, 2006 Malignant gliomas are highly proliferative and angiogenic cancers resistant to conventional therapies. Although RAS and RAF mutations are uncommon in gliomas, RAS activity is increased in gliomas. Additionally, vascular endothelial growth factor and its co ... Full text Link to item Cite

Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor.

Journal article Cancer Res · August 15, 2006 Malignant gliomas are highly lethal cancers dependent on angiogenesis. Critical tumor subpopulations within gliomas share characteristics with neural stem cells. We examined the potential of stem cell-like glioma cells (SCLGC) to support tumor angiogenesis ... Full text Link to item Cite

Systemic anti-CD25 monoclonal antibody administration safely enhances immunity in murine glioma without eliminating regulatory T cells.

Journal article Clin Cancer Res · July 15, 2006 PURPOSE: Elevated proportions of regulatory T cells (T(reg)) are present in patients with a variety of cancers, including malignant glioma, yet recapitulative murine models are wanting. We therefore examined T(regs) in mice bearing malignant glioma and eva ... Full text Link to item Cite

A novel low molecular weight inhibitor of focal adhesion kinase and insulin-like growth factor-1 receptor, TAE226, inhibits glioma growth.

Journal article J Clin Oncol · June 20, 2006 11505 Background: Glioblastomas are highly lethal cancers that resist current therapies. Focal adhesion kinase (FAK) is a non-receptor tyrosine kinase overexpressed in glioblastoma patient specimens that may promote glioma growth and invasion by increasing ... Link to item Cite

Tumor-specific peptide vaccination in newly-diagnosed patients with GBM.

Journal article J Clin Oncol · June 20, 2006 2529 Background: Despite multimodality approaches, survival with GBM is dismal. Induction of immune responses to suppress the infiltrative, residual component with an easily manufactured and administered immunotherapy has been a theoretical ideal. The epid ... Link to item Cite

Novel human IgG2b/murine chimeric antitenascin monoclonal antibody construct radiolabeled with 131I and administered into the surgically created resection cavity of patients with malignant glioma: phase I trial results.

Journal article J Nucl Med · June 2006 UNLABELLED: Results from animal experiments have shown that human IgG2/mouse chimeric antitenascin 81C6 (ch81C6) monoclonal antibody exhibited higher tumor accumulation and enhanced stability compared with its murine parent. Our objective was to determine ... Link to item Cite

Patterns of exercise across the cancer trajectory in brain tumor patients.

Journal article Cancer · May 15, 2006 BACKGROUND: Exercise may represent a supportive intervention that may complement existing neurooncologic therapies and address a multitude of therapy-induced debilitating side effects in patients with brain tumors. Given the limited evidence, the authors c ... Full text Link to item Cite

Therapeutic aspects of chaperones/heat-shock proteins in neuro-oncology.

Journal article Expert Rev Anticancer Ther · May 2006 Tumors of the CNS frequently have devastating consequences in terms of cognitive and motor function, personality and mortality. Despite decades of work, current therapies have done little to alter the course of these deadly diseases. The discovery that cha ... Full text Link to item Cite

Comparison of intratumoral bolus injection and convection-enhanced delivery of radiolabeled antitenascin monoclonal antibodies.

Journal article Neurosurg Focus · April 15, 2006 OBJECTIVES: Convection-enhanced delivery (CED) is a novel technique used to deliver agents to the brain parenchyma for treatment of neoplastic, infectious, and degenerative conditions. The purpose of this study was to determine if CED would provide a large ... Full text Link to item Cite

Glycoprotein nonmetastatic melanoma protein B, a potential molecular therapeutic target in patients with glioblastoma multiforme.

Journal article Clin Cancer Res · April 1, 2006 PURPOSE: More brain tumor markers are required for prognosis and targeted therapy. We have identified and validated promising molecular therapeutic glioblastoma multiforme (GBM) targets: human transmembrane glycoprotein nonmetastatic melanoma protein B (GP ... Full text Link to item Cite

Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma.

Journal article Cancer Res · March 15, 2006 Immunosuppression is frequently associated with malignancy and is particularly severe in patients with malignant glioma. Anergy and counterproductive shifts toward T(H)2 cytokine production are long-recognized T-cell defects in these patients whose etiolog ... Full text Link to item Cite

Recent advances in the treatment of malignant astrocytoma.

Journal article J Clin Oncol · March 10, 2006 Malignant gliomas, including the most common subtype, glioblastoma multiforme (GBM), are among the most devastating of neoplasms. Their aggressive infiltration in the CNS typically produces progressive and profound disability--ultimately leading to death i ... Full text Link to item Cite

Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma.

Journal article Clin Cancer Res · February 1, 2006 PURPOSE: To determine the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of gefitinib, a receptor tyrosine kinase inhibitor of the epidermal growth factor receptor, plus sirolimus, an inhibitor of the mammalian target of rapamycin, among pat ... Full text Link to item Cite

Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results.

Journal article J Clin Oncol · January 1, 2006 PURPOSE: To assess the efficacy and toxicity of intraresection cavity iodine-131-labeled murine antitenascin monoclonal antibody 81C6 (131I-m81C6) among recurrent malignant brain tumor patients. PATIENTS AND METHODS: In this phase II trial, 100 mCi of 131I ... Full text Link to item Cite

Antiepidermal growth factor variant III scFv fragment: effect of radioiodination method on tumor targeting and normal tissue clearance.

Journal article Nucl Med Biol · January 2006 INTRODUCTION: MR1-1 is a single-chain Fv (scFv) fragment that binds with high affinity to epidermal growth factor receptor variant III, which is overexpressed on gliomas and other tumors but is not present on normal tissues. The objective of this study was ... Full text Link to item Cite

Nepsilon-(3-[*I]Iodobenzoyl)-Lys5-Nalpha-maleimido-Gly1-GEEEK ([*I]IB-Mal-D-GEEEK): a radioiodinated prosthetic group containing negatively charged D-glutamates for labeling internalizing monoclonal antibodies.

Journal article Bioconjug Chem · 2006 Novel methods are needed for the radiohalogenation of cell-internalizing proteins and peptides because rapid loss of label occurs after lysosomal processing when these molecules are labeled using conventional radioiodination methodologies. We have develope ... Full text Link to item Cite

Work exposures to animal neurocarcinogens.

Journal article Int J Occup Environ Health · 2006 The initiation of brain tumors has been demonstrated in animals exposed to industrial chemicals, results which have not been demonstrated in humans. This report describes the National Occupation Exposure Survey conducted by the National Institute of Occupa ... Full text Link to item Cite

Loss of phosphatase and tensin homologue increases transforming growth factor beta-mediated invasion with enhanced SMAD3 transcriptional activity.

Journal article Cancer Res · December 15, 2005 In normal epithelial tissues, the multifunctional cytokine transforming growth factor-beta (TGF-beta) acts as a tumor suppressor through growth inhibition and induction of differentiation whereas in advanced cancers, TGF-beta promotes tumor progression thr ... Full text Link to item Cite

Signal transduction through substance P receptor in human glioblastoma cells: roles for Src and PKCdelta.

Journal article Cancer Chemother Pharmacol · December 2005 Substance P receptor (SPR), a G protein-coupled receptor (GPCR), is found in human glioblastomas, and has been implicated in their growth. Consistent with a role for SPR in cell growth, activation of SPR in U373 MG human glioblastoma cells leads to the pho ... Full text Link to item Cite

ZD6474, a novel tyrosine kinase inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor, inhibits tumor growth of multiple nervous system tumors.

Journal article Clin Cancer Res · November 15, 2005 PURPOSE: Primary central nervous system (CNS) tumors represent a diverse group of tumor types with heterogeneous molecular mechanisms that underlie their formation and maintenance. CNS tumors depend on angiogenesis and often display increased activity of E ... Full text Link to item Cite

Survival analysis of presumptive prognostic markers among oligodendrogliomas.

Journal article Cancer · October 15, 2005 BACKGROUND: Allelic losses of 1p and 19q arms correlate with the oligodendroglial phenotype as well as with sensitivity to radiotherapy and chemotherapy. Furthermore, the DNA repair gene, methylguanine methyltransferase (MGMT), is diminished in 80% of olig ... Full text Link to item Cite

GNOSIS: guidelines for neuro-oncology: standards for investigational studies-reporting of phase 1 and phase 2 clinical trials.

Journal article Neuro Oncol · October 2005 We present guidelines to standardize the reporting of phase 1 and phase 2 neuro-oncology trials. The guidelines are also intended to assist with accurate interpretation of results from these trials, to facilitate the peer-review process, and to expedite th ... Full text Link to item Cite

Tenascin and microvessel stromal changes in patients with non-Hodgkin's lymphoma are isolated to the sites of disease and vary in correlation to disease activity.

Journal article Leuk Lymphoma · October 2005 This study investigated stromal changes in expression of tenascin and vasculogenesis in lymphoma. Documenting the dynamic nature of the stromal changes in lymphoma in relation to response to therapy is helpful in planning new therapies directed at these ta ... Full text Link to item Cite

Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma.

Journal article J Clin Oncol · October 1, 2005 PURPOSE: We conducted a two-phase clinical trial in patients with progressive malignant glioma (MG). The first phase of this trial was designed to determine the dose of O6-BG effective in producing complete depletion of tumor AGT activity for 48 hours. The ... Full text Link to item Cite

Neuro-Oncology impact factor for 2004

Journal article Neuro Oncology · October 1, 2005 Full text Cite

Poly(ADP-ribose) polymerase-1 inhibition reverses temozolomide resistance in a DNA mismatch repair-deficient malignant glioma xenograft.

Journal article Mol Cancer Ther · September 2005 Temozolomide is a DNA-methylating agent used in the treatment of malignant gliomas. In this study, we have examined if inhibition of poly(ADP-ribose) polymerase (PARP) could increase the cytotoxicity of temozolomide, particularly in cells deficient in DNA ... Full text Link to item Cite

Chemotherapy and novel therapeutic approaches in malignant glioma.

Journal article Front Biosci · September 1, 2005 Glial neoplasms represent 0.5-1% of all cancers in most Western countries. Malignant gliomas are among the most devastating cancers, leading to death in most cases. They present unique challenges due to their location, aggressive biological behavior and di ... Full text Link to item Cite

Chaperone proteins and brain tumors: potential targets and possible therapeutics.

Journal article Neuro Oncol · July 2005 Chaperone proteins are most notable for the proteo- and cyotoprotective capacities they afford during cellular stress. Under conditions of cellular normalcy, chaperones still play integral roles in the folding of nascent polypeptides into functional entiti ... Full text Link to item Cite

Dosimetry and radiographic analysis of 131I-labeled anti-tenascin 81C6 murine monoclonal antibody in newly diagnosed patients with malignant gliomas: a phase II study.

Journal article J Nucl Med · June 2005 UNLABELLED: The objective was to perform dosimetry and evaluate dose-response relationships in newly diagnosed patients with malignant brain tumors treated with direct injections of (131)I-labeled anti-tenascin murine 81C6 monoclonal antibody (mAb) into su ... Link to item Cite

Gene expression profiling and genetic markers in glioblastoma survival.

Journal article Cancer Res · May 15, 2005 Despite the strikingly grave prognosis for older patients with glioblastomas, significant variability in patient outcome is experienced. To explore the potential for developing improved prognostic capabilities based on the elucidation of potential biologic ... Full text Link to item Cite

Identification of OTX2 as a medulloblastoma oncogene whose product can be targeted by all-trans retinoic acid.

Journal article Cancer Res · February 1, 2005 Through digital karyotyping of permanent medulloblastoma cell lines, we found that the homeobox gene OTX2 was amplified more than 10-fold in three cell lines. Gene expression analyses showed that OTX2 transcripts were present at high levels in 14 of 15 (93 ... Link to item Cite

Sustained radiographic and clinical response in patient with bifrontal recurrent glioblastoma multiforme with intracerebral infusion of the recombinant targeted toxin TP-38: case study.

Journal article Neuro Oncol · January 2005 Glioblastoma multiforme remains refractory to conventional therapy, and novel therapeutic modalities are desperately needed. TP-38 is a recombinant chimeric protein containing a genetically engineered form of the cytotoxic Pseudomonas exotoxin fused to tra ... Full text Link to item Cite

Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition.

Journal article Mol Cancer Ther · January 2005 Malignant gliomas are highly lethal tumors that display striking genetic heterogeneity. Novel therapies that inhibit a single molecular target may slow tumor progression, but tumors are likely not dependent on a signal transduction pathway. Rather, maligna ... Link to item Cite

Tenascin-C, over expressed in lung cancer down regulates effector functions of tumor infiltrating lymphocytes.

Journal article Lung Cancer · January 2005 PURPOSE: Extracellular matrix (ECM) proteins play a significant role in the survival and metastasis of cancer cells. Tenascin-C (TN-C) is an extracellular matrix protein and its large isoform has been implicated in tumor progression. Goal of this study was ... Full text Link to item Cite

Secreted protein acidic, rich in cysteine (SPARC), mediates cellular survival of gliomas through AKT activation.

Journal article J Biol Chem · December 10, 2004 Secreted protein acidic, rich in cysteine (SPARC), is an extracellular matrix protein expressed in many advanced cancers, including malignant gliomas. We and others have previously shown that human glioma cell lines engineered to overexpress SPARC adopt an ... Full text Link to item Cite

Immune responses of breast cancer patients to mutated epidermal growth factor receptor (EGF-RvIII, Delta EGF-R, and de2-7 EGF-R).

Journal article J Immunol · November 15, 2004 Mutated epidermal growth factor receptor (EGF-RvIII, DeltaEGF-R, and de2-7 EGF-R) is the result of an 801-bp deletion within the extracellular domain of wild-type EGF-R and is expressed by breast carcinomas, but not by normal breast tissues. EGF-RvIII is e ... Full text Link to item Cite

Evaluation of an internalizing monoclonal antibody labeled using N-succinimidyl 3-[131I]iodo-4-phosphonomethylbenzoate ([131I]SIPMB), a negatively charged substituent bearing acylation agent.

Journal article Nucl Med Biol · October 2004 Monoclonal antibodies such as L8A4, reactive with the epidermal growth factor receptor variant III, internalize after receptor binding resulting in proteolytic degradation by lysosomes. Labeling internalizing mAbs requires the use of methodologies that res ... Full text Link to item Cite

EDITORIAL

Journal article Neuro-oncology · October 2004 Full text Cite

Monoclonal antibodies for brain tumour treatment.

Journal article Expert Opin Biol Ther · September 2004 Conventional treatment of brain tumours includes surgical, radiotherapeutic and chemotherapeutic modalities. Nonetheless, the outcome of patients with brain tumours, in particular glioblastoma, remains poor. Immunotherapy with armed or unarmed monoclonal a ... Full text Link to item Cite

Brain tumor cell lines resistant to O6-benzylguanine/1,3-bis(2-chloroethyl)-1-nitrosourea chemotherapy have O6-alkylguanine-DNA alkyltransferase mutations.

Journal article Mol Cancer Ther · September 2004 The chemotherapeutic activity of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU or carmustine) may be improved by the addition of O6-benzylguanine (O6-BG). The reaction of O6-BG with O6-alkylguanine-DNA alkyltransferase (AGT) prevents the repair of O6-chloroet ... Link to item Cite

Phase 1 trial study of 131I-labeled chimeric 81C6 monoclonal antibody for the treatment of patients with non-Hodgkin lymphoma.

Journal article Blood · August 1, 2004 We report a phase 1 study of pharmacokinetics, dosimetry, toxicity, and response of (131)I anti-tenascin chimeric 81C6 for the treatment of lymphoma. Nine patients received a dosimetric dose of 370 MBq (10 mCi). Three patients received an administered acti ... Full text Link to item Cite

Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas.

Journal article Cancer Res · August 1, 2004 The phosphatidylinositol 3'-kinase pathway is activated in multiple advanced cancers, including glioblastomas, through inactivation of the PTEN tumor suppressor gene. Recently, mutations in PIK3CA, a member of the family of phosphatidylinositol 3'-kinase c ... Full text Link to item Cite

Comparative genomic hybridization analysis of astrocytomas: prognostic and diagnostic implications.

Journal article J Mol Diagn · August 2004 Astrocytoma is comprised of a group of common intracranial neoplasms that are classified into four grades based on the World Health Organization histological criteria and patient survival. To date, histological grade, patient age, and clinical performance, ... Full text Link to item Cite

Erlotinib HCL for glioblastoma multiforme in first relapse, a phase II trial.

Journal article J Clin Oncol · July 15, 2004 1555 Background: Erlotinib HCL (Tarceva), an orally active, highly potent and selective inhibitor of the epidermal growth factor receptor (HER1/EGFR), has documented clinical activity in glioblastoma multiforme (GBM) (M Prados ASCO 02). GBM is an interesti ... Link to item Cite

Phase II trial of iodine 131-labeled murine anti-tenascin monoclonal anti-body 81C6 (M81C6) via surgically created resection cavity in the treatment of patients with recurrent malignant brain tumors.

Journal article J Clin Oncol · July 15, 2004 1569 Background: In a prior phase I study we established the dose of 100mCi as the maximum tolerated dose of iodine 131-labeled murine anti-tenascin antibody 81C6 (131I-81C6) injected into a surgically created resection cavity (SCRC) for the treatment of r ... Link to item Cite

Poliovirus receptor CD155-targeted oncolysis of glioma.

Journal article Neuro Oncol · July 2004 Cell adhesion molecules of the immunoglobulin superfamily are aberrantly expressed in malignant glioma. Amongst these, the human poliovirus receptor CD155 provides a molecular target for therapeutic intervention with oncolytic poliovirus recombinants. Poli ... Full text Link to item Cite

SB-431542, a small molecule transforming growth factor-beta-receptor antagonist, inhibits human glioma cell line proliferation and motility.

Journal article Mol Cancer Ther · June 2004 Transforming growth factor-beta (TGF-beta) is a multifunctional cytokine that promotes malignant glioma invasion, angiogenesis, and immunosuppression. Antisense oligonucleotide suppression of TGF-beta(2) ligand expression has shown promise in preclinical a ... Link to item Cite

Resistance to tyrosine kinase inhibition by mutant epidermal growth factor receptor variant III contributes to the neoplastic phenotype of glioblastoma multiforme.

Journal article Clin Cancer Res · May 1, 2004 PURPOSE: We have reported previously that tumors expressing wild-type epidermal growth factor receptor (EGFR) in a murine model are sensitive to the EGFR tyrosine kinase inhibitor gefitinib, whereas tumors expressing mutant EGFR variant III (EGFRvIII) are ... Full text Link to item Cite

Human/murine chimeric 81C6 F(ab')(2) fragment: preclinical evaluation of a potential construct for the targeted radiotherapy of malignant glioma.

Journal article Nucl Med Biol · April 2004 We have obtained encouraging responses in recent Phase I studies evaluating (131)I-labeled human/murine chimeric 81C6 anti-tenascin monoclonal antibody (ch81C6) administered into surgically-created tumor resection cavities in brain tumor patients. However, ... Full text Link to item Cite

Phase 1 trial of irinotecan plus BCNU in patients with progressive or recurrent malignant glioma.

Journal article Neuro Oncol · April 2004 Irinotecan is a topoisomerase I inhibitor previously shown to be active in the treatment of malignant glioma. We now report the results of a phase 1 trial of irinotecan plus BCNU, or 1,3-bis(2-chloroethyl)-1-nitrosourea, for patients with recurrent or prog ... Full text Link to item Cite

Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma.

Journal article Neuro Oncol · April 2004 In preclinical studies, BCNU, or 1,3-bis(2-chloroethyl)-1-nitrosourea, plus CPT-11 (irinotecan) exhibits schedule-dependent, synergistic activity against malignant glioma (MG). We previously established the maximum tolerated dose of CPT-11 when administere ... Full text Link to item Cite

Consistency of primary brain tumor diagnoses and codes in cancer surveillance systems.

Journal article Neuroepidemiology · 2004 High-quality cancer registry data are essential for assessing trends in incidence rates. This study evaluated the consistency of brain tumor surveillance data using a random sample of cases from the Connecticut Tumor Registry. Three neuropathologists indep ... Full text Link to item Cite

Phase II trial of gefitinib in recurrent glioblastoma.

Journal article J Clin Oncol · January 1, 2004 PURPOSE: To evaluate the efficacy and tolerability of gefitinib (ZD1839, Iressa; AstraZeneca, Wilmington, DE), a novel epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. PATIENTS AND METHODS: This was an op ... Full text Link to item Cite

Efficacy of intracerebral microinfusion of trastuzumab in an athymic rat model of intracerebral metastatic breast cancer.

Journal article Clin Cancer Res · November 15, 2003 PURPOSE: The monoclonal antibody (MAb) trastuzumab (Herceptin) effectively treats HER2-overexpressing extracerebral breast neoplasms. Delivery of such macromolecule therapeutic agents to intracerebral metastases, however, is limited by the tight junctions ... Link to item Cite

Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors.

Journal article J Neurooncol · October 2003 TP-38 is a recombinant chimeric targeted toxin composed of the EGFR binding ligand TGF-alpha and a genetically engineered form of the Pseudomonas exotoxin, PE-38. After in vitro and in vivo animal studies that showed specific activity and defined the maxim ... Full text Link to item Cite

Editorial

Journal article Neuro Oncology · October 1, 2003 Full text Cite

Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors.

Journal article Clin Cancer Res · September 15, 2003 PURPOSE: The epidermal growth factor receptor (EGFR) is often amplified and structurally rearranged in malignant gliomas and other tumors such as breast and lung, with the most common mutation being EGFRvIII. In the study described here, we tested in mouse ... Link to item Cite

Bone-related genes expressed in advanced malignancies induce invasion and metastasis in a genetically defined human cancer model.

Journal article J Biol Chem · May 2, 2003 We employed a genetically defined human cancer model to investigate the contributions of two genes up-regulated in several cancers to phenotypic changes associated with late stages of tumorigenesis. Specifically, tumor cells expressing two structurally unr ... Full text Link to item Cite

N-succinimidyl 3-[211At]astato-4-guanidinomethylbenzoate: an acylation agent for labeling internalizing antibodies with alpha-particle emitting 211At.

Journal article Nucl Med Biol · May 2003 The objective of this study was to develop a method for labeling internalizing monoclonal antibodies (mAbs) such as those reactive to the anti-epidermal growth factor receptor variant III (EGFRvIII) with the alpha-particle emitting radionuclide (211)At. Ba ... Full text Link to item Cite

Phase II trial of temozolomide in patients with progressive low-grade glioma.

Journal article J Clin Oncol · February 15, 2003 PURPOSE: Temozolomide (Temodar; Schering-Plough Corp, Kenilworth, NJ) is an imidazole tetrazinone that undergoes chemical conversion to the active methylating agent 5-(3-methyltriazen-1yl)imidazole-4-carboximide under physiologic conditions. Previous studi ... Full text Link to item Cite

The history, evolution, and clinical use of dendritic cell-based immunization strategies in the therapy of brain tumors.

Journal article J Neurooncol · 2003 Despite advancements in therapeutic regimens, the prognosis remains poor for patients with malignant gliomas. Specificity has been an elusive goal for current modalities, but immunotherapy has emerged as a potential means of designing more tumor-specific t ... Full text Link to item Cite

Vascular targeted endoradiotherapy of tumors using alpha-particle-emitting compounds: theoretical analysis.

Journal article Int J Radiat Oncol Biol Phys · November 15, 2002 PURPOSE: To establish the theoretical framework and study the feasibility of (211)At-labeled anti-tenascin chimeric 81C6 monoclonal antibody (mAb) as anti-vascular endoradiotherapy for the treatment of glioblastoma multiforme (GBM) tumors. METHODS AND MATE ... Full text Link to item Cite

Brain tumors in mice are susceptible to blockade of epidermal growth factor receptor (EGFR) with the oral, specific, EGFR-tyrosine kinase inhibitor ZD1839 (iressa).

Journal article Clin Cancer Res · November 2002 Iressa (ZD1839) is a p.o.-active, selective, epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that blocks signal transduction pathways implicated in cancer cell proliferation, survival, and host-dependent processes promoting cancer gro ... Link to item Cite

Editorial

Journal article Neuro Oncology · October 1, 2002 Full text Cite

Screen and identification of proteins interacting with ADAM19 cytoplasmic tail.

Journal article Mol Biol Rep · September 2002 ADAM family plays important roles in neurogenesis. The cytoplasmic tail of ADAM19 (ADAM19-CT) contains 193 residues. The presence of two putative SH3 ligand-binding sites suggests potential interactions with cytosolic proteins, which could be possibly link ... Full text Link to item Cite

O6-benzylguanine-mediated enhancement of chemotherapy.

Journal article Mol Cancer Ther · September 2002 We have previously demonstrated (A. E. Pegg, Cancer Res., 50: 6119-6129, 1990) that O6-benzylguanine (O6-BG) enhances nitrosourea, temozolomide, and cyclophosphamide activity in malignant glioma xenografts growing in athymic nude mice. More recently, we ha ... Link to item Cite

Mechanisms of resistance to 1,3-bis(2-chloroethyl)-1-nitrosourea in human medulloblastoma and rhabdomyosarcoma.

Journal article Mol Cancer Ther · July 2002 Medulloblastoma (D-341 MED) and rhabdomyosarcoma (TE-671) cell lines, which are resistant to either 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) or the combination of BCNU and O6-benzylguanine (O6-BG), were generated by serial escalation of BCNU. The activi ... Link to item Cite

Mutations of the BRAF gene in human cancer.

Journal article Nature · June 27, 2002 Cancers arise owing to the accumulation of mutations in critical genes that alter normal programmes of cell proliferation, differentiation and death. As the first stage of a systematic genome-wide screen for these genes, we have prioritized for analysis si ... Full text Link to item Cite

Molecular markers of prognosis in astrocytic tumors.

Journal article Cancer · May 15, 2002 BACKGROUND: Astrocytoma is a primary brain tumor that affects 20,000 Americans each year. To date, only age and histologic grade stand out as independent predictors of survival. There is now increased interest in the use of molecular markers as objective s ... Full text Link to item Cite

Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma.

Journal article J Clin Oncol · May 1, 2002 PURPOSE: We conducted a phase II trial of carmustine (BCNU) plus the O(6)-alkylguanine-DNA alkyltransferase inhibitor O(6)-benzylguanine (O(6)-BG) to define the activity and toxicity of this regimen in the treatment of adults with progressive or recurrent ... Full text Link to item Cite

Comprehensive molecular cytogenetic investigation of chromosomal abnormalities in human medulloblastoma cell lines and xenograft.

Journal article Neuro Oncol · April 2002 Cell lines and xenografts derived from medulloblastomas are useful tools to investigate the chromosomal changes in these tumors. Here we used G-banding, fluorescence in situ hybridization (FISH), spectral karyotyping (SKY), and comparative genomic hybridiz ... Full text Link to item Cite

Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas.

Journal article J Clin Oncol · March 1, 2002 Featured Work PURPOSE: To assess the efficacy and toxicity of intraresection cavity (131)I-labeled murine antitenascin monoclonal antibody 81C6 and determine its true response rate among patients with newly diagnosed malignant glioma. PATIENTS AND METHODS: In this phase ... Full text Link to item Cite

Generation of anti-idiotypic reagents in the EGFRvIII tumor-associated antigen system.

Journal article Cancer Immunol Immunother · February 2002 The use of anti-idiotype (anti-id) vaccines for immunotherapy of human cancers is attractive, as immunization with true anti-id reagents (Ab2 beta) has been shown to induce both cellular and humoral immunity, frequently when the original antigen does not, ... Full text Link to item Cite

Dendritic cells pulsed with a tumor-specific peptide induce long-lasting immunity and are effective against murine intracerebral melanoma.

Journal article Neurosurgery · January 2002 OBJECTIVE: Dendritic cells (DCs) are specialized cells of the immune system that are capable of generating potent immune responses that are active even within the "immunologically privileged" central nervous system. However, immune responses generated by D ... Full text Link to item Cite

Improved xenograft targeting of tumor-specific anti-epidermal growth factor receptor variant III antibody labeled using N-succinimidyl 4-guanidinomethyl-3-iodobenzoate.

Journal article Nucl Med Biol · January 2002 Monoclonal antibodies (mAbs) such as the tumor-specific anti-epidermal growth factor receptor variant III (EGFRvIII) that are internalized and degraded after cell binding necessitate the use of radioiodination methods that minimize the loss of radioactivit ... Full text Link to item Cite

Activity of irofulven (6-hydroxymethylacylfulvene) in the treatment of glioblastoma multiforme-derived xenografts in athymic mice.

Journal article Cancer Chemother Pharmacol · November 2001 PURPOSE: This study was conducted to define the activity of irofulven in the treatment of a series of xenografts derived from human glioblastoma multiforme growing subcutaneously and intracranially in athymic nude mice. METHODS: Athymic mice bearing subcut ... Full text Link to item Cite

Positively charged templates for labeling internalizing antibodies: comparison of N-succinimidyl 5-iodo-3-pyridinecarboxylate and the D-amino acid peptide KRYRR.

Journal article Nucl Med Biol · October 2001 Receptor-mediated internalization of monoclonal antibodies (mAbs), such as those specific for the epidermal growth factor receptor variant III (EGFRvIII), can lead to rapid loss of radioactivity from the target cell. In the current study, the anti-EGFRvIII ... Full text Link to item Cite

High-level production of alpha-particle-emitting (211)At and preparation of (211)At-labeled antibodies for clinical use.

Journal article J Nucl Med · October 2001 UNLABELLED: In vitro and in vivo studies in human glioma models suggest that the antitenascin monoclonal antibody 81C6 labeled with the 7.2-h-half-life alpha-particle emitter (211)At might be a valuable endoradiotherapeutic agent for the treatment of brain ... Link to item Cite

Therapeutic activity of the topoisomerase I inhibitor J-107088 [6-N-(1-hydroxymethyla-2-hydroxyl) ethylamino-12,13-dihydro-13-(beta-D-glucopyranosyl) -5H-indolo[2,3-a]-pyrrolo[3,4-c]-carbazole-5,7(6H)-dione]] against pediatric and adult central nervous system tumor xenografts.

Journal article Cancer Chemother Pharmacol · September 2001 PURPOSE: The in vivo antitumor activity of a novel topoisomerase I inhibitor, J-107088, was tested in athymic nude mice bearing subcutaneous or intracranial pediatric and adult malignant CNS tumor-derived xenografts. METHODS: J-107088 was administered to a ... Full text Link to item Cite

Therapeutic activity of 7-[(2-trimethylsilyl)ethyl)]-20 (S)-camptothecin against central nervous system tumor-derived xenografts in athymic mice.

Journal article Cancer Chemother Pharmacol · July 2001 PURPOSE: Camptothecins have emerged as an important new class of antitumor drugs. Camptothecin derivatives such as CPT-11 and topotecan are commercially available and approved for the treatment of colorectal (CPT-11) and ovarian and small-cell lung cancer ... Full text Link to item Cite

A genetically tractable model of human glioma formation.

Journal article Cancer Res · May 1, 2001 Gliomas remain one of the deadliest forms of cancer. Improved therapeutics will require a better understanding of the molecular nature of these tumors. We, therefore, mimicked the most common genetic changes found in grade III-IV gliomas, disruption of the ... Link to item Cite

Long term response in a patient with neoplastic meningitis secondary to melanoma treated with (131)I-radiolabeled antichondroitin proteoglycan sulfate Mel-14 F(ab')(2): a case study.

Journal article Cancer · May 1, 2001 Even with novel chemotherapeutic agents and external beam radiation therapy, the prognosis of neoplastic meningitis secondary to malignant melanoma is still dismal. The authors report a case study of a 46-year-old white female who presented with progressiv ... Link to item Cite

Molecular profiling of astrocytomas.

Journal article JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY · May 1, 2001 Link to item Cite

Beta emitter glioma therapy

Journal article MODERN PATHOLOGY · January 1, 2001 Link to item Cite

Beta emitter glioma therapy

Journal article LABORATORY INVESTIGATION · January 1, 2001 Link to item Cite

Increased binding affinity enhances targeting of glioma xenografts by EGFRvIII-specific scFv.

Journal article Int J Cancer · December 15, 2000 Combinatorial variation of CDR3 of V(H) and V(L), followed by phage display, was used to select affinity mutants of the parental anti-epidermal growth factor receptor-vIII (EGFRvIII) scFv MR1. One mutant, MR1-1(scFv), had increased specific binding affinit ... Full text Link to item Cite

Phase I trial results of iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomas.

Journal article J Clin Oncol · November 15, 2000 PURPOSE: To determine the maximum-tolerated dose (MTD) of iodine-131 ((131)I)-labeled 81C6 antitenascin monoclonal antibody (mAb) administered clinically into surgically created resection cavities (SCRCs) in malignant glioma patients and to identify any ob ... Full text Link to item Cite

Phase I trial of carmustine plus O6-benzylguanine for patients with recurrent or progressive malignant glioma.

Journal article J Clin Oncol · October 15, 2000 PURPOSE: The major mechanism of resistance to alkylnitrosourea therapy involves the DNA repair protein O(6)-alkylguanine-DNA alkyltransferase (AGT), which removes chloroethylation or methylation damage from the O(6) position of guanine. O(6)-benzylguanine ... Full text Link to item Cite

Schedule-dependent activity of temozolomide plus CPT-11 against a human central nervous system tumor-derived xenograft.

Journal article Clin Cancer Res · October 2000 Temozolomide, an imidazole tetrazinone, and CPT-11, a camptothecin derivative, have previously been shown to have anti-central nervous system tumor activity in laboratory and clinical studies. The current experiments were designed to evaluate the activity ... Link to item Cite

Temozolomide delivered by intracerebral microinfusion is safe and efficacious against malignant gliomas in rats.

Journal article Clin Cancer Res · October 2000 Intracerebral microinfusion (ICM) is an innovative technique of delivering therapeutic agents throughout large portions of the brain that circumvents the blood-brain barrier, minimizes systemic toxicity, and provides a homogeneous distribution of the infus ... Link to item Cite

Identifying potential tumor markers and antigens by database mining and rapid expression screening.

Journal article Genome Res · September 2000 Genes expressed specifically in malignant tissue may have potential as therapeutic targets but have been difficult to locate for most cancers. The information hidden within certain public databases can reveal RNA transcripts specifically expressed in trans ... Full text Link to item Cite

Design of a novel small peptide targeted against a tumor-specific receptor.

Journal article Biochem Biophys Res Commun · August 28, 2000 EGFRvIII is the most common deletion variant of the epidermal growth factor receptor and is found in cancers of the brain, breast, ovary, and lung. The complete absence of the receptor in healthy tissues makes it an ideal tumor marker. We sought to design ... Full text Link to item Cite

Radioiodination via D-amino acid peptide enhances cellular retention and tumor xenograft targeting of an internalizing anti-epidermal growth factor receptor variant III monoclonal antibody.

Journal article Cancer Res · August 15, 2000 The mutant epidermal growth factor receptor variant III (EGFRvIII) has been found on gliomas and other tumors but not on normal tissues, including those that express the wild-type receptor. Monoclonal antibodies (mAbs) specific for EGFRvIII are rapidly int ... Link to item Cite

Glioma-associated antigen expression in oligodendroglial neoplasms. Tenascin and epidermal growth factor receptor.

Journal article J Histochem Cytochem · August 2000 Epidermal growth factor receptor (EGFR), its variant, EGFRvIII, and tenascin are glioma-associated antigens that are hyperexpressed by neoplastic glial cells relative to normal brain, making them attractive antigenic targets for immunotherapy. Preliminary ... Full text Link to item Cite

EGFRvIII: An oncogene deletion mutant cell surface receptor target expressed by multiple tumour types

Journal article Expert Opinion on Therapeutic Targets · August 1, 2000 Optimal immunotherapeutic approaches to cancer cell eradication require the specific recognition of neoplastic cells and minimal destruction of bystander, normal cells. This is especially crucial within the CNS because of the infiltrative growth pattern of ... Full text Cite

Immunotoxins with increased activity against epidermal growth factor receptor vIII-expressing cells produced by antibody phage display.

Journal article Clin Cancer Res · July 2000 Recombinant immunotoxins are fusion proteins composed of Fv regions of antibodies and bacterial or plant toxins that are being developed for the targeted therapy of cancer. MR1(Fv)-PE38 is a single-chain recombinant immunotoxin that targets a mutant form o ... Link to item Cite

Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors.

Journal article Proc Natl Acad Sci U S A · June 20, 2000 The epidermal growth factor receptor (EGFR) is often amplified and rearranged structurally in tumors of the brain, breast, lung, and ovary. The most common mutation, EGFRvIII, is characterized by an in-frame deletion of 801 base pairs, resulting in the gen ... Full text Link to item Cite

Characterization of chromosome 17 abnormalities in medulloblastomas.

Journal article Acta Neuropathol · April 2000 Loss of portions of chromosome 17p, usually through the formation of i(17qp) is a well-known finding in medulloblastomas. Loss of heterozygosity (LOH) studies, however, occasionally demonstrate loss of the more distal portions of 17p, a pattern which is mo ... Full text Link to item Cite

Dosimetry and dose-response relationships in newly diagnosed patients with malignant gliomas treated with iodine-131-labeled anti-tenascin monoclonal antibody 81C6 therapy.

Journal article Int J Radiat Oncol Biol Phys · March 1, 2000 PURPOSE: The objective of this study was to perform the dosimetry and evaluate the dose-response relationships in newly diagnosed patients with malignant brain tumors treated by direct injections of (131)I-labeled 81C6 monoclonal antibody (MAb) into surgic ... Full text Link to item Cite

Bone marrow-derived dendritic cells pulsed with tumor homogenate induce immunity against syngeneic intracerebral glioma.

Journal article J Neuroimmunol · February 1, 2000 To evaluate the efficacy and toxicity of dendritic cell (DC) based therapy for intracerebral gliomas, we utilized a cell line derived from an astrocytoma that arose spontaneously in a VM/Dk mouse. This astrocytoma mirrors human gliomas phenotypically, morp ... Full text Link to item Cite

O6-benzylguanine-mediated enhancement of nitrosourea activity in Mer- central nervous system tumor xenografts--implications for clinical trials.

Journal article Cancer Chemother Pharmacol · 2000 PURPOSE: To evaluate the role of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) plus O6-benzylguanine (O6-BG) in the treatment of both Mer+ and Mer- tumors. METHODS: The effect of pretreatment with O6-BG on the activity of BCNU against Mer- human central nerv ... Full text Link to item Cite

Schedule-dependent activity of irinotecan plus BCNU against malignant glioma xenografts.

Journal article Cancer Chemother Pharmacol · 2000 PURPOSE: To further evaluate the activity of irinotecan (CPT-11) plus 1,3-bis-(chloroethyl)-1-nitrosourea (BCNU) in the treatment of central nervous system tumor-derived xenografts in athymic nude mice. METHODS: We report studies evaluating the schedule-de ... Full text Link to item Cite

EGFRvIII as a promising target for antibody-based brain tumor therapy.

Journal article Brain Tumor Pathol · 2000 Cell surface receptors are attractive candidates for targeted therapy of cancer. Growth factors and their receptors play important roles in the regulation of cell division, development, and differentiation. Among those, the epidermal growth factor receptor ... Full text Link to item Cite

O6-benzylguanine-mediated enhancement of nitrosourea activity in Mer- central nervous system tumor xenografts - Implications for clinical trials

Journal article Cancer Chemotherapy and Pharmacology · 2000 Purpose: To evaluate the role of 1,3-bis(2-chloroethyl)-l-nitrosourea (BCNU) plus O6-benzylguanine (O6-BG) in the treatment of both Mer+ and Mer- tumors. Methods: The effect of pretreatment with O6-BG on the activity of BCNU against Mer- human central nerv ... Cite

Transforming growth factor-beta-mediated p15(INK4B) induction and growth inhibition in astrocytes is SMAD3-dependent and a pathway prominently altered in human glioma cell lines.

Journal article J Biol Chem · December 3, 1999 We sought to characterize the pathway by which the multifunctional cytokine transforming growth factor-beta (TGF-beta) inhibits the proliferation of normal astrocytes, and we analyzed the alterations in the TGF-beta pathway in human glioma cell lines. Upon ... Full text Link to item Cite

Radiotoxicity of systemically administered 211At-labeled human/mouse chimeric monoclonal antibody: a long-term survival study with histologic analysis.

Journal article Int J Radiat Oncol Biol Phys · September 1, 1999 PURPOSE: The antitenascin human/mouse chimeric monoclonal antibody labeled with the alpha-particle-emitting radionuclide 211At is of interest as an endoradiotherapeutic agent for the treatment of brain tumors. To facilitate the investigation of 211At-label ... Full text Link to item Cite

Regional treatment of epidermal growth factor receptor vIII-expressing neoplastic meningitis with a single-chain immunotoxin, MR-1.

Journal article Clin Cancer Res · September 1999 The incidence of neoplastic meningitis is on the rise. Neoplastic meningitis can result from a direct seeding of the neuraxis by primary brain tumors or by hematogeneous spread of systemic solid tumors. A frequent genetic alteration in primary brain tumors ... Link to item Cite

Molecular genetic aspects of oligodendrogliomas including analysis by comparative genomic hybridization.

Journal article Am J Pathol · August 1999 Oligodendroglial neoplasms are a subgroup of gliomas with distinctive morphological characteristics. In the present study we have evaluated a series of these tumors to define their molecular profiles and to determine whether there is a relationship between ... Full text Link to item Cite

125I-labeled anti-epidermal growth factor receptor-vIII single-chain Fv exhibits specific and high-level targeting of glioma xenografts.

Journal article Clin Cancer Res · June 1999 A single-chain antibody fragment, MR1(scFv), with specific binding to epidermal growth factor receptor-vIII (EGFRvIII), was produced, radiolabeled, and evaluated for biodistribution in human glioma-bearing athymic mice. The mutant receptor EGFRvIII has a d ... Link to item Cite

Astatine-211 labeling of internalizing anti-EGFRvIII monoclonal antibody using N-succinimidyl 5-[211At]astato-3-pyridinecarboxylate.

Journal article Nucl Med Biol · May 1999 Monoclonal antibodies (MAbs) such as the anti-epidermal growth factor variant III (EGFRvIII) MAb L8A4 are rapidly internalized, which can lead to rapid loss of radioactivity from the tumor cell. The aim of this study was to evaluate the potential utility o ... Full text Link to item Cite

Molecular pathogenesis of malignant gliomas.

Journal article Curr Opin Oncol · May 1999 De novo glioblastomas develop in older patients without prior clinical history of less malignant tumors. Progressive glioblastomas are common among younger patients and arise through progression from lower-grade astrocytomas. CDKN2A deletions, PTEN alterat ... Full text Link to item Cite

Treatment of neoplastic meningitis with intrathecal temozolomide.

Journal article Clin Cancer Res · May 1999 Neoplastic meningitis (NM) results from leptomeningeal dissemination of cancers arising within the central nervous system or metastasizing to the leptomeninges from systemic neoplasms. The inability to produce therapeutic drug levels intrathecally (i.t.) w ... Link to item Cite

Irinotecan therapy in adults with recurrent or progressive malignant glioma.

Journal article J Clin Oncol · May 1999 PURPOSE: To determine the activity, toxicity, and pharmacokinetics of irinotecan (CPT-11, Camptosar; Pharmacia & Upjohn, Kalamazoo, MI) in the treatment of adults with progressive, persistent, or recurrent malignant glioma. PATIENTS AND METHODS: Patients w ... Full text Link to item Cite

Dosimetry of 131I-labeled 81C6 monoclonal antibody administered into surgically created resection cavities in patients with malignant brain tumors.

Journal article J Nucl Med · April 1999 UNLABELLED: The objective of this study was to perform the dosimetry of 131I-labeled 81C6 monoclonal antibody (MAb) in patients with recurrent malignant brain tumors, treated by direct injections of MAb into surgically created resection cavities (SCRCs). M ... Link to item Cite

Monoclonal antibody therapy of human gliomas: current status and future approaches.

Journal article Cancer Metastasis Rev · 1999 The development of immunotherapeutic protocols for the treatment of human CNS neoplasia over the past two decades has been impressive. Several crucial aspects have been defined, characterized, and in many cases, optimized (Wikstrand CJ, Zalutsky MR, Bigner ... Full text Link to item Cite

Modulation of cyclophosphamide activity by O6-alkylguanine-DNA alkyltransferase.

Journal article Cancer Chemother Pharmacol · 1999 PURPOSE: The human medulloblastoma cell line D283 Med (4-HCR), a line resistant to 4-hydroperoxycyclophosphamide (4-HC), displays enhanced repair of DNA interstrand crosslinks induced by phosphoramide mustard. D283 Med (4-HCR) cells are cross-resistant to ... Full text Link to item Cite

Preparation and characterization of anti-tenascin monoclonal antibody-streptavidin conjugates for pretargeting applications.

Journal article Bioconjug Chem · 1999 Radioimmunopretargeting is based on the separate injection of a modified mAb and the radionuclide and most frequently exploits the very high avidity of biotin for streptavidin (SA). Currently, we are evaluating the therapeutic potential of directly labeled ... Full text Link to item Cite

Multiple DNA repair mechanisms and alkylator resistance in the human medulloblastoma cell line D-283 Med (4-HCR).

Journal article Cancer Chemother Pharmacol · 1999 PURPOSE: We have previously reported preferential repair of DNA interstrand crosslinks in the 4-hydroperoxycyclophosphamide-resistant human medulloblastoma cell line D-283 Med (4-HCR). We now report further studies that explored the potential mechanisms un ... Full text Link to item Cite

Intrathecal busulfan treatment of human neoplastic meningitis in athymic nude rats.

Journal article J Neurooncol · 1999 The current study was designed to evaluate the toxicity and activity of Spartaject Busulfan, a microcrystalline preparation of busulfan, following its intrathecal administration into a nude rat model of human neoplastic meningitis. Animals were treated thr ... Full text Link to item Cite

Radioiodinated D-peptides as prosthetic groups for radiolabeling internalizing antibodies

Journal article Journal of Labelled Compounds and Radiopharmaceuticals · January 1, 1999 Cite

125I-labeled anti-epidermal growth factor receptor-vIII single-chain Fv exhibits specific and high-level targeting of glioma xenografts

Journal article Clinical Cancer Research · 1999 A single-chain antibody fragment, MR1(scFv), with specific binding to epidermal growth factor receptor-vIII (EGFRvIII), was produced, radiolabeled, and evaluated for biodistribution in human glioma-bearing athymic mice. The mutant receptor EGFRvIII has a d ... Cite

DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma.

Journal article J Clin Oncol · December 1998 PURPOSE: We evaluated the response to Temodal (Schering-Plough Research Institute, Kenilworth, NJ) of patients with newly diagnosed malignant glioma, as well as the predictive value of quantifying tumor DNA mismatch repair activity and O6-alkylguanine-DNA ... Full text Link to item Cite

Phase I trial of O6-benzylguanine for patients undergoing surgery for malignant glioma.

Journal article J Clin Oncol · November 1998 PURPOSE: The major mechanism of resistance to alkylnitrosourea therapy is the DNA repair protein O6-alkylguanine-DNA alkyltransferase (AGT), which removes chlorethylation or methylation damage from the O6-position of guanine. O6-benzylguanine (O6-BG) is an ... Full text Link to item Cite

Human IgG2 constant region enhances in vivo stability of anti-tenascin antibody 81C6 compared with its murine parent.

Journal article Clin Cancer Res · October 1998 The in vivo properties of radiolabeled chimeric monoclonal antibodies (mAbs) with human IgG1 and IgG3 constant regions generally are similar to those of their corresponding murine construct. In contrast, we have observed that chimeric anti-tenascin mAb 81C ... Link to item Cite

Local production of TGF beta1 inhibits cerebral edema, enhances TNF-alpha induced apoptosis and improves survival in a murine glioma model.

Journal article J Neuroimmunol · June 1, 1998 We have previously reported that local secretion of either TNF-alpha or TGF beta1 by intracerebral SMA-560 malignant glioma tumor cells can reduce or eliminate tumor growth in mice. However, the use of TNF-alpha, while improving the overall survival of tum ... Full text Link to item Cite

Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial results.

Journal article J Clin Oncol · June 1998 PURPOSE: To determine the maximum-tolerated dose (MTD) of iodine 131 (131I)-labeled 81C6 monoclonal antibody (mAb) in brain tumor patients with surgically created resection cavities (SCRCs) and to identify any objective responses to this treatment. METHODS ... Full text Link to item Cite

Analysis of DNA mismatch repair proteins in human medulloblastoma.

Journal article Clin Cancer Res · June 1998 During replication, the primary function of the eukaryotic DNA mismatch repair (MMR) system is to recognize and correct mismatched base pairs within the DNA helix. Deficiencies in MMR have been reported previously in cases of hereditary nonpolyposis colore ... Link to item Cite

Molecular and immunohistologic (IHC) studies on oligodendroglial (O) tumors

Journal article JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY · May 1, 1998 Link to item Cite

The class III variant of the epidermal growth factor receptor (EGFRvIII): characterization and utilization as an immunotherapeutic target.

Journal article J Neurovirol · April 1998 Any immunotherapeutic approach to cancer cell eradication is based upon the specific recognition of neoplastic cells and the sparing of surrounding normal tissue; perhaps nowhere is this distinction more important than within the central nervous system, du ... Full text Link to item Cite

Endogenous expression of transforming growth factor beta1 inhibits growth and tumorigenicity and enhances Fas-mediated apoptosis in a murine high-grade glioma model.

Journal article Cancer Res · January 15, 1998 It has been hypothesized that transforming growth factor beta (TGF-beta) may prevent immune-mediated glioma cell elimination; however, previous work has also indicated that increased TGF-beta may lead to reduced proliferation, induction of apoptosis, and e ... Link to item Cite

Therapeutic efficacy of vinorelbine against pediatric and adult central nervous system tumors.

Journal article Cancer Chemother Pharmacol · 1998 PURPOSE: The activity of vinorellbine, a new semisynthetic vinca alkaloid, was evaluated against a battery of human tumor xenografts derived from adult and pediatric CNS malignancies. METHODS: Tumors included adult high-grade gliomas (D-54 MG, D-245 MG), c ... Full text Link to item Cite

Enhancement of irinotecan (CPT-11) activity against central nervous system tumor xenografts by alkylating agents.

Journal article Cancer Chemother Pharmacol · 1998 Two major obstacles in the treatment of patients with central nervous system malignancies are drug resistance and host toxicity. The goal of combination chemotherapy is to achieve therapeutic effects that are more favorable than using a single drug alone, ... Full text Link to item Cite

Recent advances in the biology of central nervous system tumors.

Journal article Curr Opin Neurol · December 1997 The failure of conventional therapies for many malignant brain tumors has led to a search for more promising alternatives. Recent advances have elucidated a variety of biological factors that act to determine the growth and invasiveness of central nervous ... Full text Link to item Cite

Characterization of a spontaneous murine astrocytoma and abrogation of its tumorigenicity by cytokine secretion.

Journal article Neurosurgery · December 1997 OBJECTIVE: The promise of immunotherapies developed against brain tumors in animal models has not been realized in human clinical trials. This may be because of the routine use of rodent tumors artificially induced by chemicals or viruses that do not accur ... Full text Link to item Cite

Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors.

Journal article J Exp Med · October 6, 1997 Recent studies have shown that the brain is not a barrier to successful active immunotherapy that uses gene-modified autologous tumor cell vaccines. In this study, we compared the efficacy of two types of vaccines for the treatment of tumors within the cen ... Full text Link to item Cite

In vitro and in vivo behavior of radiolabeled chimeric anti-EGFRvIII monoclonal antibody: comparison with its murine parent.

Journal article Nucl Med Biol · October 1997 The mutant version of the epidermal growth factor receptor EGFRvIII has been found on gliomas and other tumors, but not on normal tissues. Radioiodinated murine (mu) L8A4 monoclonal antibody (MAb) specifically targets EGFRvIII xenografts in vivo when label ... Full text Link to item Cite

PTEN gene mutations are seen in high-grade but not in low-grade gliomas.

Journal article Cancer Res · October 1, 1997 The PTEN gene, located on 10q23, has recently been implicated as a candidate tumor suppressor gene in brain, breast and prostate tumors. In the present study, 123 brain tumors, including various grades and histological types of gliomas occurring in childre ... Link to item Cite

Cell surface localization and density of the tumor-associated variant of the epidermal growth factor receptor, EGFRvIII.

Journal article Cancer Res · September 15, 1997 The potential of therapeutic targeting of tumor cell surface epidermal growth factor receptors (EGFRs) by modified ligands or specific antibodies has been limited by the normal tissue distribution of the receptor. The identification and characterization of ... Link to item Cite

A genetically modified allogeneic cellular vaccine generates MHC class I-restricted cytotoxic responses against tumor-associated antigens and protects against CNS tumors in vivo.

Journal article J Neuroimmunol · September 1997 An active immunotherapeutic strategy using transfected allogeneic cells for targeting the mutant epidermal growth factor receptor (EGFRvIII) on intracranial tumors was examined. Immunization with allogeneic 300.19/EGFRvIII cells induced CD8+ cytotoxic T-ly ... Full text Link to item Cite

Methylator resistance mediated by mismatch repair deficiency in a glioblastoma multiforme xenograft.

Journal article Cancer Res · July 15, 1997 A methylator-resistant human glioblastoma multiforme xenograft, D-245 MG (PR), in athymic nude mice was established by serially treating the parent xenograft D-245 MG with procarbazine. D-245 MG xenografts were sensitive to procarbazine, temozolomide, N-me ... Link to item Cite

Receptor dimerization is not a factor in the signalling activity of a transforming variant epidermal growth factor receptor (EGFRvIII).

Journal article Biochem J · June 15, 1997 The type-III deletion variant of the epidermal growth factor receptor (EGFRvIII) is frequently found in glioblastomas and other malignant human tumours. Although EGFRvIII confers ligand-independent oncogenic transformation of cell lines, the mechanism by w ... Full text Link to item Cite

Extracellular matrix antigens in capillary hemangioblastoma.

Journal article JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY · May 1, 1997 Link to item Cite

Viruses and oncogenes in brain tumors.

Journal article J Neurovirol · May 1997 Link to item Cite

A method for labeling internalizing antibodies with astatine-211.

Journal article JOURNAL OF NUCLEAR MEDICINE · May 1, 1997 Link to item Cite

Improved targeting of an anti-epidermal growth factor receptor variant III monoclonal antibody in tumor xenografts after labeling using N-succinimidyl 5-iodo-3-pyridinecarboxylate.

Journal article Cancer Res · April 15, 1997 Monoclonal antibody (mAb) L8A4, specific for the tumor-associated mutant epidermal growth factor receptor variant III (EGFRvII), is internalized and degraded after cell binding. Four paired-label experiments were performed in athymic mice bearing EGFRvIII- ... Link to item Cite

Tissue distribution and radiation dosimetry of astatine-211-labeled chimeric 81C6, an alpha-particle-emitting immunoconjugate.

Journal article Nucl Med Biol · April 1997 A paired-label study was performed in athymic mice bearing subcutaneous D-54 MG human glioma xenografts to compare the localization of human/mouse anti-tenascin chimeric antibody 81C6 labeled by reaction with N-succinimidyl 3-[211At]astatobenzoate and N-su ... Full text Link to item Cite

Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against pediatric and adult central nervous system tumor xenografts.

Journal article Cancer Chemother Pharmacol · 1997 Therapy of patients with malignant central nervous system tumors is frequently unsuccessful, reflecting limitations of current surgical, radiotherapeutic, and pharmacotherapeutic treatments. The camptothecin derivative irinotecan (CPT-11) has been shown to ... Full text Link to item Cite

L-amino acid oxidase (LOX) modulation of melphalan activity against intracranial glioma.

Journal article Cancer Chemother Pharmacol · 1997 These studies evaluated the efficacy of sequential pretreatment with L-amino acid oxidase (LOX) and LOX antiserum in the modulation of melphalan activity against intracranial glioma in athymic nude mice. LOX produced statistically significant (P < 0.01) de ... Full text Link to item Cite

Local hyperthermia improves uptake of a chimeric monoclonal antibody in a subcutaneous xenograft model.

Journal article Clin Cancer Res · January 1997 This study was undertaken to determine the effect of local hyperthermia on the tissue distribution of a chimeric human/mouse IgG2 monoclonal antibody, 81C6, reactive with the extracellular matrix protein tenascin, which is expressed at high levels in gliom ... Link to item Cite

Characterization of the mechanisms of busulfan resistance in a human glioblastoma multiforme xenograft.

Journal article Cancer Chemother Pharmacol · 1997 Busulfan is an alkylating agent commonly used in the treatment of chronic myelogenous leukemia and in combination with cyclophosphamide in preparation for allogeneic bone marrow transplantation. Serial treatment of a childhood high-grade glioma xenograft ( ... Full text Link to item Cite

Intraarterial O6-benzylguanine enables the specific therapy of nitrosourea-resistant intracranial human glioma xenografts in athymic rats with 1,3-bis(2-chloroethyl)-1-nitrosourea.

Journal article Cancer Chemother Pharmacol · 1997 The prognosis for patients with malignant gliomas continues to be dismal. The high degree of resistance of gliomas to nitrosourea-based chemotherapy is one major factor in poor treatment outcome. The identification of O6-alkylguanine-DNA alkyltransferase ( ... Full text Link to item Cite

2013 The impact of hypoxia and oxygenation modification on the radiation response of an intracranial rat glioma

Journal article International Journal of Radiation Oncology*Biology*Physics · January 1997 Full text Cite

Recombinant immunotoxins specific for a mutant epidermal growth factor receptor: targeting with a single chain antibody variable domain isolated by phage display.

Journal article Proc Natl Acad Sci U S A · December 10, 1996 EGFRvIII is a mutant epidermal growth factor receptor found in glioblastoma, and in carcinoma of the breast, ovary, and lung. The mutant receptor has a deletion in its extracellular domain that results in the formation of a new, tumor-specific extracellula ... Full text Link to item Cite

Radioiodination of internalizing monoclonal antibodies using N-succinimidyl 5-iodo-3-pyridinecarboxylate.

Journal article Cancer Res · November 1, 1996 Monoclonal antibodies (mAbs) that internalize following binding to cell-surface receptors require radiolabeling approaches that minimize loss of radioactivity from the cell after intracellular processing. One class of internalizing mAbs of great interest f ... Link to item Cite

A method for the radiohalogenation of internalizing antibodies.

Journal article JOURNAL OF NUCLEAR MEDICINE · October 1, 1996 Link to item Cite

Subcutaneous vaccination with irradiated, cytokine-producing tumor cells stimulates CD8+ cell-mediated immunity against tumors located in the "immunologically privileged" central nervous system.

Journal article Proc Natl Acad Sci U S A · September 17, 1996 Vaccination with cytokine-producing tumor cells generates potent immune responses against tumors outside the central nervous system (CNS). The CNS, however, is a barrier to allograft and xenograft rejection, and established tumors within the CNS have faile ... Full text Link to item Cite

Successful treatment of childhood pilocytic astrocytomas metastatic to the leptomeninges with high-dose cyclophosphamide.

Journal article Med Pediatr Oncol · July 1996 Leptomeningeal dissemination of childhood pilocytic astrocytoma (PA) is a rare event with little information available regarding therapy. We report here four children with disseminated PA whom we treated with high doses of cyclophosphamide with clinical be ... Full text Link to item Cite

Treatment of patients with pineoblastoma with high dose cyclophosphamide

Journal article Medical and Pediatric Oncology · June 1996 Full text Cite

In vivo growth conditions suppress the expression of ganglioside GM2 and favour that of lacto series gangliosides in the human glioma D-54MG cell line.

Journal article Glycoconj J · June 1996 The human glioma D-54MG cell line grown in vitro primarily expresses ganglio series gangliosides, particularly GM2. Subcutaneous injection of these cells into nude mice produced xenografts with an increased content of the human glioma-associated lacto seri ... Full text Link to item Cite

Intrathecal 131I-labeled antitenascin monoclonal antibody 81C6 treatment of patients with leptomeningeal neoplasms or primary brain tumor resection cavities with subarachnoid communication: phase I trial results.

Journal article Clin Cancer Res · June 1996 We aimed to determine the maximum tolerated dose (MTD) of 131I-labeled 81C6 in patients with leptomeningeal neoplasms or brain tumor resection cavities with subarachnoid communication and to identify any objective responses. 81C6 is a murine IgG monoclonal ... Link to item Cite

Treatment of patients with pineoblastoma with high dose cyclophosphamide.

Journal article Med Pediatr Oncol · June 1996 The outcome for patients with pineoblastoma has historically been very poor, with most patients dying of disseminated disease despite irradiation. Furthermore, the low incidence of this tumor has hindered progress toward defining better treatment strategie ... Full text Link to item Cite

Chimeric anti-tenascin antibody 81C6: increased tumor localization compared with its murine parent.

Journal article Nucl Med Biol · May 1996 When labeled using the Iodogen method, a chimeric antibody composed of the human IgG2 constant region and the variable regions of murine anti-tenascin 81C6 exhibited superior uptake in human glioma xenografts compared with its murine parent. In the current ... Full text Link to item Cite

Production and characterization of two ependymoma xenografts.

Journal article J Neuropathol Exp Neurol · May 1996 Childhood ependymomas exhibit epidemiologic, anatomic, histologic, and biologic features and distinguish them from other gliomas. Because of their propensity to grow in functionally sensitive regions of the brain, adequate tumor sampling for basic and ther ... Full text Link to item Cite

Radiotoxicity of systematically administered [211At]astatide in B6C3F1 and BALB/c (nu/nu) mice: a long-term survival study with histologic analysis.

Journal article Int J Radiat Oncol Biol Phys · April 1, 1996 PURPOSE: The present study undertook to establish the dose (LD) of systematically administered (via tail vein) sodium [211At]astatide that would kill 10% (LD10) of exposed animals in two mouse models and to evaluate the resulting histologic lesions. METHOD ... Full text Link to item Cite

Repair analysis of 4-hydroperoxycyclophosphamide-induced DNA interstrand crosslinking in the c-myc gene in 4-hydroperoxycyclophosphamide-sensitive and -resistant medulloblastoma cell lines.

Journal article Cancer Chemother Pharmacol · 1996 Cyclophosphamide is one of the most active agents in the treatment of medulloblastoma. However, development of resistance to this alkylator frequently occurs and is the harbinger of tumor progression and death. In order to understand the biochemical basis ... Full text Link to item Cite

Enhancement of melphalan activity by inhibition of DNA polymerase-alpha and DNA polymerase-beta.

Journal article Cancer Chemother Pharmacol · 1996 Our previous studies exploring melphalan resistance in the human rhabdomyosarcoma xenograft TE-671 MR revealed elevation of DNA polymerase-alpha and DNA polymerase-beta. The present study evaluated the alteration of melphalan activity in TE-671 (melphalan- ... Full text Link to item Cite

Primary brain tumor incidence rates in four United States regions, 1985-1989: a pilot study.

Journal article Neuroepidemiology · 1996 There has been controversy in the last decade over whether the reported increase in brain tumors reflects a real increase in incidence rates. Incidence data on the full spectrum of brain tumors is lacking in the discussion since current cancer reports in t ... Full text Link to item Cite

Radioimmunotherapy with alpha-particle emitting radioimmunoconjugates.

Journal article Acta Oncol · 1996 Radionuclides which decay by the emission of alpha-particles are attractive for certain radioimmunotherapeutic applications. These include the treatment of lymphomas, compartmentally spread malignancies such as ovarian cancer and neoplastic meningitis, and ... Full text Link to item Cite

A structural basis for a phosphoramide mustard-induced DNA interstrand cross-link at 5'-d(GAC).

Journal article Proc Natl Acad Sci U S A · December 19, 1995 Phosphoramide mustard-induced DNA interstrand cross-links were studied both in vitro and by computer simulation. The local determinants for the formation of phosphoramide mustard-induced DNA interstrand cross-links were defined by using different pairs of ... Full text Link to item Cite

Efficacy of compartmental administration of immunotoxin LMB-1 (B3-LysPE38) in a rat model of carcinomatous meningitis.

Journal article Clin Cancer Res · December 1995 LMB-1 (B3-LysPE38) is an immunotoxin composed of the tumor-reactive monoclonal antibody B3 and a genetically engineered form of Pseudomonas exotoxin. Monoclonal antibody B3 reacts with a carbohydrate epitope that is found on a number of solid tumors (e.g., ... Link to item Cite

Tumor antigens in astrocytic gliomas.

Journal article Glia · November 1995 Gliomas affect 15,000 to 17,000 Americans every year and carry a dismal prognosis. The potential of immunologically mediated diagnosis and therapy, although greatly enhanced since the advent of monoclonal antibodies, has not been fully realized due to sign ... Full text Link to item Cite

Tumor-specific anti-epidermal growth factor receptor variant III monoclonal antibodies: use of the tyramine-cellobiose radioiodination method enhances cellular retention and uptake in tumor xenografts.

Journal article Cancer Res · October 1, 1995 Amplification and rearrangement of the epidermal growth factor receptor (EGFR) gene are characteristics of many types of tumors. One class of EGFR mutations, EGFRvIII, is characterized by an in-frame deletion resulting in a truncated external domain of the ... Link to item Cite

Epidermal growth factor ligand-independent, unregulated, cell-transforming potential of a naturally occurring human mutant EGFRvIII gene.

Journal article Cell Growth Differ · October 1995 The type III deletion-mutant gene for the epidermal growth factor receptor (EGFRvIII) is frequently expressed in glioblastomas and in breast and non-small cell lung carcinomas. To understand its contribution to the malignant phenotype in humans, we transfe ... Link to item Cite

Intraarterial administration of melphalan for treatment of intracranial human glioma xenografts in athymic rats.

Journal article Cancer Res · September 1, 1995 Malignant gliomas will affect 15,000-17,000 Americans each year and carry a dismal prognosis. Adjuvant chemotherapy is hampered by inadequate drug delivery, systemic toxicity, and a markedly variable biological sensitivity. Intraarterial (i.a.) therapy may ... Link to item Cite

Cyclophosphamide in combination with sargramostim for treatment of recurrent medulloblastoma.

Journal article Med Pediatr Oncol · September 1995 Thirteen patients with recurrent medulloblastoma were treated with cyclophosphamide in association with Sargramostim. Cyclophosphamide was given at doses ranging between 1.0-2.5 g/m2 daily for two doses. Sargramostim was given at a fixed dose of 250 microg ... Full text Link to item Cite

The effect of L-amino acid oxidase on activity of melphalan against an intracranial xenograft

Journal article Cancer Chemotherapy and Pharmacology · August 1, 1995 Full text Cite

Immunotoxins that target an oncogenic mutant epidermal growth factor receptor expressed in human tumors.

Journal article Clin Cancer Res · August 1995 Human cancers arise from a series of mutations, many of which direct the expression of mutant proteins with altered functions. These aberrant proteins are attractive targets for new therapeutic agents. One such protein is a mutant epidermal growth factor r ... Link to item Cite

Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas.

Journal article Cancer Res · July 15, 1995 Despite molecular biological advances in understanding human cancers, translation into therapy has been less forthcoming; targeting neoplastic cells still requires that tumor-specific markers, preferably those on the cell surface, be identified. The epider ... Link to item Cite

Activity of temozolomide in the treatment of central nervous system tumor xenografts.

Journal article Cancer Res · July 1, 1995 The activity of 8-carbamoyl-3-methylimidazo[5,1-d]-1,2,3,5-tetrazin- 4(3H)-one (temozolomide) in the treatment of a panel of xenografts derived from ependymoma, medulloblastoma, and childhood and adult high-grade glioma was evaluated in athymic nude mice b ... Link to item Cite

Flunarizine enhancement of melphalan activity against drug-sensitive/resistant rhabdomyosarcoma.

Journal article Br J Cancer · June 1995 Flunarizine, a diphenylpiperazine calcium channel blocker, is known to increase tumor blood flow. It also interferes with calmodulin function, repair of DNA damage and drug resistance associated with P-glycoprotein. Flunarizine was tested for its ability t ... Full text Link to item Cite

A pial window model for the intracranial study of human glioma microvascular function.

Journal article Neurosurgery · May 1995 A new model for human brain tumor uses the intracranial placement of tumor xenografts under transparent glass cranial windows in nude rats, which require no immunosuppression for tumor engraftment. Adult male nude rats underwent implantation of human anapl ... Full text Link to item Cite

Dose escalation trial of cyclophosphamide with Sargramostim in the treatment of central nervous system (CNS) neoplasms.

Journal article Med Pediatr Oncol · April 1995 We conducted a dose escalation trial of cyclophosphamide plus Sargramostim in the therapy of patients with newly diagnosed or recurrent central nervous system tumors. Cyclophosphamide was administered at doses ranging between 1.0 and 2.5 g/m2 daily for two ... Full text Link to item Cite

Intrathecal administration of single-chain immunotoxin, LMB-7 [B3(Fv)-PE38], produces cures of carcinomatous meningitis in a rat model.

Journal article Proc Natl Acad Sci U S A · March 28, 1995 LMB-7 [B3(Fv)-PE38] is a single-chain immunotoxin constructed from the murine monoclonal antibody B3 and a truncated from of Pseudomonas exotoxin PE38. Antibody B3 recognizes a carbohydrate epitope found on solid tumors that frequently invade the intrathec ... Full text Link to item Cite

The effect of L-amino acid oxidase on activity of melphalan against an intracranial xenograft.

Journal article Cancer Chemother Pharmacol · 1995 We have previously shown that diet restriction-induced depletion of large neutral amino acids (LNAAs) in murine plasma to 46% of control significantly enhances intracranial delivery of melphalan without enhancing delivery to other organs. Studies have now ... Full text Link to item Cite

Cyclophosphamide therapy of medulloblastoma: from the laboratory to the clinic and back again (and again and again).

Journal article J Neurooncol · 1995 Medulloblastoma, the most common malignancy of childhood, was originally shown to be sensitive to cyclophosphamide in 1981. We have used combined laboratory and clinical investigations to demonstrate the synergy of cyclophosphamide and vincristine in the t ... Full text Link to item Cite

Hyperthermic modulation of radiolabelled antibody uptake in a human glioma xenograft and normal tissues.

Journal article Int J Hyperthermia · 1995 These experiments investigate the biodistribution of radiolabelled MAb in a human glioma xenograft model after 4 h of local hyperthermia (HT) with a twofold purpose: to maximize the ratio of cumulative isotope activity in tumour relative to normal tissues, ... Full text Link to item Cite

Prognostic implications of chromosome 17p deletions in human medulloblastomas.

Journal article J Neurooncol · 1995 DNA derived from medulloblastoma biopsies was analyzed to determine if deletions of the 17p region, mutations of the TP53 gene, or amplification of the c-myc, N-myc, EGFR (epidermal growth factor receptor), or MDM2 (murine double-minute-2) genes was indica ... Full text Link to item Cite

Phase I studies of treatment of malignant gliomas and neoplastic meningitis with 131I-radiolabeled monoclonal antibodies anti-tenascin 81C6 and anti-chondroitin proteoglycan sulfate Me1-14 F (ab')2--a preliminary report.

Journal article J Neurooncol · 1995 The advent of monoclonal antibody (MAb) technology has made Ehrlich's postulate of the 'magic bullet' an attainable goal. Although specific localization of polyvalent antibodies to human gliomas was demonstrated in the 1960s, the lack of specific, high aff ... Full text Link to item Cite

Deletion of p16 and p15 genes in brain tumors.

Journal article Cancer Res · December 15, 1994 We have used molecular genetic methods to examine the status of cell cycle-inhibitory genes in human brain tumors. We found that p16 and a neighboring gene, p15, were often homozygously deleted in glioblastoma multiformes but not in medulloblastomas or epe ... Link to item Cite

Intrathecal melphalan therapy of human neoplastic meningitis in athymic nude rats.

Journal article Cancer Res · September 1, 1994 We report the activity and toxicity of intrathecal melphalan in the treatment of human neoplastic meningitis in the subarachnoid space of athymic nude rats. Animals received injections via chronic indwelling subarachnoid catheters with 5 x 10(5) or 5 x 10( ... Link to item Cite

Radioimmunotherapy of neoplastic meningitis in rats using an alpha-particle-emitting immunoconjugate.

Journal article Cancer Res · September 1, 1994 Because of their short range and high linear energy transfer, alpha-particles may be particularly effective in the treatment of neoplastic meningitis. Monoclonal antibody 81C6 was labeled with alpha-particle-emitting 211At using N-succinimidyl3-[211At]asta ... Link to item Cite

Elevated DNA polymerase alpha, DNA polymerase beta, and DNA topoisomerase II in a melphalan-resistant rhabdomyosarcoma xenograft that is cross-resistant to nitrosoureas and topotecan.

Journal article Cancer Res · July 1, 1994 Previous investigations have revealed that the human TE-671 MR human rhabdomyosarcoma xenograft selected in vivo for melphalan resistance (M. C. Rosenberg, et al., Cancer Res., 49: 6917-6922, 1989) is cross-resistant to a wide variety of alkylating agents ... Link to item Cite

Generation and characterization of a mouse/human chimeric antibody directed against extracellular matrix protein tenascin.

Journal article J Neuroimmunol · July 1994 The murine anti-tenascin monoclonal antibody 81C6, following iodination, has been shown to be an efficient localizing and therapeutic agent in both subcutaneous and intracranial human glioma xenograft models in athymic mice and rats. Similarly, effective m ... Full text Link to item Cite

Immunohistochemistry of the glial fibrillary acidic protein: basic and applied considerations.

Journal article Brain Pathol · July 1994 The immunohistochemical localization of glial fibrillary acidic protein has proven its utility in the histologic identification of benign astrocytes and neoplastic cells of glial lineage in the central nervous system. Its application in the developing nerv ... Full text Link to item Cite

Re: Toxicity of intrathecal melphalan.

Journal article J Natl Cancer Inst · June 1, 1994 Full text Link to item Cite

Mouse/human chimeric Me1-14 antibody: genomic cloning of the variable region genes, linkage to human constant region genes, expression, and characterization.

Journal article Hybridoma · April 1994 Murine monoclonal antibody Me1-14, which recognizes an epitope on chondroitin proteoglycan sulfate expressed in malignant glioma and melanoma, has been used for radioimmunolocalization and therapy both in animal models and in patients. Here, we report the ... Full text Link to item Cite

Immunobiology of malignant astrocytomas.

Journal article Semin Oncol · April 1994 Link to item Cite

Alterations of the TP53 gene in human gliomas.

Journal article Cancer Res · March 1, 1994 Glial tumors of all grades and histological types from 72 adults and 48 children were analyzed for mutations of the TP53 gene, loss of heterozygosity (LOH) for 17p, and accumulation of TP53 protein to determine whether the incidence and type of TP53 altera ... Link to item Cite

Busulfan therapy of central nervous system xenografts in athymic mice.

Journal article Cancer Chemother Pharmacol · 1994 We evaluated the antitumor activity of busulfan against a panel of tumor cell lines and xenografts in athymic nude mice derived from childhood high-grade glioma, adult high-grade glioma, ependymoma, and medulloblastoma. Busulfan displayed similar activity ... Full text Link to item Cite

Altered expression of ganglioside phenotypes of human gliomas in vivo and in vitro.

Journal article Mol Chem Neuropathol · 1994 A library of epitope-defined antiganglioside monoclonal antibodies has been used to analyze the ganglioside phenotype of human glioma cell lines, rodent xenografts derived from them, and a separate panel of human glioma biopsies by multiple quantitative an ... Full text Link to item Cite

Activity of 9-dimethylaminomethyl-10-hydroxycamptothecin against pediatric and adult central nervous system tumor xenografts.

Journal article Cancer Chemother Pharmacol · 1994 The activity of dimethylaminomethyl-10-hydroxycamptothecin (topotecan) was evaluated against a panel of xenografts derived from ependymomas (D528 EP, D612 EP), childhood high-grade gliomas (D-456 MG, D-212 MG), adult high-grade gliomas (D-245 MG, D-54 MG), ... Full text Link to item Cite

Detection of glioma-associated gangliosides GM2, GD2, GD3, 3'-isoLM1 3',6'-isoLD1 in central nervous system tumors in vitro and in vivo using epitope-defined monoclonal antibodies.

Journal article Prog Brain Res · 1994 In this study, MAbs to the 'conventional' gangliosides expressed by human gliomas were generated and used to detect ganglioside species previously unisolated or defined in normal adult CNS tissue. Despite the marked phenotypic and genotypic heterogeneity s ... Full text Link to item Cite

Radioiodination of a monoclonal antibody using N-succinimidyl 5-iodo-3-pyridinecarboxylate.

Journal article Nucl Med Biol · October 1993 The potential utility of N-succinimidyl 5-iodo-3-pyridinecarboxylate (SIPC) for the radioiodination of monoclonal antibodies was investigated. Paired-label studies were performed using the anti-tenascin antibody 81C6 in athymic mice bearing subcutaneous D- ... Full text Link to item Cite

Tenascin expression in prostatic hyperplasia, intraepithelial neoplasia, and carcinoma.

Journal article Hum Pathol · September 1993 The expression of tenascin, an extracellular matrix glycoprotein, was studied in three human prostatic carcinoma cell lines by Northern and Western blot analyses and in human prostate tissues by immunohistochemistry and Western blot analysis. All three car ... Full text Link to item Cite

Expression of mutated epidermal growth factor receptor by non-small cell lung carcinomas.

Journal article Cancer Res · July 15, 1993 The development of novel immunotherapy strategies for non-small cell lung cancer (NSCLC) will be facilitated by the identification of tumor-specific targets. Although the epidermal growth factor receptor (EGFR) is overexpressed in many cases of NSCLC, its ... Link to item Cite

Investigation of a synthetic peptide as immunogen for a variant epidermal growth factor receptor associated with gliomas.

Journal article J Neuroimmunol · July 1993 We have previously demonstrated antibody production to a glioma-associated variant form of the human epidermal growth factor receptor in rabbits that had received a synthetic peptide mimicking the unique primary structure of the variant protein as immunoge ... Full text Link to item Cite

Distribution and dosimetry of I-123-labeled monoclonal antibody 81C6 in patients with anaplastic glioma.

Journal article Invest Radiol · June 1993 RATIONALE AND OBJECTIVES: Monoclonal antibody 81C6 reacts with the extracellular matrix antigen, tenascin, present on gliomas and other tumors, as well as several normal tissues, including spleen and liver tissue. Single photon emission computed tomography ... Link to item Cite

Intraarterial therapy of human glioma xenografts in athymic rats using 4-hydroperoxycyclophosphamide.

Journal article Cancer Res · May 15, 1993 The addition of chemotherapy, notably using nitrosoureas, in the treatment of patients with glioblastoma multiforme has resulted in only modest improvements in long-term patient survival over the use of surgical intervention and irradiation alone. Intraart ... Link to item Cite

EXPRESSION OF C-MYC IN MEDULLOBLASTOMA XENOGRAFTS

Journal article Journal of Neuropathology and Experimental Neurology · May 1993 Full text Cite

GENERATION AND CHARACTERIZATION OF MOUSE-HUMAN CHIMERIC MEL-14 ANTIBODY

Journal article JOURNAL OF IMMUNOLOGY · April 15, 1993 Link to item Cite

Development of a model of melphalan-induced gastrointestinal toxicity in mice.

Journal article Cancer Chemother Pharmacol · 1993 The tolerated dose of melphalan is limited by bone marrow suppression; when this complication is ameliorated by bone marrow transplantation, the dose-limiting toxicity becomes gastrointestinal mucositis. No intervention to date has been successful in modul ... Full text Link to item Cite

Identification of nitrosourea-resistant human rhabdomyosarcomas by in situ immunostaining of O6-methylguanine-DNA methyltransferase.

Journal article Oncol Res · 1993 Cellular levels of O6-methylguanine-DNA methyltransferase (MGMT) correlate strongly with cellular resistance to carcinogenic and chemotherapeutic agents that produce adducts at the O6-position of guanine in DNA. Although biochemical and molecular assays ca ... Link to item Cite

Lactotetraose series ganglioside 3',6'-isoLD1 in tumors of central nervous and other systems in vitro and in vivo.

Journal article Cancer Res · January 1, 1993 Two monoclonal antibodies, DMAb-21 and DMAb-22, directed against the lactotetraose series ganglioside-associated epitope IV3NeuAc,III6-NeuAcLcOse4Cer (3',6'-isoLD1), were found to define the minimum binding epitope NeuAc(or NeuGc)alpha 2-3Gal beta 1-3(NeuA ... Link to item Cite

Randomized comparison of diaziquone and carmustine in the treatment of adults with anaplastic glioma.

Journal article J Clin Oncol · January 1993 PURPOSE: We conducted a phase III trial comparing intravenous (IV) diaziquone (AZQ) and carmustine (BCNU) as single agents in patients with cerebral anaplastic gliomas who had received surgery and radiotherapy. Its purpose was to compare the efficacy of AZ ... Full text Link to item Cite

Intraarterial Therapy of Human Glioma Xenografts in Athymic Rats Using 4-Hydroperoxycyclophosphamide

Journal article Cancer Research · January 1, 1993 The addition of chemotherapy, notably using nitrosoureas, in the treatment of patients with glioblastoma multiforme has resulted in only modest improvements in long-term patient survival over the use of surgical intervention and irradiation alone. Intraart ... Cite

Enhancement of nitrosourea activity in medulloblastoma and glioblastoma multiforme.

Journal article J Natl Cancer Inst · December 16, 1992 BACKGROUND: Although chemotherapy offers promise of increased survival for children with medulloblastoma and glioblastoma multiforme, drug resistance occurs frequently, resulting in tumor progression and death. Resistance to nitrosoureas and methylating ag ... Full text Link to item Cite

The effect of an amino acid-lowering diet on the rate of melphalan entry into brain and xenotransplanted glioma.

Journal article Cancer Res · October 15, 1992 Melphalan (L-phenylalanine mustard, L-PAM, alkeran; molecular weight, 305,000) is transported across tumor cell membranes and the blood-brain barrier by the large neutral amino acid (LNAA) transport system. Normally, plasma LNAA levels are high enough and ... Link to item Cite

Monoclonal antibodies to malignant human gliomas.

Journal article Mol Chem Neuropathol · October 1992 Operationally specific monoclonal antibodies (MAbs) reactive with tumor but not normal adult tissues offer great potential for diagnosis and therapy of CNS neoplasms. Two targets for specific MAb localization were chosen for this study: (1) glioma-associat ... Full text Link to item Cite

Cyclophosphamide resistance in medulloblastoma.

Journal article Cancer Res · October 1, 1992 Mechanisms of tumor resistance to 4-hydroperoxycyclophosphamide (4-HC) were studied by using a panel of human medulloblastoma cell lines either passaged in the laboratory for resistance to 4-HC or established from tumors showing clinical resistance to cycl ... Link to item Cite

Localization of fluorine-18-labeled Mel-14 monoclonal antibody F(ab')2 fragment in a subcutaneous xenograft model.

Journal article Cancer Res · September 15, 1992 Positron emission tomography is an imaging method that might improve the effectiveness of radioimmunoscintigraphy and might provide more accurate estimates of monoclonal antibody dosimetry prior to therapy. Because of its widespread availability, 2-h half- ... Link to item Cite

Immunoreactivity, pharmacokinetics and bone marrow dosimetry of intrathecal radioimmunoconjugates.

Journal article Int J Cancer · August 19, 1992 Ten patients with neoplastic meningitis were treated with a variety of 131I-monoclonal antibody (MAb) conjugates, chosen to bind to their particular malignancy. Pharmacokinetic studies revealed that MAbs leave the ventricular compartment, enter the sub-ara ... Full text Link to item Cite

Fluorine-18-labeled monoclonal antibody fragments: a potential approach for combining radioimmunoscintigraphy and positron emission tomography.

Journal article J Nucl Med · August 1992 Monoclonal antibody fragments labeled with 18F could be useful for PET if selective tumor uptake could be achieved within a few half-lives of this nuclide. To evaluate this possibility, the F(ab')2 fragment of Mel-14, an antibody reactive with gliomas and ... Link to item Cite

Loss of heterozygosity for 10q loci in human gliomas.

Journal article Genes Chromosomes Cancer · July 1992 Cytogenetic and RFLP studies have shown that chromosome 10 is frequently lost in tumor cells from glioblastomas, suggesting that a suppressor gene important in tumorigenesis is present on this chromosome. Forty-one tumors were examined for loss of heterozy ... Full text Link to item Cite

Immunotherapy and monoclonal antibody therapies.

Journal article Curr Opin Oncol · June 1992 High-grade malignancies of the central nervous system continue to be refractory to multimodality therapy. Immunotherapy with monoclonal antibodies, biologic response modifiers (eg, interleukin-2), and autologous, activated lymphocytes offer the potential f ... Full text Link to item Cite

Structural alterations of the epidermal growth factor receptor gene in human gliomas.

Journal article Proc Natl Acad Sci U S A · April 1, 1992 The epidermal growth factor receptor (EGFR) gene is amplified in 40% of malignant gliomas, and the amplified genes are frequently rearranged. We have characterized the genetic alterations associated with these rearrangements in five malignant gliomas. In o ... Full text Link to item Cite

The ligand binding domain of the epidermal growth factor receptor is not required for receptor dimerization.

Journal article Biochim Biophys Acta · March 16, 1992 To examine the role of the ligand binding domain of epidermal growth factor receptor in its dimerization, we studied the dimerization of a truncated form of the receptor that resembles v-erbB in that it lacks a ligand binding domain. Receptor dimerization ... Full text Link to item Cite

Expression of O6-methylguanine-DNA methyltransferase in six human medulloblastoma cell lines.

Journal article Cancer Res · March 1, 1992 Six well characterized human medulloblastoma cell lines (D283 Med, Daoy, D341 Med, D384 Med, D425 Med, and D458 Med) were examined for the expression of O6-methylguanine-DNA methyltransferase (MGMT) by activity and Western and Northern blot analysis. High ... Link to item Cite

Characterization of cDNA encoding mouse DNA repair protein O6-methylguanine-DNA methyltransferase and high-level expression of the wild-type and mutant proteins in Escherichia coli.

Journal article Biochemistry · February 25, 1992 A mouse cDNA clone encoding O6-methylguanine-DNA methyltransferase (MGMT), responsible for repair of mutagenic O6-alkylguanine in DNA, was cloned from a lambda gt11 library. On the basis of an open reading frame in cDNA, the mouse protein contains 211 amin ... Full text Link to item Cite

Hyperthermia-induced enhancement of melphalan activity against a melphalan-resistant human rhabdomyosarcoma xenograft.

Journal article Radiat Res · February 1992 The effects of regional hyperthermia (42 degrees C for 70 min) on the antitumor activity of melphalan were examined in athymic mice bearing melphalan-resistant human rhabdomyosarcoma (TE-671 MR) xenografts growing in the right hind limb, and results were c ... Link to item Cite

The radiation dose-response relationship in a human glioma xenograft and an evaluation of the influence of glutathione depletion by buthionine sulfoximine.

Journal article Int J Radiat Oncol Biol Phys · 1992 We have used an extensively characterized human glioma cell line in an athymic mouse model to evaluate new therapeutic approaches for human supratentorial high grade gliomas. The tumor, D-54MG, is a subline of a human anaplastic glioma. Eight days after ho ... Full text Link to item Cite

Cytosine methylation and suppression of O6-methylguanine-DNA methyltransferase expression in human rhabdomyosarcoma cell lines and xenografts.

Journal article Oncol Res · 1992 Human tumor cell lines that do not express O6-methylguanine-DNA methyltransferase (MGMT) in detectable quantities (Mer-) are hypersensitive to the effects of O6-guanine-alkylating agents. Because the Mer- phenotype enhances tumor response to such agents, w ... Link to item Cite

Application of a panel of antiganglioside monoclonal antibodies to cytologic specimens.

Journal article Acta Cytol · 1992 The cytologic evaluation of poorly differentiated tumors frequently poses a diagnostic dilemma as to the tissue of origin. To assess the diagnostic utility of monoclonal antibodies (MAbs) in these situations, we applied a panel of three highly purified MAb ... Link to item Cite

Tenascin expression in human glioma cell lines and normal tissues.

Journal article J Neuroimmunol · January 1992 Tenascin expression was evaluated in 21 human glioma cell lines and in normal adult tissue extracts by Western and Northern blotting. The cell lines differed in their relative expression of tenascin in the cell-associated and supernatant compartments. Glio ... Full text Link to item Cite

Effects of glutathione or polyamine depletion on in vivo thermosensitization.

Journal article Int J Hyperthermia · 1992 Investigations with the melphalan-sensitive and -resistant human rhabdomyosarcoma xenografts TE-671 and TE-671 MR were performed to examine the effect of glutathione and polyamine modulation on thermosensitivity. Regimens of intraperitoneally injected and ... Full text Link to item Cite

Enhancement of melphalan-induced gastrointestinal toxicity in mice treated with regional hyperthermia and BSO-mediated glutathione depletion.

Journal article Int J Hyperthermia · 1992 Both hyperthermia and glutathione depletion have been shown to increase the antineoplastic activity of melphalan. Investigations were carried out to define the toxicity and activity of melphalan given in conjunction with local (right hind limb) hyperthermi ... Full text Link to item Cite

The radiation dose-response relationship in a human glioma xenograft and an evaluation of the influence of glutathione depletion by buthionine sulfoximine

Journal article International Journal of Radiation Oncology, Biology, Physics · 1992 We have used an extensively characterized human glioma cell line in an athymic mouse model to evaluate new therapeutic approaches for human supratentorial high grade gliomas. The tumor, D-54MG, is a subline of a human anaplastic glioma. Eight days after ho ... Cite

Occurrence of lacto series gangliosides 3'-isoLM1 and 3',6'-isoLD1 in human gliomas in vitro and in vivo.

Journal article J Neuropathol Exp Neurol · November 1991 Monoclonal antibodies (MAb; DMAb, monoclonal antibodies derived at Duke Medical Center) directed against the oncofetally expressed lactotetraosyl gangliosides 3'-isoLM1 (IV3NeuAc-LcOse4Cer) and 3',6'-isoLD1 (IV3NeuAc,III6NeuAc-LcOse4Cer) were produced and ... Full text Link to item Cite

The origin of O6-methylguanine-DNA methyltransferase in Chinese hamster ovary cells transfected with human DNA.

Journal article Mutat Res · September 1991 Transfection of Chinese hamster ovary (CHO) cells with human DNA has been shown in several laboratories to produce clones which stably express the DNA-repair protein, O6-methylguanine-DNA methyltransferase (MGMT), that is lacking in the parent cell lines ( ... Full text Link to item Cite

Expression of O6-methylguanine-DNA methyltransferase in malignant human glioma cell lines.

Journal article Carcinogenesis · September 1991 When animals are treated with carcinogenic agents that alkylate O6-guanine residues, the incidence of tumors in specific tissues often relates inversely to the level of the DNA repair enzyme O6-methylguanine-DNA methyltransferase (MGMT) present in the tiss ... Full text Link to item Cite

Infrequent p53 gene mutations in medulloblastomas.

Journal article Cancer Res · September 1, 1991 Cytogenetic and molecular studies of medulloblastomas have demonstrated frequent loss of sequences from the short arm of chromosome 17, possibly implicating loss or inactivation of the p53 tumor suppressor gene. We amplified exons 5 through 8 of the p53 ge ... Link to item Cite

Anti-GM2 monoclonal antibodies induce necrosis in GM2-rich cultures of a human glioma cell line.

Journal article Cancer Res · September 1, 1991 The effects of four anti-GM2 monoclonal antibodies (DMAb-1, DMAb-2, DMAb-3, and DMAb-5) were studied on spheroid cultures from a human glioma cell line (D-54 MG) that is known to express high levels of GM2. The spheroids developed central necrosis 48 h aft ... Link to item Cite

Deletion-mutant epidermal growth factor receptor in human gliomas: effects of type II mutation on receptor function.

Journal article Biochem Biophys Res Commun · August 15, 1991 Malignant human glioma D-298 MG amplifies a rearranged epidermal growth factor receptor (EGFR) gene (c-erbB proto-oncogene), resulting in an in-frame deletion of 83 amino acids in domain IV of the extracellular domain of the EGFR. EGF and transforming grow ... Full text Link to item Cite

Improved therapeutic efficacy of a monoclonal antibody radioiodinated using N-succinimidyl-3-(tri-n-butylstannyl)benzoate.

Journal article Cancer Res · August 15, 1991 Improvements in efficacy of radioimmunotherapy will require increased tumor uptake relative to normal tissue. We previously demonstrated that labeling the IgG2b glioma-reactive antitenascin monoclonal antibody 81C6 with 131I using N-succinimidyl-3-(tri-n-b ... Link to item Cite

Medulloblastoma: tumor biological and clinical perspectives.

Journal article J Neurooncol · August 1991 Medulloblastoma is the most common central nervous system malignancy of childhood, with approximately 350 new cases seen in the United States each year. Although the low incidence of this tumor, compared with adult neoplasms such as breast or colon carcino ... Full text Link to item Cite

Therapeutic analysis of melphalan-resistant human rhabdomyosarcoma xenograft TE-671 MR.

Journal article Cancer Res · August 1, 1991 Investigations with the melphalan-resistant human rhabdomyosarcoma xenograft TE-671 MR were carried out to identify patterns of cross-resistance and collateral sensitivity and to define the mechanism(s) mediating melphalan resistance. TE-671 MR was cross-r ... Link to item Cite

Production and characterization of antipeptide antibodies against human O6-methylguanine-DNA methyltransferase.

Journal article Cancer Res · July 1, 1991 Four synthetic peptides from the sequence of human O6-methylguanine-DNA methyltransferase (MGMT), three corresponding to different hydrophilic regions and one corresponding to the sequence containing the alkyl acceptor residue cysteine 145, were used to im ... Link to item Cite

Differentiation characteristics of newly established medulloblastoma cell lines (D384 Med, D425 Med, and D458 Med) and their transplantable xenografts.

Journal article Lab Invest · June 1991 Three new human medulloblastoma (MB) cell lines (D384 Med, D425 Med, and D458 Med) and their transplantable xenografts were examined for antigenic expression with antibodies against neuroectodermal antigens, cytoskeletal proteins, neuroendocrine markers, g ... Link to item Cite

Therapeutic analysis of in vitro and in vivo brain tumor models.

Journal article Neurol Clin · May 1991 Virtually all brain tumor models studied to date have demonstrated the activity of the nitrosoureas, an observation confirmed in a cohort of adult patients with high-grade gliomas. However, studies with animal brain tumor models have not led to the selecti ... Link to item Cite

EXPRESSION OF LACTO SERIES GANGLIOSIDES 3'-ISOLM1 AND 3',6'-ISOLD1 IN HUMAN GLIOMAS INSITU AND INVIVO

Journal article JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY · May 1, 1991 Link to item Cite

Radioiodination and astatination of monoclonal antibodies using heterocyclic acylation agents

Journal article Journal of Labelled Compounds and Radiopharmaceuticals · April 5, 1991 Cite

Glycolipids and glycosyltransferases in permanent cell lines established from human medulloblastomas.

Journal article Biochim Biophys Acta · February 5, 1991 Medulloblastoma biopsies are heterogenous and might contain normal brain tissue, which limits the usefulness of such tumor material for biochemical analyses. We have, therefore, examined the gangliosides and their metabolism using the medulloblastoma cell ... Full text Link to item Cite

Structural and immunological comparison of indigenous human O6-methylguanine-DNA methyltransferase with that encoded by a cloned cDNA.

Journal article J Biol Chem · January 15, 1991 O6-Methylguanine-DNA methyltransferase, a ubiquitous and unusual DNA repair protein, eliminates mutagenic and cytotoxic O6-alkylguanine from DNA by transferring the alkyl group to one of its cysteine residues in a second-order suicide reaction. This 22-kDa ... Link to item Cite

Melphalan-induced toxicity in nude mice following pretreatment with buthionine sulfoximine.

Journal article Cancer Chemother Pharmacol · 1991 Melphalan-induced toxicity in nude mice following pretreatment with a regimen of L-buthionine sulfoximine (BSO), previously shown to enhance the activity of this alkylating agent against rhabdomyosarcoma and glioma xenografts, was examined. Mice were pretr ... Full text Link to item Cite

Positive therapeutic interaction between thiopurines and alkylating drugs in human glioma xenografts.

Journal article Cancer Chemother Pharmacol · 1991 We used human anaplastic glioma xenografts to evaluate the therapeutic efficacy of combinations of alkylating drugs, either 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), 1-(2-chloroethyl)-3-(2,5-dioxo-3-piperidyl)-1-nitrosourea (PCNU), or procarbazine, and ... Full text Link to item Cite

Medulloblastoma cell-substrate interaction in vitro.

Journal article Invasion Metastasis · 1991 Medulloblastoma, a highly malignant pediatric tumor of the posterior fossa, demonstrates a marked propensity for leptomeningeal dissemination. Although the predominant site of relapse is the posterior fossa, the prevention of subarachnoid spread would be o ... Link to item Cite

Disialoganglioside GD2 in human neuroectodermal tumor cell lines and gliomas.

Journal article Acta Neuropathol · 1991 Monoclonal antibodies (mAbs) recognizing the disialoganglioside II3(NeuAc)2GgOse3Cer (GD2) were produced by immunizing mice with the GD2-expressing neuroblastoma cell line LAN-1 and a prefusion boost with purified GD2 coupled to Salmonella minnesota. Two I ... Full text Link to item Cite

Characterization of the epidermal growth factor receptor in human glioma cell lines and xenografts.

Journal article Cancer Res · December 15, 1990 Both permanent cultured cell lines and athymic mouse xenografts were established from two human glioblastomas. Biopsies from D-245 MG and D-270 MG contained amplified and rearranged epidermal growth factor receptor (EGFR) genes. Although the gene amplifica ... Link to item Cite

Determination of gangliosides in six human primary medulloblastomas.

Journal article J Neurochem · October 1990 The ganglioside composition of six human medulloblastomas was analyzed. The characterization was performed by thin-layer chromatography, sialidase hydrolysis, and immunological staining with a panel of characterized antiganglioside monoclonal antibodies. T ... Full text Link to item Cite

Effect of epidermal growth factor on glioma cell growth, migration, and invasion in vitro.

Journal article Cancer Res · September 15, 1990 Effects of epidermal growth factor (EGF) and an antibody (Ab-528) reactive against the binding site for EGF on human EGF receptors were studied on multicellular tumor spheroids obtained from three human glioma cell lines with high (D-37 MG), medium (D-247 ... Link to item Cite

RUBINSTEIN,LUCIEN,J. (1924-1990) - IN MEMORIAM

Journal article JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY · September 1990 Link to item Cite

Circulating glycoconjugates in CSF of meningioma patients.

Journal article Acta Neurol Scand · September 1990 This study investigated whether tumor-associated gangliosides or glycoproteins may be markers for meningiomas in CSF. The concentrations of a number of gangliosides and sulphatide were determined with specific monoclonal antibodies and cholera toxin B-subu ... Full text Link to item Cite

Gangliosides in the human glioma cell line U-118 MG grown in culture or as xenografts in nude rats.

Journal article Biochim Biophys Acta · August 6, 1990 This study was undertaken to characterize gangliosides in the human glioma cell line U-118 MG. The cell line was grown both in cell culture and as xenografts in nude rats. A common finding in both culture and xenograft cells was the high proportion of the ... Full text Link to item Cite

Cytogenetics of human brain tumors.

Journal article Cancer Genet Cytogenet · July 15, 1990 The most frequent cytogenetic alterations in primary brain tumors are losses of chromosomes or chromosomal regions and the presence of double minute chromosomes (dmins). The regions which are lost and the genes which are amplified are distinctive for indiv ... Full text Link to item Cite

Monoclonal antibody and F(ab')2 fragment delivery to tumor in patients with glioma: comparison of intracarotid and intravenous administration.

Journal article Cancer Res · July 1, 1990 Non-i.v. delivery of radiolabeled monoclonal antibodies (MAbs) has been shown to increase tumor uptake and decrease dose to normal tissues. In this study, we have examined the potential advantage of intracarotid (i.c.) versus i.v. administration for the de ... Link to item Cite

Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma.

Journal article Proc Natl Acad Sci U S A · June 1990 We have investigated human gliomas that amplify and rearrange the epidermal growth factor receptor gene, with generation of an in-frame deletion mutation of 802 nucleotides in the external domain. This in-frame deletion mutation generates a local amino aci ... Full text Link to item Cite

Oncogene amplification in pediatric brain tumors.

Journal article Cancer Res · May 15, 1990 Despite a considerable amount of information concerning chromosomal and molecular abnormalities found in gliomas in adults, relatively little is known regarding these abnormalities in pediatric brain tumors. We have analyzed DNA from 37 primary brain tumor ... Link to item Cite

GENE AMPLIFICATION IN HUMAN GLIOMAS

Journal article Journal of Neuropathology and Experimental Neurology · May 1990 Full text Cite

Successful laboratory growth and analysis of CUSA-obtained medulloblastoma samples. Technical note.

Journal article J Neurosurg · May 1990 The development of the Cavitron ultrasonic surgical aspirator (CUSA) has facilitated neurosurgical intervention for removal of central or peripheral nervous system tumors adjacent to or within vital structures. However, laboratory studies defining the phen ... Full text Link to item Cite

NEURON-ASSOCIATED MICROTUBULE PROTEINS IN THE U-251 MALIGNANT GLIOMA CELL LINE

Journal article Journal of Neuropathology and Experimental Neurology · May 1990 Full text Cite

Characterization of the binding epitope of the monoclonal antibody DMAb-1 to ganglioside GM2.

Journal article Biochim Biophys Acta · April 17, 1990 Several derivatives of ganglioside GM2 were synthesized for mapping of the binding epitope of a monoclonal antibody raised against this ganglioside. The GM2 ganglioside was modified in both the hydrophobic and the hydrophobilic part of the molecule. The sy ... Full text Link to item Cite

Glutathione protects cardiac and skeletal muscle from cyclophosphamide-induced toxicity.

Journal article Cancer Res · April 15, 1990 Administration of cyclophosphamide at a dose which is lethal to 10% of control athymic nude mice resulted in sudden death within 3 h in all mice that had been pretreated with the glutathione synthesis inhibitor L-buthionine-SR-sulfoximine. In Fischer 344 r ... Link to item Cite

Amplification of the c-myc gene in human medulloblastoma cell lines and xenografts.

Journal article Cancer Res · April 15, 1990 Cultured cell lines and xenografts derived from 7 human medulloblastomas were evaluated for amplification of the c-myc, N-myc, epidermal growth factor receptor, and gli genes by Southern blot analysis. Karyotypes of the original biopsies and early passaged ... Link to item Cite

Enhanced delivery of a monoclonal antibody F(ab')2 fragment to subcutaneous human glioma xenografts using local hyperthermia.

Journal article Cancer Res · March 15, 1990 The purpose of this study was to investigate the effects of tumor-localized hyperthermia at 42 degrees C on the tissue distribution of radioiodinated monoclonal antibody F(ab')2 fragments. Paired-label biodistribution measurements were performed in athymic ... Link to item Cite

Radioimmunotherapy of intracerebral human glioma xenografts with 131I-labeled F(ab')2 fragments of monoclonal antibody Mel-14.

Journal article Cancer Res · March 15, 1990 The administration of radiolabeled monoclonal antibodies to improve the treatment of malignant gliomas is dependent upon achieving effective tumor radiation dose while sparing normal tissues. We have evaluated the efficacy of 131I-labeled F(ab')2 fragment ... Link to item Cite

Activity of intrathecal 4-hydroperoxycyclophosphamide in a nude rat model of human neoplastic meningitis.

Journal article Cancer Res · March 15, 1990 Neoplastic meningitis can result from leptomeningeal dissemination of a variety of cancers. We now report the development of animal models of human neoplastic meningitis and activity of intrathecal 4-hydroperoxycyclophosphamide (4-HC) against the human rha ... Link to item Cite

Rate of buthionine sulfoximine entry into brain and xenotransplanted human gliomas.

Journal article Cancer Res · February 15, 1990 Buthionine sulfoximine (BSO) is an inhibitor of glutathione synthesis and can be used to potentiate the effects of chemotherapeutic alkylating agents and radiotherapy. We examined the rates of influx and efflux of [35S]BSO administered to athymic mice with ... Link to item Cite

L-Buthionine-Sulfoximine-Mediated Radiosensitization in Experimental Interstitial Radiotherapy of Intracerebral D-54 MG Glioma Xenografts in Athymic Mice

Journal article Neurosurgery · February 1, 1990 AbstractAn intracranial (i.c.) interstitial radiotherapy model in athymic nude mice bearing i.c. D-54 MG human glioma xenografts was developed, allowing evaluation of the therapeutic benefits seen after L-bu ... Full text Cite

L-buthionine-sulfoximine-mediated radiosensitization in experimental interstitial radiotherapy of intracerebral D-54 MG glioma xenografts in athymic mice.

Journal article Neurosurgery · February 1990 An intracranial (i.c.) interstitial radiotherapy model in athymic nude mice bearing i.c. D-54 MG human glioma xenografts was developed, allowing evaluation of the therapeutic benefits seen after L-buthionine-S,R-sulfoximine (L-BSO)-mediated depletion of tu ... Full text Link to item Cite

Kinetics and glial fibrillary acidic (GFA) protein production in a transplantable human giant cell glioblastoma (D-212 MG) of near haploid karyotype maintained in an organ culture system. An immunohistochemistry study.

Journal article Neuropathol Appl Neurobiol · February 1990 A transplantable subcutaneous tumour (designated D-212 MG), sequentially passaged in athymic nude mice and originally derived from a human giant cell glioblastoma, was maintained in an organ culture (matrix) system and studied immunohistochemically after i ... Full text Link to item Cite

Synergistic interactions between cyclophosphamide or melphalan and VP-16 in a human rhabdomyosarcoma xenograft.

Journal article Cancer Res · January 15, 1990 Based on previous work demonstrating the activity of cyclophosphamide and melphalan in a series of human medulloblastoma and rhabdomyosarcoma cell lines and transplantable xenografts, investigations were conducted to define the effects of combining cycloph ... Link to item Cite

A panel of antibodies useful in the cytologic diagnosis of metastatic melanoma.

Journal article Acta Cytol · 1990 Five antibodies, 2D.1 (pan-leukocyte), AE-1,3 (anti-keratin), B72.3 (anti-carcinoma), ME 1-14 (alpha-chondroitin sulfate proteoglycan) and polyclonal S-100 protein (P-S100), were tested to determine if this panel could be used immunocytochemically to diffe ... Link to item Cite

Immunoaffinity purification of human O6-alkylguanine-DNA alkyltransferase using newly developed monoclonal antibodies.

Journal article Cancer Res · January 1, 1990 As well as repairing mutagenic lesions induced by simple methylating agents, O6-alkylguanine-DNA alkyltransferase repairs precursors of cytotoxic interstrand cross-links induced by chloroethylating anticancer drugs. Moreover, levels of the transferase corr ... Link to item Cite

Establishment of a melphalan-resistant rhabdomyosarcoma xenograft with cross-resistance to vincristine and enhanced sensitivity following buthionine sulfoximine-mediated glutathione depletion.

Journal article Cancer Res · December 15, 1989 A melphalan-resistant human rhabdomyosarcoma xenograft, TE-671 MR, was established in athymic mice by serial melphalan treatment of the parent xenograft, TE-671, at the 10% lethal dosage (LD10); significant resistance was evident after ten passages of the ... Link to item Cite

Establishment of a Melphalan-Resistant Rhabdomyosarcoma Xenograft with Cross-Resistance to Vincristine and Enhanced Sensitivity Following Buthionine Sulfoximine-Mediated Glutathione Depletion

Journal article Cancer Research · December 15, 1989 A melphalan-resistant human rhabdomyosarcoma xenograft, TE-671 MR, was established in athymic mice by serial melphalan treatment of the parent xenograft, TE-671, at the 10% lethal dosage (LD10); significant resistance was evident after ten passages of the ... Cite

A controlled study of efficacy of interstitial or external irradiation in a virus-induced brain-tumor model in rats.

Journal article J Neurosurg · December 1989 In a controlled study of interstitial radiotherapy in the avian sarcoma virus (ASV)-induced glioma model in rats, prolongation of survival was demonstrated (p = 0.08 in Experiment 1 and p = 0.03 in Experiment 2) following mean dosages of 7582 to 9902 cGy 1 ... Full text Link to item Cite

Five new epitope-defined monoclonal antibodies reactive with GM2 and human glioma and medulloblastoma cell lines.

Journal article Cancer Res · December 1, 1989 In order to investigate GM2 expression in gliomas, the GM2-positive human glioma cell line (HGL) D-54 MG, which contains 0.6 nmol GM2/mg protein, representing 77% of the total monosialoganglioside fraction, was used as an immunogen for the production of an ... Link to item Cite

Enhanced tumor localization and in vivo stability of a monoclonal antibody radioiodinated using N-succinimidyl 3-(tri-n-butylstannyl)benzoate.

Journal article Cancer Res · October 15, 1989 Loss of radiolabel after in vivo administration of labeled monoclonal antibodies (MAbs) to cancer patients is a likely cause of the low levels of tumor uptake of MAb which have been observed. In this study, we have evaluated the utility of N-succinimidyl 3 ... Link to item Cite

CYTOGENETICS AND GENE AMPLIFICATION IN MALIGNANT HUMAN-BRAIN TUMORS

Journal article CANCER GENETICS AND CYTOGENETICS · September 1, 1989 Link to item Cite

Relationship of the demonstration of intermediate filament protein to kinetics of three human neuroepithelial tumor cell lines. Lack of neural-related proteins in most cells in S phase: a double-labeled immunohistochemical study on matrix cultures.

Journal article Lab Invest · September 1989 The immunocytochemical demonstration of intermediate filament proteins in three human neuroepithelial tumor cell lines maintained in vitro on a three-dimensional matrix was correlated with the proportion of cells in S phase. The cell lines of a medulloblas ... Link to item Cite

Labeling monoclonal antibodies and F(ab')2 fragments with the alpha-particle-emitting nuclide astatine-211: preservation of immunoreactivity and in vivo localizing capacity.

Journal article Proc Natl Acad Sci U S A · September 1989 alpha-Particles such as those emitted by 211At may be advantageous for radioimmunotherapy since they are radiation of high linear energy transfer, depositing high energy over a short distance. Here we describe a strategy for labeling monoclonal antibodies ... Full text Link to item Cite

A new ganglioside of the lactotetraose series, GalNAc-3'-isoLM1, detected in human meconium.

Journal article J Biol Chem · July 25, 1989 A monoclonal antibody produced by immunization with cells of the human glioma cell line D-54 MG reacted with ganglioside GM2. The binding epitope of the antibody was found to be GalNAc beta 1-4(NeuAc alpha 2-3)Gal. Immunological detection of glycolipid ant ... Link to item Cite

Phase II treatment of medulloblastoma and pineoblastoma with melphalan: clinical therapy based on experimental models of human medulloblastoma.

Journal article J Clin Oncol · July 1989 We conducted a phase II study of intravenous (IV) melphalan in the treatment of children with recurrent medulloblastoma and in the initial treatment of children with poor-prognosis medulloblastoma and pineoblastoma. There was one complete response (CR) and ... Full text Link to item Cite

Chromosomal composition of malignant human gliomas through serial subcutaneous transplantation in athymic mice.

Journal article Cancer Genet Cytogenet · July 1, 1989 The karyotypes of seven human glioblastomas were followed through serial subcutaneous passage in athymic mice. One tumor maintained the same hypodiploid stemline as seen in the original biopsy. Three tumors that originally had near-diploid stemlines showed ... Full text Link to item Cite

Tenascin/hexabrachion in human skin: biochemical identification and localization by light and electron microscopy.

Journal article J Cell Biol · June 1989 Tenascin/hexabrachion is a large glycoprotein of the extracellular matrix. Previous reports have demonstrated that tenascin is associated with epithelial-mesenchymal interfaces during embryogenesis and is prominent in the matrix of many tumors. However, th ... Full text Link to item Cite

Pharmacokinetics and tumor localization of 131I-labeled anti-tenascin monoclonal antibody 81C6 in patients with gliomas and other intracranial malignancies.

Journal article Cancer Res · May 15, 1989 We previously have reported that radioiodinated anti-tenascin monoclonal antibody 81C6 exhibits therapeutic potential against both s.c. and intracranial human glioma xenografts in athymic mice and rats. Herein we report the selective tumor localization of ... Link to item Cite

Increased melphalan activity in intracranial human medulloblastoma and glioma xenografts following buthionine sulfoximine-mediated glutathione depletion.

Journal article J Natl Cancer Inst · April 5, 1989 In previous studies we demonstrated that administration of buthionine sulfoximine (BSO) to athymic BALB/c mice bearing intracranial human glioma xenografts resulted in highly selective depletion of glutathione in neoplastic tissue with minimal effects on c ... Full text Link to item Cite

O6-alkylguanine-DNA alkyltransferase and sensitivity to procarbazine in human brain-tumor xenografts.

Journal article J Neurosurg · April 1989 The level of O6-alkylguanine-deoxyribonucleic acid (DNA) alkyltransferase (AT) was determined in 15 human brain-tumor xenografts in athymic mice. This enzyme is a primary intracellular repair mechanism for lesions produced at the O6 position of guanine by ... Full text Link to item Cite

Phenotypic analysis of four human medulloblastoma cell lines and transplantable xenografts.

Journal article J Neuropathol Exp Neurol · January 1989 An extensive panel of monoclonal antibodies (MAb) and monospecific antisera reactive against neuroectodermal-, neuronal-, glial-, and lymphoid-associated antigens, extracellular matrix, HLA, and cell-surface receptors was used to characterize the phenotype ... Full text Link to item Cite

Ganglioside mapping of a human medulloblastoma xenograft.

Journal article Acta Neuropathol · 1989 The ganglioside patterns of medulloblastomas have never been established; in this study we report the ganglioside profile of the human medulloblastoma cell line TE-671 grown as a xenograft in nude mice. Gangliosides were isolated and structurally analyzed ... Full text Link to item Cite

Expression of O6-alkylguanine-DNA alkyltransferase in Mer+ and Mer- human cell extracts probed with specific monoclonal antibodies.

Journal article Cancer Commun · 1989 The response of human cells to the mutagenic, carcinogenic, and lethal effects of alkylating agents that produce O6-alkylguanine adducts in DNA is largely determined by the cellular content of O6-alkylguanine-DNA alkyltransferase. Because a subgroup of hum ... Full text Link to item Cite

GD3 expression by cultured human tumor cells of neuroectodermal origin.

Journal article Acta Neuropathol · 1989 Seven monoclonal antibodies (mAbs) reactive with ganglioside II3(NeuAc)2-LacCer (GD3) were generated; four of these mAbs (DMAb-21, DMAb-22, DMAb-23, and DMAb-24) by immunizing mice with GD3 adsorbed to Salmonella minnesota and the remaining three (DMAb-7, ... Full text Link to item Cite

Synthesis of radioiodinated N-succinimidyl iodobenzoate: optimization for use in antibody labelling.

Journal article Int J Rad Appl Instrum A · 1989 N-succinimidyl-3-(tri-n-butylstannyl)benzoate (m-BuATE), N-succinimidyl-3-(tri-methylstannyl)benzoate (m-MeATE) and N-succinimidyl-4-(tri-n-butylstannyl)benzoate (p-BuATE) were synthesized and radioiodinated using either N-chlorosuccinimide (NCS) or t-buty ... Full text Link to item Cite

O6-Alkylguanine-DNA alkyltransferase and sensitivity to procarbazine in human brain-tumor xenografts

Journal article Journal of Neurosurgery · 1989 The level of O6-alkylguanine-deoxyribonucleic acid (DNA) alkyltransferase (AT) was determined in 15 human brain-tumor xenografts in athymic mice. This enzyme is a primary intracellular repair mechanism for lesions produced at the O6 position of guanine by ... Cite

Buthionine sulfoximine-mediated depletion of glutathione in intracranial human glioma-derived xenografts.

Journal article Biochem Pharmacol · November 15, 1988 D-54 MG, a human glioma-derived continuous cell line growing as subcutaneous or intracranial xenografts in athymic mice, was found to be sensitive to the effects of D,L-buthionine-(SR)-sulfoximine, a selective inhibitor of gamma-glutamylcysteine synthetase ... Full text Link to item Cite

Comparative localization of murine monoclonal antibody Me1-14 F(ab')2 fragment and whole IgG2a in human glioma xenografts.

Journal article Cancer Res · October 15, 1988 Monoclonal antibodies (MAbs) targeted to glioma-associated antigens may allow the selective delivery of imaging and therapeutic agents to brain tumors; the use of MAb fragments may be a strategy to further improve tumor uptake of such agents relative to no ... Link to item Cite

Melphalan transport, glutathione levels, and glutathione-S-transferase activity in human medulloblastoma.

Journal article Cancer Res · October 1, 1988 Melphalan transport, glutathione levels, and glutathione-S-transferase activity were measured in two continuous human medulloblastoma cell lines and transplantable xenografts in athymic nude mice, TE-671 and Daoy. In vitro mean glutathione levels were 10.0 ... Link to item Cite

Experimental chemotherapy of human medulloblastoma cell lines and transplantable xenografts with bifunctional alkylating agents.

Journal article Cancer Res · August 1, 1988 A series of bifunctional alkylators were tested against the genotypically and phenotypically heterogeneous continuous human medulloblastoma cell lines, TE-671, Daoy, and D283 Med in vitro and against TE-671 and Daoy growing as s.c. and intracranial xenogra ... Link to item Cite

ASTATINE-211 LABELED MONOCLONAL-ANTIBODY - A POTENTIAL AGENT FOR RADIOIMMUNOTHERAPY

Journal article EUROPEAN JOURNAL OF NUCLEAR MEDICINE · August 1, 1988 Link to item Cite

Treatment of intracranial human glioma xenografts with 131I-labeled anti-tenascin monoclonal antibody 81C6.

Journal article Cancer Res · May 15, 1988 Lack of tumor specificity renders current modalities for treating malignant glioma ineffective. The administration of 131I-labeled monoclonal antibody (Mab) 81C6, which reacts with the glioma-associated extracellular matrix antigen, tenascin, to nude mice ... Link to item Cite

Enhanced melphalan cytotoxicity following buthionine sulfoximine-mediated glutathione depletion in a human medulloblastoma xenograft in athymic mice.

Journal article Cancer Res · May 15, 1988 The effect and therapeutic consequences of buthionine-(SR)-sulfoximine (BSO)-mediated depletion of glutathione in the human medulloblastoma-derived cell line, TE-671, growing as s.c. xenografts in athymic nude mice were examined. The glutathione content of ... Link to item Cite

Gene amplification in malignant human gliomas: clinical and histopathologic aspects.

Journal article J Neuropathol Exp Neurol · May 1988 Gene amplification occurs in 45-50% of malignant human gliomas (MHG). In the present study, 64 genetically characterized gliomas were evaluated to determine if tumors with amplification of the epidermal growth factor receptor (EGFR), N-myc, c-myc, or gli g ... Full text Link to item Cite

ANTIGENIC PHENOTYPES OF 4 HUMAN MEDULLOBLASTOMA CELL-LINES AND XENOGRAFTS

Journal article JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY · May 1, 1988 Link to item Cite

Amplification and expression of the epidermal growth factor receptor gene in human glioma xenografts.

Journal article Cancer Res · April 15, 1988 Xenografts from eight malignant human gliomas were established in athymic mice and were used to study amplification and expression of the epidermal growth factor receptor (EGFR) gene. Tissue identity between biopsy and xenografts was confirmed by karyotypi ... Link to item Cite

METHOTREXATE (MTX), SCHEDULE DEPENDENT DRUG ACCUMULATION

Journal article PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH · March 1, 1988 Link to item Cite

Phenotypic and genotypic analysis of a human medulloblastoma cell line and transplantable xenograft (D341 Med) demonstrating amplification of c-myc.

Journal article Am J Pathol · March 1988 D341 Med is a new continuous cell line and transplantable xenograft derived from a cerebellar medulloblastoma. This line grew in vitro in suspension culture with spontaneous macroscopic spheroid formation and demonstrated 20-fold amplification of c-myc. Cu ... Link to item Cite

LOSS OF EPIDERMAL GROWTH-FACTOR RECEPTOR GENE AMPLIFICATION AS MALIGNANT HUMAN GLIOMAS ESTABLISH IN CULTURE

Journal article PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH · March 1, 1988 Link to item Cite

Therapeutic efficacy of antiglioma mesenchymal extracellular matrix 131I-radiolabeled murine monoclonal antibody in a human glioma xenograft model.

Journal article Cancer Res · February 1, 1988 The development of Mabs, particularly those reactive with primary brain tumors but not with normal brain, provides a potential means of delivering therapeutic agents selectively to human malignant gliomas. Mab 81C6, an IgG2b immunoglobulin, which defines a ... Link to item Cite

Specific chromosomal abnormalities in malignant human gliomas.

Journal article Cancer Res · January 15, 1988 Karyotypic analysis of 54 malignant human gliomas (5 anaplastic astrocytomas, 43 glioblastoma multiformes, 3 gliosarcomas, 2 giant cell glioblastomas, 1 anaplastic mixed glioma) has demonstrated that 12 tumors contained normal stemlines or only lacked one ... Link to item Cite

CHROMOSOMAL-ABNORMALITIES AND GENE AMPLIFICATION IN MALIGNANT GLIOMAS

Journal article ISI ATLAS OF SCIENCE-BIOCHEMISTRY · January 1, 1988 Link to item Cite

Therapeutic Efficacy of Antiglioma Mesenchymal Extracellular Matrix 131I-Radiolabeled Murine Monoclonal Antibody in a Human Glioma Xenograft Model

Journal article Cancer Research · January 1, 1988 The development of Mabs, particularly those reactive with primary brain tumors but not with normal brain, provides a potential means of delivering therapeutic agents selectively to human malignant gliomas. Mab 81C6 an IgG2b immunoglobulin, which defines an ... Cite

Growth effects of epidermal growth factor (EGF) and a monoclonal antibody against the EGF receptor on four glioma cell lines.

Journal article Acta Neuropathol · 1988 Epidermal growth factor (EGF) has been shown to stimulate DNA synthesis and cell division in normal glia. At least half of malignant human gliomas (MHG) express high levels of the EGF receptor (EGFR), which are above those detected in normal brain. The dem ... Full text Link to item Cite

The localisation of radiolabelled murine monoclonal antibody 81C6 and its Fab fragment in human glioma xenografts in athymic mice.

Journal article Br J Neurosurg · 1988 The localisation of the radioiodinated Fab fragment of monoclonal antibody (Mab) 81C6, reactive with a glioma-associated extracellular matrix antigen, was studied in athymic mice bearing subcutaneous and intracranial xenografts of D-54 MG glioma cells. In ... Full text Link to item Cite

Structural chromosomal abnormalities in human medulloblastoma.

Journal article Cancer Genet Cytogenet · January 1988 Seven human medulloblastomas (four primary cerebellar, three recurrent or metastatic) were karyotyped in direct preparation and/or short-term or early culture. One tumor had a 46,XX stem line. Four of the six remaining tumors contained one or more i(17q), ... Full text Link to item Cite

Intravenous adenosine selectively increases blood flow to xenotransplanted intracerebral gliomas.

Journal article Neurology · December 1987 Adenosine was infused intravenously at 10 mumol/(kg.min) into athymic ("nude") rats with intracerebral D-54MG xenotransplanted brain tumors, in an attempt to increase tumor blood flow. Cerebral blood flow (F) was measured with 14C-iodoantipyrine and quanti ... Full text Link to item Cite

Distribution of type VI collagen in human gliomas: comparison with fibronectin and glioma-mesenchymal matrix glycoprotein.

Journal article J Neuropathol Exp Neurol · November 1987 The distribution of type VI collagen was examined immunohistochemically in normal tissues and in 24 human gliomas and six medulloblastomas. Its localization in the neoplasms was compared with that of fibronectin and glioma-mesenchymal extracellular matrix ... Full text Link to item Cite

Relationship between gene amplification and chromosomal deviations in malignant human gliomas.

Journal article Cancer Genet Cytogenet · November 1987 Biopsies of 33 malignant human gliomas were karyotyped and evaluated for amplification (more than eight gene copies per cell) of the epidermal growth factor receptor (EGFR), N-myc, c-myc, and gli genes by Southern blot analysis. Fifteen of 33 tumors showed ... Full text Link to item Cite

Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification.

Journal article Proc Natl Acad Sci U S A · October 1987 Primary malignant gliomas from 63 patients were analyzed to determine the relationship between amplification of the gene encoding the epidermal growth factor receptor (EGFR) and expression of the corresponding mRNA. Twenty-four tumors were found to have am ... Full text Link to item Cite

DNA content and chromosomes in permanent cultured cell lines derived from malignant human gliomas.

Journal article Anal Quant Cytol Histol · October 1987 DNA content, as determined by flow cytometry (FCM), and ploidy, as determined planimetrically from chromosomes, were measured for 17 established human glioma-derived cell lines. Values obtained by these methods corresponded well for two of two near-diploid ... Link to item Cite

13 Chromosomes and gene amplification in malignant human gliomas (MHG)

Journal article Cancer Genetics and Cytogenetics · September 1987 Full text Cite

Therapeutic profile of the human glioma line D-54 MG in athymic mice.

Journal article Cancer Treat Rep · September 1987 We treated D-54 MG, an extensively characterized human glioma tumor line, in athymic mice with each of 20 antineoplastic drugs and two radiation doses. PCNU, melphalan, cyclophosphamide, and fludarabine were highly active against sc tumors. A single radiat ... Link to item Cite

Regional localization of a glioma-associated antigen defined by monoclonal antibody 81C6 in vivo: kinetics and implications for diagnosis and therapy.

Journal article Cancer Res · August 15, 1987 The pharmacokinetics and regional tissue distribution of two IgG2b immunoglobulins were studied in athymic mice with D54MG human glioma xenografts. Monoclonal antibody (Mab) 81C6, an antiglioma antibody, had a plasma half-life of 2.7 +/- 0.3 (SE) days; 45. ... Link to item Cite

Concurrent measurements of blood flow and transcapillary transport in xenotransplanted human gliomas in immunosuppressed rats.

Journal article J Natl Cancer Inst · July 1987 Neonatal Fischer 344 rats were immunosuppressed with antithymocyte serum and later were given an injection intracerebrally of cells from the human glioma permanent line D-54MG. Symptomatic tumor-bearing rats were studied with double-label quantitative auto ... Link to item Cite

MORPHOLOGIC CHARACTERISTICS OF MALIGNANT HUMAN GLIOMAS (MHG) WITH GENE AMPLIFICATION

Journal article Journal of Neuropathology and Experimental Neurology · May 1987 Full text Cite

Comparative localization of glioma-reactive monoclonal antibodies in vivo in an athymic mouse human glioma xenograft model.

Journal article J Neuroimmunol · May 1987 Radioiodinated murine monoclonal antibodies (Mabs) 81C6, Me 1-14, C12, D12, and E9, made against or reactive with human gliomas but not normal brain, and Mab UJ13A, a pan-neuroectodermal Mab reactive with normal human glial and neural cells, were evaluated ... Full text Link to item Cite

Identification of an amplified, highly expressed gene in a human glioma.

Journal article Science · April 3, 1987 A gene, termed gli, was identified that is amplified more than 50-fold in a malignant glioma. The gene is expressed at high levels in the original tumor and its derived cell line and is located at chromosome 12 position (q13 to q14.3). The gli gene is a me ... Full text Link to item Cite

Comparison of monoclonal antibody delivery to intracranial glioma xenografts by intravenous and intracarotid administration.

Journal article Cancer Res · April 1, 1987 Monoclonal antibody 81C6, which is directed against a human gliomamesenchymal extracellular matrix antigen, was used to evaluate the potential advantage of intracarotid (i.c.) administration versus i.v. delivery to D-54 MG human glioma intracranial xenogra ... Link to item Cite

Simultaneous measurements of blood flow and blood-to-tissue transport in xenotransplanted medulloblastomas.

Journal article Cancer Res · March 15, 1987 We used double-label quantitative autoradiography to study blood flow (with [131I]iodoantipyrine) and blood-to-tissue transport (with [14C]-alpha-aminoisobutyric acid) in 20 TE-671 medulloblastomas xenotransplanted into nude rats. Microscopically, two dist ... Link to item Cite

THERAPEUTIC SYNERGY OF THIOPURINES AND ALKYLATING DRUGS IN A HUMAN GLIOMA XENOGRAFT

Journal article PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH · March 1, 1987 Link to item Cite

AMPLIFICATION AND EXPRESSION OF THE EPIDERMAL GROWTH-FACTOR RECEPTOR (EGFR) GENE IN HUMAN GLIOMA (HGL) XENOGRAFTS

Journal article PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH · March 1, 1987 Link to item Cite

MELPHALAN CYTOTOXICITY AND RESISTANCE IN MEDULLOBLASTOMA (MBT)

Journal article PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH · March 1, 1987 Link to item Cite

A rapidly dividing human medulloblastoma cell line (D283 MED) expresses all three neurofilament subunits.

Journal article Am J Pathol · February 1987 The majority of cells in a rapidly dividing human medulloblastoma cell line (D283 MED) are shown to express the two high-molecular-weight human neurofilament (NF) subunits, whereas a minority express the low-molecular-weight NF subunit. These three polypep ... Link to item Cite

Differential retention of rhodamine 123 by avian sarcoma virus-induced glioma and normal brain tissue of the rat in vivo.

Journal article Cancer · January 15, 1987 The time course of uptake, retention and clearance of the cationic lipophilic dye, rhodamine 123 (Rh123), within the central nervous system was qualitatively evaluated in rats. Weanling rats were injected intracerebrally with avian sarcoma virus, which ind ... Full text Link to item Cite

IDENTIFICATION OF AN AMPLIFIED, HIGHLY EXPRESSED GENE IN A HUMAN GLIOMA

Journal article CYTOGENETICS AND CELL GENETICS · January 1, 1987 Link to item Cite

Invasiveness of human glioma cell lines in vitro: relation to tumorigenicity in athymic mice.

Journal article Acta Neuropathol · 1987 Five established cell lines derived from human anaplastic astrocytomas or glioblastoma multiforme were tested for invasiveness into precultured chick heart fragments in vitro. Four of the cell lines (U118 MG, D54 MG, U373 MG and A172) were strongly invasiv ... Full text Link to item Cite

The use of a panel of monoclonal antibodies in the evaluation of cytologic specimens from the central nervous system.

Journal article Acta Cytol · 1987 A panel of monoclonal antibodies was tested immunohistochemically to determine the utility of such reagents in distinguishing among metastatic carcinoma, lymphoma, leukemia and primary brain tumors. The monoclonal antibodies used were: (1) a cocktail compr ... Link to item Cite

Treatment of autochthonous rat brain tumors with steroid plus heparin: a brief report.

Journal article J Neurooncol · 1987 Treatment of rats bearing intracranial gliomas induced by the avian sarcoma virus with heparin plus steroid has failed to effectively extend survival time. ... Full text Link to item Cite

Chromosomal progression of malignant human gliomas from biopsy to establishment as permanent lines in vitro.

Journal article Cancer Genet Cytogenet · January 1987 Karyotypes of four malignant human gliomas were followed from direct preparation and/or short-term culture through their establishment in vitro to determine whether the cultured cells maintained the original karyotypes, or were the products of selection, p ... Full text Link to item Cite

Effect of methylprednisolone on radiotherapy of F344 rats with avian sarcoma virus induced gliomas.

Journal article J Neurooncol · 1987 We have examined the impact of methylprednisolone acetate (MPA) on survival of F344 rats that were bearing avian sarcoma virus (ASV)-induced gliomas and that were treated optimally with radiotherapy. Toxicity of MPA (dose range of 0.2-5.0 mg/kg X 7 over 3 ... Full text Link to item Cite

Correlation of neuropathologic findings, computerized tomographic and high-resolution ultrasound scans of canine avian sarcoma virus-induced brain tumors.

Journal article J Neurooncol · 1987 The location, size, geometry and neuropathological findings of anaplastic astrocytomas (AA), gliosarcomas and sarcomas induced by the avian sarcoma virus (ASV) in dogs were compared with images generated using computerized tomography (CT) and real time hig ... Full text Link to item Cite

Hydroxyurea synchronization increases mitotic yield in human glioma cell lines.

Journal article Acta Neuropathol · 1987 Karyotypic studies of human gliomas are often limited by a low mitotic index and the appearance of contracted chromosomes that do not exhibit clear banding patterns. The purpose of this study was to investigate the use of hydroxyurea (HU) as a synchronizin ... Full text Link to item Cite

Specific imaging of human brain tumor xenografts utilizing radiolabelled monoclonal antibodies (MAbs).

Journal article Nuklearmedizin · December 1986 At the present time, specific imaging and treatment of central nervous system malignancies is not possible. The development of monoclonal hybridoma technology may provide the solution to this problem. We have utilized human glioma-derived cell lines (HGCL) ... Link to item Cite

Partial purification and characterization of a murine glioma-associated antigen defined by syngeneic rat monoclonal antibodies.

Journal article J Neuroimmunol · December 1986 A glioma-associated antigen was previously identified on an avian sarcoma virus-induced F-344 rat astrocytoma cell line S69-c15 by four rat monoclonal antibodies (7G4, 9F1, 10E3 and 10E7) produced after syngeneic immunization. Earlier data suggested all fo ... Full text Link to item Cite

Glioma-associated antigens defined by monoclonal antibodies against an avian sarcoma virus-induced rat astrocytoma.

Journal article J Neuroimmunol · December 1986 S69-c15 is a highly immunogenic cell line derived from an avian sarcoma virus (ASV)-induced astrocytoma in F-344 rats. Monoclonal antibody (Mab) production was attempted by fusing F-344 rat splenocytes and mouse P3 X 63/Ag8.653 myeloma cells after a syngen ... Full text Link to item Cite

A glial fibrillary acidic protein-expressing and tumorigenic cell line derived from an avian sarcoma virus-induced rat astrocytoma.

Journal article J Neuropathol Exp Neurol · November 1986 A permanent cell line, S635c15, was derived from an anaplastic astrocytoma induced by the Schmidt-Ruppin strain of avian sarcoma virus (ASV) in a female F-344 rat. Persistent expression of the astrocytic differentiation protein, glial fibrillary acidic pro ... Full text Link to item Cite

Production and characterization of two human glioma xenograft-localizing monoclonal antibodies.

Journal article Cancer Res · November 1986 Multiple fusions following immunization of athymic mice with the extensively characterized human glioma cell line D-54 MG resulted in the selection of several antibodies (Mabs) highly reactive with tumors of neuroectodermal origin and unreactive with norma ... Link to item Cite

The immunohistochemical application of three anti-GFAP monoclonal antibodies to formalin-fixed, paraffin-embedded, normal and neoplastic brain tissues.

Journal article J Neuropathol Exp Neurol · November 1986 The intermediate filament, glial fibrillary acidic protein (GFAP) has proven to be an important glial marker in diagnostic neuropathology. We report the histochemical application of three monoclonal antibodies (Mab) produced in this laboratory, 1B4, 2E1, a ... Full text Link to item Cite

Brain tumors in man and animals: report of a workshop.

Journal article Environ Health Perspect · September 1986 This report summarizes the results of a workshop on brain tumors in man and animals. Animals, especially rodents are often used as surrogates for man to detect chemicals that have the potential to induce brain tumors in man. Therefore, the workshop was foc ... Full text Link to item Cite

Experimental chemotherapy of human medulloblastoma with classical alkylators.

Journal article Cancer Res · June 1986 Seven classical alkylators were tested for activity against the continuous human medulloblastoma cell line TE-671 grown in vitro and as s.c. and intracranial xenografts in athymic mice. Drugs tested included melphalan, cyclophosphamide (4-hydroperoxycyclop ... Link to item Cite

Chromosomal evolution in malignant human gliomas starts with specific and usually numerical deviations.

Journal article Cancer Genet Cytogenet · June 1986 Our previous karyotypic studies of malignant human gliomas have demonstrated that their most consistent early or primary gross changes include gains of #7, losses of #10, #22, and the gonosomes, and the presence of double minutes. Karyotypes of 15 addition ... Full text Link to item Cite

Characterization of new gangliosides of the lactotetraose series in murine xenografts of a human glioma cell line.

Journal article FEBS Lett · May 26, 1986 The major mono- and disialogangliosides of the extensively characterized established human glioma line D54MG were isolated and purified from subcutaneous solid xenografts grown in athymic (nu/nu) mice. Structural determination showed that they belonged to ... Full text Link to item Cite

Efficacy of vincristine and cyclophosphamide in the therapy of recurrent medulloblastoma.

Journal article Neurosurgery · March 1986 We conducted a Phase II study of combination therapy with vincristine and cyclophosphamide in the treatment of patients with recurrent or metastatic medulloblastoma. Fourteen patients were treated with vincristine 2 mg/m2 (2.0-mg maximal dose) by intraveno ... Full text Link to item Cite

Immunobiology of human gliomas.

Journal article Semin Oncol · March 1986 Link to item Cite

CHEMOTHERAPY OF HUMAN MEDULLOBLASTOMA WITH CLASSICAL ALKYLATORS

Journal article PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH · March 1, 1986 Link to item Cite

KARYOTYPIC FINDINGS IN 6 CASES OF HUMAN MEDULLOBLASTOMA

Journal article PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH · March 1, 1986 Link to item Cite

LOCALIZATION OF ANTI-HUMAN GLIOMA MONOCLONAL-ANTIBODIES (MABS) IN SUBCUTANEOUS (SC) AND INTRACEREBRAL (IC) GLIOMA XENOGRAFTS

Journal article PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH · March 1, 1986 Link to item Cite

Primary brain tumours in Fischer 344 rats chronically exposed to acrylonitrile in their drinking-water.

Journal article Food Chem Toxicol · February 1986 Acrylonitrile (ACN) has been tested for carcinogenicity by various routes in a number of rat strains. At relatively high levels of administration (e.g. 500 ppm in the drinking-water) there were statistically significant increases in microscopically detecta ... Full text Link to item Cite

In vivo imaging of intracranial human glioma xenografts comparing specific with nonspecific radiolabeled monoclonal antibodies.

Journal article J Neurosurg · February 1986 Current diagnostic and therapeutic modalities for malignant human gliomas are largely nonspecific. The development of monoclonal antibodies (MA's) with their high degree of specificity may allow precise tumor imaging and selective administration of therape ... Full text Link to item Cite

CHROMOSOMES AND GENE AMPLIFICATION IN MALIGNANT HUMAN GLIOMAS

Journal article JOURNAL OF NEURO-ONCOLOGY · January 1, 1986 Link to item Cite

SPECIFIC ABNORMALITIES OF 9P IN MALIGNANT HUMAN GLIOMAS (MHG)

Journal article CANCER GENETICS AND CYTOGENETICS · January 1, 1986 Link to item Cite

SYNCHRONIZATION OF HUMAN GLIOMA CELL-LINES WITH HYDROXYUREA

Journal article JOURNAL OF NEURO-ONCOLOGY · January 1, 1986 Link to item Cite

Specific chromosomal abnormalities characterize four established cell lines derived from malignant human gliomas.

Journal article Acta Neuropathol · 1986 The four permanent human glioma-derived cell lines reported here are the first such lines for which the karyotypes have been followed from the original biopsies through the establishment of the lines in culture. Although ploidy changes were seen, each line ... Full text Link to item Cite

Chemotherapy of subcutaneous and intracranial human medulloblastoma xenografts in athymic nude mice.

Journal article Cancer Res · January 1986 The continuous human medulloblastoma cell line TE-671 was grown as s.c. and intracranial xenografts in athymic nude mice. Tumor-bearing animals were treated with chemotherapeutic agents at the 10% lethal dose; s.c. xenografts were sensitive to melphalan, 1 ... Link to item Cite

MOUSE MONOCLONAL-ANTIBODIES TO HUMAN GLIOMA-CELLS

Journal article JOURNAL OF NEURO-ONCOLOGY · January 1, 1986 Link to item Cite

ACRYLONITRILE NEUROONCOGENESIS IN F344 RATS

Journal article JOURNAL OF NEURO-ONCOLOGY · January 1, 1986 Link to item Cite

COOPERATIVE STUDIES OF CHEMOTHERAPY FOR GLIOMAS AND MEDULLOBLASTOMAS

Journal article JOURNAL OF NEURO-ONCOLOGY · January 1, 1986 Link to item Cite

CHARACTERIZATION OF LOCALIZING GLIOMA-REACTIVE MONOCLONAL-ANTIBODIES (MABS)

Journal article JOURNAL OF NEURO-ONCOLOGY · January 1, 1986 Link to item Cite

Monoclonal antibody transport across tumor and systemic tissue

Journal article Journal of Neuroimmunology · December 1985 Full text Cite

Vasoactive drugs produce selective changes in flow to experimental brain tumors.

Journal article Ann Neurol · December 1985 Most vasoactive drugs do not readily penetrate the blood-brain barrier and do not affect cerebral blood flow. We tested the hypothesis that vasoactive drugs may alter blood flow to brain tumors in which the blood-brain barrier is abnormal. Blood flow was m ... Full text Link to item Cite

Foreword

Journal article Neurologic Clinics · November 1985 Full text Cite

Comparison of intravenous versus intracarotid therapy with 1,3-bis(2-chloroethyl)-1-nitrosourea in a rat brain tumor model.

Journal article Cancer Res · November 1985 Currently numerous clinical trials are in progress utilizing intracarotid (i.c.) 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) for the treatment of malignant gliomas based upon the proposed focal nature of these tumors and the assumption that the i.c. route ... Link to item Cite

Aspects of immunobiology and immunotherapy and uses of monoclonal antibodies and biologic immune modifiers in human gliomas.

Journal article Neurol Clin · November 1985 Recent progress in brain tumor biology research has helped us to understand the causes of our failure to improve patient survival with current therapeutic approaches. Present combination regimens of surgery, radiotherapy, and chemotherapy fail to address a ... Link to item Cite

Establishment and characterization of the human medulloblastoma cell line and transplantable xenograft D283 Med.

Journal article J Neuropathol Exp Neurol · November 1985 A new continuous cell line and transplantable xenograft, D283 Med, was derived from the peritoneal implant and ascitic fluid of a child with metastatic medulloblastoma and grew in vitro in suspension culture with spontaneous macroscopic spheroid formation. ... Full text Link to item Cite

Comparison of Intravenous versus Intracarotid Therapy with 1,3-Bis(2-chloroethyi)-1-nitrosourea in a Rat Brain Tumor Model

Journal article Cancer Research · November 1, 1985 Currently numerous clinical trials are in progress utilizing intracarotid (i.c.) 1,3-bis(2-chloroethyl)-1 -nitrosourea (BCNU) for the treatment of malignant gliomas based upon the proposed focal nature of these tumors and the assumption that the i.e. route ... Cite

Effect of glutamate analogues on brain tumor cell lines.

Journal article J Neurochem · October 1985 Glutamate analogues have been used in many different experimental approaches in neurobiology. A small number of these analogues have been classified as gliotoxic. We have examined the effect of seven glutamate analogues (five gliotoxic and two neurotoxic) ... Full text Link to item Cite

A serially transplantable human giant cell glioblastoma that maintains a near-haploid stem line.

Journal article Cancer Genet Cytogenet · October 1985 We have karyotyped a human giant cell glioblastoma removed from an 11-year-old girl and have established from it a subcutaneously transplantable line in athymic nude mice. The original tumor contained near-haploid cells with 25 or 26 chromosomes, including ... Full text Link to item Cite

Combination chemotherapy in vitro exploiting glutamine metabolism of human glioma and medulloblastoma.

Journal article Cancer Res · September 1985 The human glioma-derived cell line D-54 MG and the human medulloblastoma-derived cell line TE-671 have been shown to be sensitive in culture to the pharmacological interference with glutamine metabolism by acivicin, 6-diazo-5-oxo-L-norleucine, and methioni ... Link to item Cite

Influence of glutamine on the growth of human glioma and medulloblastoma in culture.

Journal article Cancer Res · September 1985 Cellular supply of glutamine, an essential substrate for growth, is derived from extracellular fluid and de novo synthesis. We investigated the relative importance of these sources to the growth of six human anaplastic glioma- and one human medulloblastoma ... Link to item Cite

Applications of monoclonal antibodies in the diagnosis and treatment of primary brain tumors.

Journal article J Neurosurg · July 1985 The development of monoclonal antibodies has resulted in marked expansion in understanding the central nervous system (CNS). This has been especially true in the study of human neuroectodermal tumors where monoclonal antibodies have been used as physiologi ... Full text Link to item Cite

The lens epithelium contains glial fibrillary acidic protein (GFAP).

Journal article J Neuroimmunol · June 1985 Both polyclonal and monoclonal antibodies to glial fibrillary acidic protein (GFAP) intensely immunostain the lens epithelium. Two-dimensional gels of mouse lens epithelium protein extracts reveal a protein which co-migrates with GFAP from spinal cord. A l ... Full text Link to item Cite

DISTRIBUTION OF TYPE VI COLLAGEN IN NEUROEPITHELIAL NEOPLASMS

Journal article Journal of Neuropathology and Experimental Neurology · May 1985 Full text Cite

Antigenic heterogeneity of human anaplastic gliomas and glioma-derived cell lines defined by monoclonal antibodies.

Journal article J Neuropathol Exp Neurol · May 1985 The antigenic heterogeneity of human neuroectodermal tumors defined by both murine and human monoclonal antibodies (MAs) is reported; no patterns of reactivity defining degree of anaplasia, in vitro morphology, or immunogen used were apparent. We investiga ... Full text Link to item Cite

Immunolocalization of laminin in neoplasms of the central and peripheral nervous systems.

Journal article J Neuropathol Exp Neurol · May 1985 Laminin is a basement membrane glycoprotein that is expressed in vitro by immature and neoplastic astrocytes. The expression of laminin in vivo was examined immunohistochemically in normal adult brain and 90 neoplasms of the central and peripheral nervous ... Full text Link to item Cite

PRODUCTION AND CHARACTERIZATION OF 3 MONOCLONAL ANTIBODIES (MAs) TO GLIAL FIBRILLARY ACIDIC PROTEIN (GFAP)

Journal article Journal of Neuropathology and Experimental Neurology · May 1985 Full text Cite

CHROMOSOMAL ANALYSIS OF HUMAN GLIOMAS THROUGH SERIAL TRANSPLANTATION IN ATHYMIC NUDE-MICE

Journal article PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH · January 1, 1985 Link to item Cite

Isolation and properties of beta-glucosidase from Ruminococcus albus.

Journal article J Bacteriol · January 1985 An enzyme active against p-nitrophenyl-beta-D-glucoside was purified from logarithmic-phase cells of Ruminococcus albus cultivated in a medium containing ball-milled cellulose. The purification yielded homogeneous enzyme after an approximately 520-fold inc ... Full text Link to item Cite

Immunochemical and biochemical characterization of a glioma-associated extracellular matrix glycoprotein.

Journal article J Cell Biochem · 1985 A novel human glioma-associated extracellular matrix (ECM) glycoprotein has been identified by murine monoclonal antibody 81C6. The glycoprotein, designated GMEM, is expressed in the ECM of glioma and mesenchymal cell cultures, in the perivascular matrix o ... Full text Link to item Cite

Immunolocalization of monoclonal antibody-defined extracellular matrix antigens in human brain tumors.

Journal article J Neurooncol · 1985 The extracellular matrix is involved in many aspects of tumor cell biology, including tumor invasion and metastasis. 2A6 and 81C6 are murine monoclonal antibodies that identify glioma-mesenchymal extracellular matrix antigens. The 81C6 antigen is a high mo ... Full text Link to item Cite

Monoclonal antibodies reactive with epitopes restricted to glial fibrillary acidic proteins of several species.

Journal article Neurochem Pathol · 1985 The highly reproducible histochemical localization of glial fibrillary acidic protein (GFAP)+ qualifies it as an important marker of astrocytes in both research and clinical applications. The primary objective of this study was to produce monoclonal antibo ... Full text Link to item Cite

Immunohistochemical study of glial fibrillary acidic protein in avian sarcoma virus-induced gliomas in dogs.

Journal article J Neurooncol · 1985 Anaplastic astrocytomas, gliosarcomas and sarcomas were induced in 33 neonatal dogs by intracerebral injection of purified Schmidt-Ruppin strain of avian sarcoma virus (ASV). A total of 11 anaplastic gliomas, 7 gliosarcomas and 18 sarcomas were induced. Te ... Full text Link to item Cite

Chromosomal analysis of human gliomas through serial transplantation in athymic nude mice

Journal article Proceedings of the American Association for Cancer Research · January 1, 1985 Cite

Glutamine based combination chemotherapy in culture for human glioma and medulloblastoma

Journal article Proceedings of the American Association for Cancer Research · January 1, 1985 Cite

SENSITIVITY OF HUMAN MEDULLOBLASTOMA (MED) TO CLASSICAL ALKYLATORS

Journal article PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH · January 1, 1985 Link to item Cite

GLUTAMINE BASED COMBINATION CHEMOTHERAPY IN CULTURE FOR HUMAN GLIOMA AND MEDULLOBLASTOMA

Journal article PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH · January 1, 1985 Link to item Cite

Iodine-125 interstitial irradiation of virally induced dog brain tumours.

Journal article Neurol Res · December 1984 Brain tumours were induced by intracerebral inoculation of beagle puppies with Avian sarcoma virus (ASV) suspension. The inoculation produced solitary or multiple sarcomas in three dogs and intraventricular anaplastic gliomas in four dogs. At the time of t ... Full text Link to item Cite

Comparison of various methods for delivering radiolabeled monoclonal antibody to normal rat brain.

Journal article J Neurosurg · November 1984 Different methods were evaluated for delivering iodine-125 monoclonal antibodies (Mab's) to the central nervous system in 40- to 99-gm Fischer rats. By evaluating interhemispheric, interregional, and brain:blood ratios of Mab's, the efficacy of intracaroti ... Full text Link to item Cite

In vitro versus in vivo correlations of chemosensitivity of human medulloblastoma.

Journal article Cancer Res · November 1984 An in vitro clonogenic assay was used to test the chemosensitivity of the human medulloblastoma cell line TE-671. Dose-response relationships for reduction in colony formation were generated for cyclophosphamide, vincristine, Adriamycin, 1,3-bis(2-chloroet ... Link to item Cite

Characterization of three restricted specificity monoclonal antibodies raised against the human glioma cell line D-54 MG.

Journal article J Neuroimmunol · June 1984 Monoclonal antibodies ( MCAs ) have been derived from a fusion of P3-NS1/1-Ag 4-1 (NS1) myeloma cells and splenocytes immunized to human glioma cell line D-54 MG. MCAs 2F3 , 4C7 , and 5B7 were analyzed by cell surface radioimmunoassay (CS-RIA), quantitativ ... Full text Link to item Cite

Treatment of human glioma and medulloblastoma tumor lines in athymic mice with diaziquone and diaziquone-based drug combinations.

Journal article Cancer Res · June 1984 We used diaziquone (NSC 182986) alone and in combination with other antineoplastic drugs to treat six human glioma and one human medulloblastoma tumor lines growing s.c. in athymic mice. Pharmacokinetic studies of diaziquone in the plasma of athymic mice i ... Link to item Cite

130 INFLUENCE OF GLUTAMINE ON GROWTH OF HUMAN MEDULLOBLASTOMA IN CULTURE

Journal article Journal of Neuropathology and Experimental Neurology · May 1984 Full text Cite

128 RELATIONSHIP BETWEEN KARYOTYPE AND HISTOLOGIC PARAMETERS OF MALIGNANT HUMAN GLIOMAS (MHG)

Journal article Journal of Neuropathology and Experimental Neurology · May 1984 Full text Cite

24 IMMUNOCHEMICAL AND BIOCHEMICAL ANALYSIS OF THE HUMAN GLIOMA EXTRACELLULAR MATRIX GLYCOPROTEIN (GMEM)

Journal article Journal of Neuropathology and Experimental Neurology · May 1984 Full text Cite

Carotid artery injections in 40- to 99-g Fischer rats: technical note and evaluation of blood flow by various injection techniques.

Journal article Neurosurgery · April 1984 Despite extensive clinical use of brain tumor chemotherapy via the internal carotid artery (ICA), demonstration of efficacy and toxicity screening of ICA chemotherapy in brain tumor models has been limited. A method for performing ICA injections in 40- to ... Full text Link to item Cite

Blood-brain barrier disruption in immature Fischer 344 rats.

Journal article J Neurosurg · April 1984 Methods for transiently disrupting the blood-brain barrier (BBB) which are consistent with survival are described for immature Fischer 344 rats weighing 40 to 99 gm. A catheter was retrogradely inserted into the external carotid artery to the level of the ... Full text Link to item Cite

Intracerebral transplantation of a human glioma line in immunosuppressed rats.

Journal article J Neurosurg · March 1984 A model was developed for in vivo study of the human glioma-derived D-54 MG cell line in the brains of immunosuppressed Fischer 344 rats. The rats were injected with horse anti-rat thymocyte serum before and after intracerebral inoculation with 5 or 10 mic ... Full text Link to item Cite

RESPONSIVENESS OF EXPERIMENTAL BRAIN-TUMORS TO VASOACTIVE STIMULI

Journal article CLINICAL RESEARCH · January 1, 1984 Link to item Cite

KARYOTYPIC EVOLUTION OF HUMAN GLIOBLASTOMA-MULTIFORME (HGM) DURING ESTABLISHMENT IN CULTURE

Journal article PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH · January 1, 1984 Link to item Cite

Monoclonal antibody localization in subcutaneous and intracranial human glioma xenografts: paired-label and imaging analysis.

Journal article Anticancer Res · 1984 The murine antiglioma monoclonal antibody 81C6 has been shown to specifically localize in U-251 MG and D-54 MG human glioma subcutaneous and intracranial athymic mouse xenografts expressing the human gliomamesenchymal extracellular matrix glycoprotein GMEM ... Link to item Cite

The biology of malignant gliomas--a comprehensive survey.

Journal article Clin Neuropathol · 1984 Malignant gliomas constitute a morphologically diverse group of neoplasms that respond poorly to therapy. The median survival of patients with glioblastoma multiforme, the most common malignant glioma, is only 11 months. Several factors influence the thera ... Link to item Cite

In vivo measurement of regional brain tissue pH using positron emission tomography.

Journal article Ann Neurol · 1984 Carbon-11-labeled dimethyloxazolidinedione ([11C]DMO) was injected intravenously into human subjects, and serial positron emission tomographic (PET) scans were obtained until brain-blood equilibration was achieved or could be accurately predicted from dyna ... Full text Link to item Cite

THE USE OF HUMAN MEDULLOBLASTOMA MODELS TO DESIGN RATIONAL THERAPY

Journal article JOURNAL OF NEURO-ONCOLOGY · January 1, 1984 Link to item Cite

INVITRO AND INVIVO CHEMOSENSITIVITY OF HUMAN MEDULLOBLASTOMA

Journal article PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH · January 1, 1984 Link to item Cite

GLUTAMINE REQUIREMENTS OF HUMAN GLIOMA AND MEDULLOBLASTOMA IN CULTURE

Journal article JOURNAL OF NEURO-ONCOLOGY · January 1, 1984 Link to item Cite

KARYOTYPIC AND HISTOLOGIC ANALYSIS OF MALIGNANT HUMAN GLIOMAS (MHG)

Journal article JOURNAL OF NEURO-ONCOLOGY · January 1, 1984 Link to item Cite

Chromosomal composition of four permanent cultured cell lines derived from human gliomas.

Journal article Cancer Genet Cytogenet · December 1983 Four permanent cell lines derived from malignant human gliomas were karyotyped using Giemsa-trypsin banding. D-65 MG had a stemline with 44 chromosomes, including 11 markers: 1p+, 2q-, 3p-, 3q+, 4p-, 9q-, 11q+, 15q-, 17p+, 21p+, 22q-. The net effect after ... Full text Link to item Cite

A model for human medulloblastoma. Growth, morphology, and chromosomal analysis in vitro and in athymic mice.

Journal article J Neuropathol Exp Neurol · September 1983 A model was developed for the in vitro and in vivo study of the continuous cell line, TE-671, derived from a human medulloblastoma. TE-671 grew in vitro as sheets of uniform triangular- to spindle-shaped cells with round to oval nuclei and sparse cytoplasm ... Full text Link to item Cite

Treatment of five subcutaneous human glioma tumor lines in athymic mice with carmustine, procarbazine, and mithramycin.

Journal article Cancer Treat Rep · September 1983 Five human glioma tumor lines were transplanted subcutaneously in athymic nude mice. Three of the lines (D-54 MG, U-118 MG, and U-251 MG) were derived from permanent human glioma cell lines, while the other two lines (N-456 and N-519) were established as d ... Link to item Cite

Immunobiology of primary intracranial tumors. Part 7: Active immunization of patients with anaplastic human glioma cells: a pilot study.

Journal article J Neurosurg · August 1983 Twenty patients with malignant gliomas were selected for active immunization within 4 weeks following surgery. Each patient had a Karnofsky Functional Rating equal to or greater than 70, a peripheral blood lymphocyte count equal to or greater than 1000 cel ... Full text Link to item Cite

Immunobiology of primary intracranial tumors. Part 8: Serological responses to active immunization of patients with anaplastic gliomas.

Journal article J Neurosurg · August 1983 Serial serological studies were carried out on 19 of 20 patients with malignant gliomas who were actively immunized with one of two human glioma tissue culture cell lines (D-54MG or U-251MG). Most patients mounted a significant serum reaction to histocompa ... Full text Link to item Cite

Chemotherapy and radiation therapy of human medulloblastoma in athymic nude mice.

Journal article Cancer Res · July 1983 The human medulloblastoma cell line TE-671 was grown s.c. and intracranially in athymic nude mice. Tumor-bearing animals treated with chemotherapeutic agents or radiation were compared to untreated tumor-bearing controls. Tumors growing s.c. were sensitive ... Link to item Cite

Demonstration of complex antigenic heterogeneity in a human glioma cell line and eight derived clones by specific monoclonal antibodies.

Journal article Cancer Res · July 1983 We have investigated the antigenic heterogeneity of human glioma cells and its correlation with other parameters of tumor cell heterogeneity (karyotype, 2':3' cyclic nucleotide 3'-phosphohydrolase expression, in vitro morphology) using the established huma ... Link to item Cite

Regional measurements of blood-to-tissue transport in experimental RG-2 rat gliomas.

Journal article Cancer Res · July 1983 Regional measurements of blood-to-tissue transport were performed in transplanted RG-2 rat gliomas using [alpha- 14C]aminoisobutyric acid (AIB), quantitative autoradiography, and equations to express a unidirectional transfer constant. Thirty-eight intracr ... Link to item Cite

Regional measurements of blood flow in experimental RG-2 rat gliomas.

Journal article Cancer Res · July 1983 Regional measurements of blood flow (F) were performed in transplanted intracerebral RG-2 rat gliomas using [14C]iodoantipyrine, Kety-Schmidt blood flow equations, and quantitative autoradiography. Twenty-nine intracranial tumors in ten rats were analyzed ... Link to item Cite

Human glioma-mesenchymal extracellular matrix antigen defined by monoclonal antibody.

Journal article Cancer Res · June 1983 The distribution and localization of a glioma-associated antigen defined by monoclonal antibody 81C6 has been examined using human cultured cell lines and tissues. Monoclonal antibody 81C6 was selected from a hybridoma fusion of spleen cells of mice immuni ... Link to item Cite

Intracerebral growth of a human glioma tumor line in athymic mice and treatment with procarbazine, 1,3-bis(2-chloroethyl)-1-nitrosourea, aziridinylbenzoquinone, and cis-platinum.

Journal article Neurosurgery · June 1983 Tumors derived from the established human glioma cell line D-54 MG were transplanted intracerebrally into athymic "nude" mice. All control mice developed tumors in the brain after the transplantation of 10(5) cells and died within 30 days. Tumor was purely ... Full text Link to item Cite

Regional blood flow in avian sarcoma virus (ASV)-induced brain tumors.

Journal article Neurology · June 1983 Regional blood flow (F) was measured in avian sarcoma virus (ASV)-induced brain tumors in rats. Blood flow was variable in individual as well as different tumors; tumor F did not correlate with histologic classification, tumor size, central versus peripher ... Full text Link to item Cite

Regional blood-to-tissue transport in avian sarcoma virus (ASV)-induced brain tumors.

Journal article Neurology · June 1983 Regional blood-to-tissue transport of 14C-alpha-aminoisobutyric acid (AIB) was measured in avian sarcoma virus (ASV)-induced rat brain tumors and expressed as a unidirectional transfer rate constant (K). The magnitude of K was variable and did not correlat ... Full text Link to item Cite

115 MONOCLONAL ANTIBODIES (MA) AGAINST HUMAN GLIOSARCOMA DERIVED CELL LINE D-32MGCL 2

Journal article Journal of Neuropathology and Experimental Neurology · May 1983 Full text Cite

9 MONOCLONAL ANTIBODY LOCALIZATION IN HUMAN GLIOMA INTRACRANIAL XENOGRAFTS

Journal article Journal of Neuropathology and Experimental Neurology · May 1983 Full text Cite

Prevention of glioma induction in rats by simultaneous intracerebral inoculation of avian sarcoma virus plus bacillus Calmette-Guerin cell-wall preparation.

Journal article Surg Neurol · May 1983 Bacillus Calmette-Guerin cell-wall preparation was injected along with avian sarcoma virus in the brains of newborn Fischer 344 rats, and subsequent glioma induction was compared with rats injected with avian sarcoma virus alone. The percentage of glioma i ... Full text Link to item Cite

139 ENTRY OF (125I) MONOCLONAL ANTIBODY (MA)FROM BLOOD INTO BRAIN

Journal article Journal of Neuropathology and Experimental Neurology · May 1983 Full text Cite

Study of glial fibrillary acidic protein in a human glioma cell line grown in culture and as a solid tumor.

Journal article J Neurochem · February 1983 A continuous human glioma cell line grown in culture and as a solid tumor was analyzed for glial fibrillary acidic (GFA) protein. This material provided a rich source for GFA protein that could also be manipulated and controlled. Immunoperoxidase staining ... Full text Link to item Cite

Spatial distribution of proliferating cells in avian sarcoma virus-induced gliomas.

Journal article Cancer Res · February 1983 We studied the regional distribution of proliferating tumor cells in five avian sarcoma virus-induced gliomas. The labeling index and spatial distribution of [3H]thymidine (dThd)-labeled tumor cells were determined in serial sections of each tumor with a c ... Link to item Cite

Growth, morphology, and serial transplantation of anaplastic human gliomas in athymic mice.

Journal article J Neurooncol · 1983 Sixteen of 17 anaplastic human gliomas (AHGs) transplanted into athymic mice produced progressively growing subcutaneous nodules at the site of implantation. Thirty-four of 68 animals (50%) receiving transplanted tissue developed 500 m3 tumors in 24 to 364 ... Full text Link to item Cite

Glial fibrillary acidic protein synthesized in vitro using messenger RNA from a human glioma cell line.

Journal article J Neuropathol Exp Neurol · January 1983 Messenger RNA (mRNA) extracted from a continuous human glioma cell line grown in culture or as a solid tumor was translated in an mRNA-dependent reticulocyte lysate system. Translation products labeled with [35S]methionine were immunoprecipitated with anti ... Full text Link to item Cite

Immunohistochemical detection of factor VIII/von Willebrand factor in hyperplastic endothelial cells in glioblastoma multiforme and mixed glioma-sarcoma.

Journal article J Neuropathol Exp Neurol · September 1982 The sarcomatous components of most glioma-sarcomas are thought to arise from the neoplastic transformation of hyperplastic endothelial and adventitial vascular cells in a preexisting glioblastoma multiforme. The expression of factor VIII/von Willebrand fac ... Link to item Cite

Human fetal brain antigen expression common to tumors of neuroectodermal tissue origin.

Journal article J Neuroimmunol · August 1982 The antigenic relationship between human tumors of neuroectodermal origin and fetal brain were further investigated by characterization of two hybridoma antibodies derived from a fusion of P3-NS1/1-Ag 4-1 (NSI) myeloma cells and splenocytes hyperimmunized ... Full text Link to item Cite

Effects of adrenal cortical steroids and osmotic blood-brain barrier opening on methotrexate delivery to gliomas in the rodent: the factor of the blood-brain barrier.

Journal article Proc Natl Acad Sci U S A · July 1982 The effect of adrenal cortical steroids and osmotic blood-brain barrier modification on methotrexate delivery to normal and glioma-bearing rats was studied. In animals with the avian sarcoma virus-induced glioma, osmotic blood-brain barrier modification re ... Full text Link to item Cite

Experimental allergic encephalomyelitis in Lewis rats bearing avian sarcoma virus-induced brain tumors.

Journal article J Neuroimmunol · June 1982 Lewis rats bearing avian sarcoma virus (ASV)-induced brain tumors were injected with guinea pig spinal cord emulsion and complete Freund's Adjuvant to determine if they remained susceptible to induction of experimental allergic encephalomyelitis (EAE). The ... Full text Link to item Cite

Specificity and sensitivity of immunohistochemical detection of factor VIII/von Willebrand factor antigen in formalin-fixed paraffin-embedded tissue.

Journal article J Histochem Cytochem · April 1982 The immunohistochemical detection of factor VIII/von Willebrand factor antigen (FVIII/vWF-AG) in formalin-fixed paraffin-embedded tissues was investigated using the peroxidase-antiperoxidase (PAP) method. Highly purified human FVIII/vWF was used to raise r ... Full text Link to item Cite

Permeability of different experimental brain tumor models to horseradish peroxidase.

Journal article J Neuropathol Exp Neurol · March 1982 The permeability of different brain tumor models to horseradish peroxidase (HRP) was examined by determining the fraction of tumor that contained HRP after intravenous administration. The intracerebral tumor models studied were Avian Sarcoma Virus (ASV)-in ... Full text Link to item Cite

Expression of human fetal brain antigens by human tumors of neuroectodermal origin as defined by monoclonal antibodies.

Journal article Cancer Res · January 1982 The antigenic relationships between human tumors of neuroectodermal origin and fetal brain were investigated by the production of hybridoma antibodies derived from a fusion of P3-NS1/1-Ag 4-1 (NS1) myeloma cells with splenocytes from a mouse multiply immun ... Link to item Cite

Evaluation of the lipid-soluble diaminopyrimidines, metoprine and etoprine, in the avian sarcoma virus rat glioma model.

Journal article Cancer Treat Rep · January 1982 Using the avian sarcoma virus (ASV) rat glioma model, we have evaluated the in vivo effectiveness of two lipid-soluble folate antagonists, metoprine (DDMP) and its 6-ethyl analog etoprine. When adult Fischer 344 rats, which were previously inoculated with ... Link to item Cite

Localization of factor VIII/von Willebrand factor and glial fibrillary acidic protein in the hemangioblastoma: implications for stromal cell histogenesis.

Journal article Acta Neuropathol · 1982 The histogenesis of hemangioblastoma stromal cells is unresolved. Ultrastructural observations suggest that the stromal cells, endothelial cells, and pericytes that compose this neoplasm are all derived from angiogenic mesenchyme. The expression of factor ... Full text Link to item Cite

TREATMENT OF HUMAN-BRAIN TUMORS IN ATHYMIC MICE WITH AZIRIDINYLBENZOQUINONE (AZQ)

Journal article PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH · January 1, 1982 Link to item Cite

Anaplastic human gliomas grown in athymic mice. Morphology and glial fibrillary acidic protein expression.

Journal article Am J Pathol · December 1981 The morphologic and biochemical characteristics of human surgical biopsy specimens taken from 17 patients with anaplastic human gliomas and of athymic mouse-grown tumors derived from them were examined. Fourteen were categorized as glioblastoma multiforme, ... Link to item Cite

Lymphocyte subpopulations and responsiveness in rats bearing intracranial tumors induced by avian sarcoma virus.

Journal article J Neurosurg · October 1981 The mitogenic responsiveness of peripheral blood lymphocytes obtained from Fischer 344 rats inoculated with avian sarcoma virus was studied. In addition, quantitative alterations in lymphocyte subpopulations were determined in these animals. Only periphera ... Full text Link to item Cite

Hyperimmunization of non-human primates with BCG-CW and cultured human glioma-derived cells. Production of reactive antisera and absence of EAE induction.

Journal article J Neuroimmunol · September 1981 The efficacy and non-toxicity of BCG-cell wall preparation (BCG-CW) + cultured human glioma-derived cells as immunogen in non-human primates (Macaca fascicularis) were investigated to determine the optimal conditions for immunization without induction of e ... Full text Link to item Cite

Computed tomography of virally induced canine brain tumors: a preliminary report.

Journal article J Comput Assist Tomogr · August 1981 Seven neonatal dogs were inoculated intracerebrally with Avian Sarcoma Virus (ASV) and studied by computed tomography (CT) for intracranial tumors. The tumor yield was five anaplastic astrocytomas and two sarcomas, with an average latency of 57 days. Compu ... Full text Link to item Cite

Growth and chemotherapeutic response in athymic mice of tumors arising from human glioma-derived cell lines.

Journal article J Neuropathol Exp Neurol · July 1981 Fifteen permanent cell lines derived from human gliomas were subcutaneously transplanted into athymic nude mice (nu/nu genotype, NIH Swiss and BALB/c backgrounds). Four were tumorigenic. Three of the four (D-54 MG, U-118 MG, and U-251 MG) produced progress ... Full text Link to item Cite

Relationship of in vitro morphologic and growth characteristics of established human glioma-derived cell lines to their tumorigenicity in athymic nude mice.

Journal article J Neuropathol Exp Neurol · July 1981 Fifteen permanent cell lines derived from human gliomas which are individually distinct by immunologic and biochemical criteria were evaluated to determine if morphologic or cell biologic parameters distinguished the 4 lines which were tumorigenic in athym ... Full text Link to item Cite

190 QUANTITATIVE AUTORADIOGRAPHIC MEASUREMENTS OF BLOOD FLOW AND PERMEABILITY IN EXPERIMENTAL RG-2 RAT GLIOMAS

Journal article Journal of Neuropathology and Experimental Neurology · May 1981 Full text Cite

The morphologic response of cell lines derived from human gliomas to dibutyryl adenosine 3':5'-cyclic monophosphate.

Journal article J Neuropathol Exp Neurol · May 1981 The addition of exogenous cyclic nucleotides to cultured neoplastic cells has been reported by others to cause changes in growth properties and cellular morphology. We have studied the in vitro morphologic response to exogeneous dibutyryl adenosine 3':5'-c ... Full text Link to item Cite

Heterogeneity of Genotypic and phenotypic characteristics of fifteen permanent cell lines derived from human gliomas.

Journal article J Neuropathol Exp Neurol · May 1981 Six new permanent cell lines were established from human gliomas and compared to nine other cell lines from human gliomas. All fifteen lines had individually distinct HLA phenotypes and all but two, which were from a black patient, had type B glucose-6-pho ... Full text Link to item Cite

Endothelial cell surface expression and binding of factor VIII/von Willebrand factor.

Journal article Am J Pathol · May 1981 Factor VIII/von Willebrand factor (FVIII/vWF), a glycoprotein molecular complex found in human plasma, has been demonstrated by cell membrane fluorescence to be present on the surface of cultured human umbilical cord vein endothelial cells. The endothelial ... Link to item Cite

Computed tomography of virally induced canine brain tumors: A preliminary report

Journal article Journal of Computer Assisted Tomography · January 1, 1981 Seven neonatal dogs were inoculated intracerebrally with Avian Sarcoma Virus (ASV) and studied by computed tomography (CT) for intracranial tumors. The tumor yield was five anaplastic astrocytomas and two sarcomas, with an average latency of 57 days. Compu ... Cite

SERIAL TRANSPLANTATION OF ANAPLASTIC HUMAN GLIOMAS (HGL) IN ATHYMIC MICE

Journal article PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH · January 1, 1981 Link to item Cite

Comparative permeability of different glioma models to horseradish peroxidase.

Journal article Cancer Treat Rep · 1981 Seven different experimental glioma models were studied to determine their capillary permeability to horseradish peroxidase. The models were the autochthonous ASV-viral model, intracerebral (ic) and (sc) injections of rat 9L and RG-2 tumor cell lines, the ... Link to item Cite

How heterogeneous are gliomas?

Journal article Cancer Treat Rep · 1981 Link to item Cite

Treatment of autochthonous rat brain tumors with fractionated radiotherapy. The effects of graded radiation doses and of combined therapy with BCNU or steroids.

Journal article J Neurosurg · July 1980 The avian sarcoma virus-induced glioma model in rats was used to evaluate radiation dose response (survival curves), giving fractionated treatments to the whole head. Groups of 14 to 20 rats received total doses of 2300, 4600, or 5750 rads over 2, 4, or 5 ... Full text Link to item Cite

MORPHOLOGIC AND FUNCTIONAL CHARACTERISTICS OF A PERMANENT CELL LINE DERIVED FROM A CEREBELLAR HEMANGIOBLASTOMA

Journal article Journal of Neuropathology and Experimental Neurology · May 1980 Full text Cite

Experimental gliomas: an autoradiographic study of the endothelial component.

Journal article Neurology · March 1980 Autochthonous gliomas were induced in rats by intracerebral inoculation of avian of avian sarcoma virus and studied by 3H-thymidine autoradiography. Parenchymal glial tumor cells had a 3H-labeling index (LI) of 3.0 to 13.6%. Endothelial cells in tumor bloo ... Full text Link to item Cite

Tumorigenic cell culture lines from a spontaneous VM/Dk murine astrocytoma (SMA).

Journal article Acta Neuropathol · 1980 One of the few spontaneous gliomas in inbred animals, the VM/Dk spontaneous murine astrocytoma (SMA), has seen limited use. Previously restricted to an in vivo system, the SMA was only transplantable intracerebrally (IC) using nonquantifiable suspensions o ... Full text Link to item Cite

Immunobiologic aspects of the brain and human gliomas. A review

Journal article American Journal of Pathology · January 1, 1980 Several facts are now clearly established about immunity and human gliomas. The cause of at least some gliomas can be recognized. Glioma patients at the time of diagnosis can be stratified in terms of immune responsiveness, from those who are severely depr ... Cite

Failure of intracerebral BCG cell wall preparation to prevent glioma induction by avian sarcoma virus in rats

Journal article Cancer Immunology Immunotherapy · January 1, 1980 Five-day-old Fischer 344 rats were inoculated intracerebrally with BCG cell walls attached to oil (BCG-CW) or with oil emulsion alone. Doses of BCG-CW of 40 μg in 0.01 ml, 200 μg in 0.05 ml, and 400 μg in 0.1 ml were used, with similar volumes of oil emuls ... Full text Cite

Synergism between BCNU and irradiation in the treatment of anaplastic gliomas. An in vivo study using the avian sarcoma virus-induced glioma model.

Journal article J Neurosurg · November 1979 The therapeutic effects of irradiation, BCNU, or combined irradiation and BCNU were studied in the avian sarrcoma virus (ASV)-induced glioma model in rats. Whole-head orthovoltage radiation therapy was given in six equal fractions over 2 weeks, and BCNU wa ... Full text Link to item Cite

VIRALLY INDUCED AUTOCHTHONOUS ASTROCYTOMAS IN THE MONGOLIAN GERBIL (MERIONES UNGUICULATUS)

Journal article Journal of Neuropathology and Experimental Neurology · May 1979 Full text Cite

FACTOR VIII-A MARKER OF ENDOTHELIAL CELLS IN NORMAL BRAIN AND GLIOMAS

Journal article Journal of Neuropathology and Experimental Neurology · May 1979 Full text Cite

THE USE OF ATHYMIC ‘NUDE’ MICE FOR THE IN VIVO STUDY OF HUMAN NERVOUS SYSTEM TUMORS

Journal article Journal of Neuropathology and Experimental Neurology · May 1979 Full text Cite

Heterotransplantation of human craniopharyngiomas in athymic "nude" mice.

Journal article Neurosurgery · April 1979 Surgical biopsies from 2 human craniopharyngiomas were transplanted subcutaneously into 6 athymic "nude" mice. Morphologically characteristic craniopharyngiomas grew in 5 of these animals. In 4 animals growth was sufficient to allow transplantation into a ... Full text Link to item Cite

Dihydrofolate reductase in primary brain tumors, cell cultures of central nervous system origin, and normal brain during fetal and neonatal growth.

Journal article Cancer Res · February 1979 Dihydrofolate reductase (DHFR) was measured during the development in rats of brain tumors induced following inoculation with avian sarcoma virus. Increasing activity of this enzyme in brain was correlated with the course of primary brain tumor growth. The ... Link to item Cite

Dihydrofolate Reductase in Primary Brain Tumors, Cell Cultures of Central Nervous System Origin, and Normal Brain during Fetal and Neonatal Growth

Journal article Cancer Research · February 1, 1979 Dihydrofolate reductase (DHFR) was measured during the development in rats of brain tumors induced following inoculation with avian sarcoma virus. Increasing activity of this enzyme in brain was correlated with the course of primary brain tumor growth. The ... Cite

Cytopathologic characteristics of permanent cell lines derived from anaplastic human gliomas.

Journal article Acta Cytol · 1979 Five permanent cell lines derived from human gliomas were examined at 24-hour intervals to determine optimal phases of their population growth curves for comparative morphologic studies. In early exponential growth phase, individual cytologic criteria were ... Link to item Cite

EXPERIMENTAL GLIOMAS: STUDIES AT THE MARGINAL ZONE

Journal article Journal of Neuropathology and Experimental Neurology · September 1978 Full text Cite

IN VITRO RESPONSE OF CELLS DERIVED FROM HUMAN GLIOMAS (HGL) TO DIBUTYRYL ADENOSINE 3′:5′-CYCLIC MONOPHOSPHATE (cAMP)

Journal article Journal of Neuropathology and Experimental Neurology · September 1978 Full text Cite

FETAL AND ADULT BRAIN-ASSOCIATED SURFACE ANTIGENS OF HUMAN GLIOMA (HGL) CELL LINES AND CLONES

Journal article Journal of Neuropathology and Experimental Neurology · September 1978 Full text Cite

ESTABLISHED TUMORIGENIC CELL LINES FROM A SPONTANEOUS MURINE (VM/Dk) ASTROCYTOMA (SMA)

Journal article Journal of Neuropathology and Experimental Neurology · September 1978 Full text Cite

Glial-mesenchymal tropism of in vivo avian sarcoma virus neuro-oncogenesis in rats.

Journal article Acta Neuropathol · January 19, 1978 Intracerebral inoculation of avian sarcoma virus (ASV) in postnatal animals induces gliomas and sarcomas but no neuronal tumors. High titer Bratislava-77 strain ASV was inoculated intracerebrally in fetal F-344 rats between 17 and 20 days of gestation: a t ... Full text Link to item Cite

ORGAN-SPECIFIC, FETAL BRAIN, AND POSSIBLE IDIOTYPIC ANTIGENS OF HUMAN GLIAL BRAIN TUMOR (HGBT) CELLS

Journal article PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH · January 1, 1978 Link to item Cite

General immunocompetence of rats bearing avian sarcoma virus-induced intracranial tumors.

Journal article Cancer Res · January 1978 The mitogenic responsiveness of spleen cells obtained from avian sarcoma virus-inoculated Fischer 344 rats was studied. Sixty % of the rats had astrocytomas, 13% had sarcomas, 7% had mixed gliosarcomas, and 20% had no evidence of tumors. Only spleen cells ... Link to item Cite

Surface antigenic characteristics of human glial brain tumor cells.

Journal article Cancer Res · December 1977 The surface antigenic characteristics of human glial brain tumor (HGBT) cells were studied by complement-dependent cytotoxic antibody assays and indirect membrane immunofluorescence. Eight permanent, well-characterized cell lines derived from human gliomas ... Link to item Cite

The role of the subependymal plate in glial tumorigenesis.

Journal article Acta Neuropathol · September 26, 1977 We have studied the sequential morphological events of glial tumorigenesis in neonatal dogs, using high titer subgroup C Bratislava-77 Avian Sarcoma Virus, given as 0.01 ml by intraventricular inoculation. The cells of the subependymal plate are those whic ... Full text Link to item Cite

Chemotherapy of brain tumors.

Journal article Arch Neurol · September 1977 Full text Link to item Cite

Surface morphology of normal and neoplastic rat cells.

Journal article Am J Pathol · July 1977 Nontumorigenic rat cells and their tumorigenic counterparts were studied with scanning electron microscopy under controlled conditions in vitro and with transmission electron microscopy after replantation in vivo to discern if external morphology reflected ... Link to item Cite

Immunobiology of primary intracranial tumors.

Journal article J Neurosurg · July 1977 The avian sarcoma virus-induced glioma model in rats was used to study the effectiveness of immunotherapy, namely, Bacillus Calmette-Guérin (BCG) with or without sarcoma cells and/or chemotherapy with 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU), upon surv ... Full text Link to item Cite

Influence of age at inoculation on avian oncornavirus-induced brain tumor incidence, tumor morphology, and postinoculation survival in F344 rats.

Journal article Cancer Res · June 1977 Intracranial neoplasms were induced by intracerebral inoculation of a standardized, cell-free inoculum of the Bratislava-77 strain of avian sarcoma virus in F344 rats at 1, 9,97 to 99, and 528 days of age. Deaths from diseases that occur spontaneously in a ... Link to item Cite

PROGRESSIVE NEOPLASTIC GROWTH IN NUDE MICE OF CULTURED CELL LINES DERIVED FROM HUMAN GLIOMAS

Journal article Journal of Neuropathology and Experimental Neurology · May 1977 Full text Cite

The role of the subependymal plate in avian sarcoma virus brain tumor induction: comparison of incipient tumors in neonatal and adult rats.

Journal article Acta Neuropathol · April 29, 1977 F-344 rats were inoculated intracerebrally at 1 and at 133 days of age with the Bratislava-77 strain of avian sarcoma virus. Groups of rats were sequentially sacrificed following inoculation so that early stages of microtumor formation could be evaluated. ... Full text Link to item Cite

Immunobiology of primary intracranial tumors. Part 1: studies of the cellular and humoral general immune competence of brain-tumor patients.

Journal article J Neurosurg · April 1977 Cellular and humoral immune parameters were evaluated in a series of brain-tumor patients, 42 with glioblastoma multiforme, 17 with other anaplastic gliomas, and 17 with meningiomas. A degree of anergy was found, which seems in the group as a whole to be p ... Full text Link to item Cite

Immunofluorescent analysis of expression of the RNA tumor virus major glycoprotein, gp71, on surfaces of virus-producing murine and other mammalian species cell lines.

Journal article Cancer Res · March 1977 The specificity of a single rabbit antiserum pool raised against the purified major glycoprotein, gp71, of Friend murine leukemia virus was determined for a variety of virus-producing mouse, feline, and gibbon ape cell lines by viable cell membrane immunof ... Link to item Cite

Immunofluorescent analysis of expression of the RNA tumor virus major glycoprotein, gp71, on the surfaces of normal murine cells.

Journal article Cancer Res · March 1977 The expression of the major glycoprotein, gp71, of murine leukemia virus was studied on the surfaces of a variety of normal murine cell lines with a monospecific rabbit antiserum raised against purified Friend murine leukemia virus gp71. Using viable cell ... Link to item Cite

COMMON SURFACE ANTIGEN(S) [HGL] OF HUMAN GLIAL BRAIN TUMOR [HGBT] CELLS

Journal article PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH · January 1, 1977 Link to item Cite

DIHYDROFOLATE-REDUCTASE LEVELS IN NORMAL BRAIN AND PRIMARY CNS TUMORS RELEVANT TO BRAIN TUMOR CHEMOTHERAPY

Journal article PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH · January 1, 1977 Link to item Cite

3 ANTIGENS OF NITROSOUREA-INDUCED (NU) RAT SCHWANNOMAS

Journal article PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH · January 1, 1977 Link to item Cite

Contained indirect viable-cell membrane immunofluorescence microassay for surface antigen analysis of cells infected with hazardous viruses.

Journal article J Clin Microbiol · January 1977 A microtechnique for an indirect viable-cell membrane immunofluorescence titration assay was developed using Friend murine leukemia virus (F-MuLV)-producing cells and monospecific rabbit antisera to F-MuLV structural antigens. The assay was sensitive and d ... Full text Link to item Cite

Dihydrofolate reductase levels in normal brain and primary CNS tumors relevant to brain tumor chemotherapy

Journal article Proceedings of the American Association for Cancer Research · January 1, 1977 Cite

Workshop on cancer of the brain

Journal article Journal of Neurosurgery · January 1, 1977 The authors provide a summary of a workshop on 'Cancer of the Brain'. This conference reviewed the current knowledge about the etiology and pathogenesis of human brain tumors and the experimental induction of comparable animal brain tumors, and considered ... Full text Cite

Immunobiology of primary intracranial tumors. Part 2: The evaluation of chemotherapy and immunotherapy protocols using the avian sarcoma virus glioma model

Journal article Journal of Neurosurgery · 1977 The avian sarcoma virus-induced glioma model in rats was used to study the effectiveness of immunotherapy, namely, Bacillus Calmette-Guerin (BCG) with or without sarcoma cells and/or chemotherapy with 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU), upon surv ... Cite

Three antigens of nitrosourea induced (NU) rat schwannomas

Journal article Proceedings of the American Association for Cancer Research · January 1, 1977 Cite

Cellular immunity in rats with primary brain tumors: inhibition of macrophage migration by soluble extracts of avian sarcoma virus-induced tumors.

Journal article J Natl Cancer Inst · June 1976 Rats bearing primary tumors of the brain induced by avian sarcoma virus (ASV) were studied with the migration-inhibition factor (MIF) assay for the presence of cell-mediated immunity to tumor-associated antigens. Astrocytomas and sarcomas of the brain were ... Full text Link to item Cite

Sequential adsorption analysis of antibodies to neuroectodermal cells by an indirect quantitative method.

Journal article J Natl Cancer Inst · June 1976 An indirect radioimmunoassay was developed for the sequential adsorption analysis of rabbit antibodies raised against rat neuroectodermal cells. The quantitativee relationship between primary adsorbed rabbit antitumor antibodies and secondary adsorbed goat ... Full text Link to item Cite

MORPHOLOGIC FEATURES OF AVIAN SARCOMA VIRUS TRANSFORMED RAT NEUROECTODERMAL CELLS IN GELATIN FOAM MATRIX CULTURE

Journal article Journal of Neuropathology and Experimental Neurology · May 1976 Full text Cite

GLIAL TUMORIGENESIS

Journal article Journal of Neuropathology and Experimental Neurology · May 1976 Full text Cite

The fine structure of intracranial neoplasms induced by the inoculation of avian sarcoma virus in neonatal and adult rats.

Journal article Am J Pathol · April 1976 Groups of F-344 rats were inoculated with the Bratislava-77 strain of avian sarcoma virus (B-77 ASV) within 24 hours of birth, at 9 days of age, or between 97 and 119 days of age. Intracranial tumors developed in each age group. Multiple tumors with mixed ... Link to item Cite

INDUCTION OF LETHAL EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS (EAE) IN NON-HUMAN PRIMATES WITH HUMAN GLIOBLASTOMA MULTIFORME (GBM)

Journal article PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH · January 1, 1976 Link to item Cite

ANALYSIS OF ANTIBODIES TO SURFACE ANTIGENS ON NEUROECTODERMAL TUMOR-CELLS USING AN INDIRECT SEQUENTIAL ADSORPTION RADIOIMMUNOASSAY

Journal article PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH · January 1, 1976 Link to item Cite

The antigenic expression of murine leukemia virus GP71 on murine and heterologous species cells

Journal article Federation Proceedings · January 1, 1976 RNA C type viruses are oncogenic agents in many animal species and in particular are associated with all types of murine leukemia. The expression of the major glycoprotein, gp71, of murine leukemia virus, in which virus neutralizing and type specific deter ... Cite

The induction of intractranial neoplasms by the inoculation of avian sarcoma virus in perinatal and adult rats.

Journal article J Neuropathol Exp Neurol · July 1975 The induction of intracranial neoplasms following the intracerebral inoculation of avian sarcoma virus (ASV) in neonatal mammals is well established. The present study demonstrates the susceptibility of adult rats and compares the incidence and morphology ... Full text Link to item Cite

R-type virus-like particles in avian sarcoma virus-induced rat central nervous system tumors.

Journal article J Natl Cancer Inst · June 1975 Morphologically distinct virus-like particles (VLP), similar to R-type VLP, were observed by electron microscopy in experimental rat central nervous system tumors induced with the B-77-C strain of avian sarcoma virus (ASV). R-type VLP have a characteristic ... Full text Link to item Cite

CELLULAR IMMUNITY TO SOLUBILIZED TUMOR ANTIGENS IN INBRED RATS BEARING AUTOCHTHONOUS VIRALLY INDUCED GLIOMAS

Journal article JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY · January 1, 1975 Link to item Cite

ADDITIVE ONCOGENIC EFFECTS OF AVIAN-SARCOMA VIRUS AND ETHYLNITROSOUREA

Journal article JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY · January 1, 1975 Link to item Cite

Expression of murine leukemia virus structural antigens on the surface of chemically induced murine sarcomas.

Journal article Proc Natl Acad Sci U S A · December 1974 Cultured cells of different chemically-induced C57BL/6N murine sarcomas produced variable amounts of infectious murine leukemia virus (MuLV) and contained proportional amounts of MuLV structural components as determined by radioimmunoassay. Monospecific an ... Full text Link to item Cite

Improved techniques for staining and enumerating focus formation in viral infectivity assays.

Journal article Appl Microbiol · July 1974 Improved techniques consisting of glutaraldehyde fixation, Giemsa staining, and colony counter enumeration of foci in viral infectivity assays were compared to microscope scanning and lantern slide projection methods. These techniques broadened the scope o ... Full text Link to item Cite

Experimental chemotherapy of viral induced brain tumors

Journal article Proceedings of the American Association for Cancer Research · January 1, 1974 Cite

Neurological disorders with abnormalities of immunoglobulin metabolism.

Journal article Res Publ Assoc Res Nerv Ment Dis · 1971 Link to item Cite

PROBLEMS INHERENT TO THE IN VIVO LOCALIZATION OF ANTI‐BRAIN TUMOR ANTIBODIES

Journal article Annals of the New York Academy of Sciences · January 1, 1969 Full text Cite